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Abstract
The type 4 family of phosphodiesterases (PDEs) are part of family of enzymes 
that provide the sole means of hydrolysing the ubiquitous second messenger, 
adenosine-3’,5’"Cyclic monophosphate. The PDE4 family is complex, consisting 
of four genes, each of which is alternatively spliced. Understanding the functional 
significance of the multiple species is crucial so as to enable the development of 
novel drugs to modulate their activities for the treatment of many disorders, 
including depression, asthma and artliritis.
In this study, the regulation of PDE4B splice variants by insulin in intact 
rat epididymal adipocytes was investigated and the expression of PDE4B species 
in a number of cell lines was detected using antisera designed to recognise the C- 
terminal region of PDE4B species. Described herein is the first demonstration of 
the interaction of PDE4 isoforms with Src homology-3 (SH3) domains. The 
PDE4A species, rpde6 (RNPDE4A5) and the PDE4D species PDE4D4, when 
expressed either transiently in COS cells or endogenously in brain, were shown to 
possess the ability to bind to SPI3 domains of certain Src family tyrosyl kinases, 
that were expressed as glutathione-S-transferase (GST) fusion proteins. Neither 
PDE isoforms interacted with GST itself. PDE4D4 and rpde6 displayed little or no 
binding to the SH3 domains of the adapter proteins Grb2 and Crk, thus displaying 
specificity for the SH3 domains with which they interacted. Interaction was 
determined by the N-terminal splice region of rpde6 since the PDE4A splice 
variant rpde39, which differs from rpde6 at the N-terminus failed to interact with 
SH3 domains at all. This occurred both when rpde39 was either transiently 
expressed in COS cells or endogenously expressed in testes. The interaction of 
PDE4D4 with SH3 domains appeared to be determined by its N-terminal splice 
region since the other PDE4D splice variants, PDE4D3 and PDE4D5, which differ 
from PDE4D4 only in their extreme N-terminally spliced regions, did not interact 
with SH3 domains. rpde6 but not PDE4D4 was shown to interact with the SH3 
domains of Crk, Lck and Csk, as well as the cytoskeletal protein fodrin, leading to 
a perturbation of the catalytic activity of rpde6. In contrast, association with the 
SH3 domains of Src family tyrosyl kinases, Src, Fyn and Lyn did not effect the 
catalytic activity, or sensitivity to the PDE4 specific inhibitor rolipram of 
rpdeb. The basis and possible functional significance of such interactions is 
described.
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Chapter 1
Introduction
1.1. INTRODUCTION
This thesis describes work which investigates the regulation and 
interactions of type 4 phosphodiesterases which specifically breakdown the 
second messenger adenosine-3’,5’-cyclic monophosphate. It pays particular 
attention to the function of the multiple splice valiants of these genes in order to 
decipher the functional role of their N-terminal splice regions in determining 
protein-protein interactions.
1.2. CYCLIC NUCLEOTIDE SIGNALLING
1.2.1. Background
Two cyclic nucleotides are laaown to be involved in intracellular signalling 
processes. These are adenosine-3’,5’-cyclic monophosphate (cAMP) and 
guanosine -3’,5’-cyclic monophosphate (cGMP). Such second messengers are 
generated as a result of the action of adenylyl cyclase which produces cAMP and 
guanylyl cyclase which produces cGMP. These enzymes can be activated in 
response to external stimuli such as hormones or neurotransmitters. Cellular 
responses to these second messengers are mediated through their activation of 
protein kinases which phosphorylate target proteins, leading, in turn to a cellular 
response.
1.2.2, cAMP generation
Binding of an effector to a cell surface receptor transmits its signal to 
adenylyl cyclase via heterotrimeric GTP-binding proteins (G-proteins). These G-
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proteins can either stimulate, in the case of Gg, or inhibit, via G;, adenylyl cyclase. 
cAMP if produced can bind to the regulatory subunits of protein kinase A (PICA), 
causing the dissociation and subsequent activation of the catalytic subunits which 
then phosphorylate target proteins. The regulatory subunits are then involved in 
transport of cAMP either to the nucleus where it is believed to bind to DNA and 
effect transcriptional events or to the cytoplasm where the complex may have 
post-translational effects.
cAMP levels must be regulated. While desensitisation plays a role in 
decreasing cAMP synthesis after stimulation, a mechanism is also required for 
degrading the second messenger. Such a mechanism is provided by a family of 
enzymes Icnown as cyclic nucleotide phosphodiesterases (PDEs) which hydrolyse 
both cAMP and cGMP into their corresponding 5’-monophosphate.
1.2.2. G-proteins
G-proteins are a heterologous, but related, group of membrane-associated 
proteins that functionally linlc surface receptors to their effectors [Gillman, AG. 
1984, Bray, P., et. al. 1986]. They are all heterotrimers, made up of an a-subimit 
which binds and hydrolyses GTP and a Py-dimer that serves as a functional 
monomer [reviewed; Neer, EJ. 1994]. In recent years, numerous members o f the 
heterotrimeric G-protein family have been cloned from vertebrates and 
inveidebrates. To date, twenty a-submiits, five p-subunits and twelve y-subunits 
have been identified. Random association of these subunits would produce 
hundreds of different heterotrimeric proteins, however it appears that there are
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preferred combinations of isoforms that associate to form a limited number of 
distinct complexes [Pronon, AN. and Gautam, N. 1992, Ray, K., et. al. 1995, Lee, 
C., et. al. 1995].
In a resting state, G-proteins exist in a holonieric inactive state, with GDP 
bomrd to the a-subunit. Ligand stimulation produces a change in conformation of 
the receptor which possesses seven transmembrane helices. This leads to a 
decreased affinity of the a-subunit of the G-protein for GDP which consequently 
dissociates and is replaced by GTP. With GTP bound, the a-subunit is activated 
and dissociates from the py-dimer. This activated state persists until GTP is 
hydrolysed to GDP by the intrinsic GTPase activity of the a-subunit which re­
associates with the py-dimer [Neubig, RR., et. al. 1994]. Activated Gg-a interacts 
with and activates adenylyl cyclase.
1.2.3. Adenylyl Cyclases
The functional role of adenylyl cyclases is to synthesise cAMP from ATP 
in response to activation in response to a number of hormones and 
neurotransmitters. These enzymes have a complex structure. A short cytoplasmic 
amino-terminus is followed by six transmembrane spans (M J, then a large 
cytoplasmic domain of about 40kDa (Cf), then a second set of six transmembrane 
domains (M2 ) and a second cytoplasmic domain (C2 ). Such a structure resembles 
that of certain channels and ATP dependent transporters, particularly the P 
glycoprotein and cystic fibrosis transmembrane conductance regulator [reviewed 
Taussig, R. and Gilman, AG. 1995]. Consequently it has prompted speculation
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that the adenylyl cyclases may also serve as channels or transporters but there is 
no evidence to support this. Hov^ever, an adenylyl cyclase from Paramecium has 
been reported to be a potassium channel, although its structure is not yet Icnown 
[Schultz, JE., et. al. 1992].
Adenylyl cyclases are expressed at relatively low levels which combined 
with their liability in detergent containing solutions hindered their purification and 
characterisation. It was not until an affinity matrix with forskolin was made that 
purification became possible [Pfeuffer, T. and Metzger, H. 1882]. It became 
apparent that were at least two distinct classes that differed in their ability to be 
stimulated by calmodulin [Pfeuffer, E., et. al. 1985, Molhier, S. and Pfeuffer, T. 
1988, Smigel, MD. 1986]. Sufficient quantities of the calmodulin sensitive form 
were isolated to sequence and full length cDNAs were subsequently cloned. This 
Ca^Vcalmodulin sensitive form was termed type-I [Krupinski, J., et. al. 1989]. 
Clones for seven additional isoenzymes have since been identified [Feinstein, PG., 
et. al. 1991, Bakalyar, HA. and Reed, RR. 1990, Gao, B. and Gilman, AG. 1991, 
Yoshimura, M. and Cooper, DMF. 1992, Cali, JJ., et. al. 1994]. The overall 
sequence homology of the different isoforms of adenylyl cyclases is 50%. 
However two regions in the cytoplasmic domains, Cj^  ^ and C2 K, have 93% 
sequence homology. Cj^  ^and C2 ^ are also highly homologous to each other as well 
as to regions of membrane bound guanylyl cyclases, and are hypothesised to be 
the sites of catalytic activity [Chinlcers, M. and Grabers, DL. 1991]. Furthermore, 
catalytic activity has been show to require both Ci„ and C2 a and several point 
mutations within these regions compromise catalytic activity severely [Tang, WJ.,
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et. al. 1992]. The amino-terminal and carboxyl-terminal halves of type-I adenylyl 
cyclase have no catalytic activity when expressed alone but activity is restored 
when they are expressed concurrently [Tang, WJ., et. al. 1991]. Analogously, 
soluble forms of guanylyl cyclase are heterodimers, each subunit containing a 
region that is homologous to and C2 „ and both subunits are required for 
catalysis [Nakane, M., et. al. 1990], suggesting that both domains contribute to the 
binding site.
The function of the divergent sequences mirrors the wide range of 
regulatory influences that effect them. All mammalian adenylyl cyclases are 
activated by the a-subunit of Gg. However, types I, III and VIII are also regulated 
by nanomolar concentrations of Ca^^/calmodulin [Krupinski, J., et. al. 1989, 
Bakalyar, HA. and Reed, RR. 1990], whereas the other isoforms are insensitive. 
Furthermore the G-protein py-subunit complex has a prominent type-specific 
regulation on adenylyl cyclases. The Gg-a stimulatory effect on type II and IV 
enzymes is greatly potentiated by py, whereas the activity of Type I is markedly 
inhibited [Tang, WJ. and Gilman, AG. 1991].
1.2.4. Guanylyl Cyclases
Guanylyl cyclases fall into two families, transmembrane and cytosolic. 
The transmembrane receptor family possesses a single transmembrane domain, an 
intracellular protein kinase homology domain and a cyclase catalytic domain. The 
extracellular, ligand binding region varies from receptor to receptor. The cytosolic 
forms are made up of two different subunits (a  and P), each of which contains a
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cyclase catalytic domain [Gerzer, R., et. al. 1981], which are related to the and 
C2 ot domains of adenylyl cyclases. They also contain boimd haem and are 
activated by nitric oxide and drugs such as nitrovasodilators [Garbers, DL. 1992].
4.2.4.1. Membrane bound guanylyl cyclases
The loiown peptide ligands for membrane bound guanylyl cyclases are the 
natriureic peptides (A-type natriureic peptide (ANP), B-type natriureic peptide 
(BNP) and C-type natriuretic peptide (CNP)) and heat stable enterotoxins / 
guanylins. Four membrane bound species have been identified, GC-A, GC-B, GC- 
C and ret-GC and it is suggested that these receptors must at least dimerise to form 
a single catalytically active site [Garbers, DL. et. al. 1994]. In fact, human GC-A 
has been shown to exist as a tetramer that is sensitive to reducing agents and that 
the cytoplasmic domain is required for this association [Lowe, DG., 1992]. The 
protein kinase homology domain (KHD) contains the majority of the conseiwed 
amino acids reported as being invariant within the catalytic domain of protein 
kinases [Hanlcs, EG., et. al. 1988]. An exception is the replacement of an invariant 
Asp with other amino acids such as Asr, Ser or Asn, a phenomenon which is also 
seen with the KHD-2 domain of JAKS [Witthulm, BA., et. al. 1994]. No protein 
kinase activity has ever been shown in either the KHD of guanylyl cyclases or 
JAKS domain 2 [Witthulm, BA., et. al. 1994]. The function of the KFID in GC-A 
appears to be that it is required to bind ATP in order to potentiate the signal 
generated by ANP binding , although no ATPase activity has been detected 
[Chinlcers, M., et. al. 1991].
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4.2.43. Cytosolic guanylyl cyclases
Four isoenzymes of the cytoplasmic cyclase subunits have been identified 
(a i, f>i and P2 ), each of which exists as an a(3-dimer. Studies [Yuen, PST., et. 
al. 1994] have shown that a single point mutation on destroys all catalytic 
activity when it is associated with p,, suggesting that, as with the membrane- 
bound forms, dimérisation produces a catalytically active site. The mechanism by 
which NO binding to haem activates soluble guanylyl cyclases is not known. 
Flowever a third class of haem proteins have been shown to exist, haem-based 
sensors, which are distinct from the oxygen caiiiers and electron transporters and 
contain the FixL proteins [David, M., et. al. 1988, Gilles-Gonzalez, MA., et. al. 
1994]. The FixL proteins are involved in a cascade that leads to nitrogen fixation, 
their protein kinase catalytic domain is inliibited by oxygen binding to haem, they 
contain a putative a-helical domain between their haem binding domain and their 
catalytic region and they normally exist as homodimers [David, M., et. al. 1988, 
Gilles-Gonzalez, MA., et. al. 1994]. In these respects they bear some resemblance 
to soluble guanylyl cyclases and it is thought that that binding of NO to haem has 
an allosteric effect that is transmitted through the a-helical region [Gilles- 
Gonzalez, MA., et. al. 1994].
1.2.5. cAMP dependent protein kinase
The discovery of cAMP-dependent protein kinase (PKA) provided the first 
clues about protein phosphorylation and its role in cellular signalling [Krebs, EG., 
1986, Walsh, DA., et. al. 1968]. It is tightly regulated and maintained in an
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inactive state in the absence of cAMP. However, unlike other protein kinases, the 
activating ligand, cAMP, binds to a distinct regulatory subunit, inducing 
conformational changes that lead to dissociation of the holoenzyme. The catalytic 
subunits share extensive sequence homologies with all eukaryotic protein kinases 
[Hanlcs, EG., et. a l 1988]. Even the closest homologue, in terms of sequence 
homology, of PKA, cGMP-dependent protein kinase has regulatory and catalytic 
domains as part of a single polypeptide chain [Takio, K., et. a l 1984].
The major function of the regulatory subunits are to bind to and maintain 
the catalytic subunits in an inactivate state in the absence of cAMP. The binding 
of cAMP to the regulatory subunits causes the holoenzyme to dissociate into two 
active catalytic units and a regulatory subunit dimer. Two major classes of 
regulatory subunits and their corresponding holoenzymes have been shown to 
exist [Flocldiart, DA. and Corbin, JA 1982]. Type I holoenzymes were originally 
classified by the presence of a high affinity binding site for MgATP in the 
regulatory subimit (RI) [Lee, DC., et. a l 1983]. Type II were distinguished by 
autophosphorylation of the regulatory subunits (RII) [Flofmaim, F., et. a l 1975]. 
More recently the RI and RII subunits have been shown to be encoded by different 
genes and differ in antigenicity, amino acid sequence and affinity for cAMP 
analogues.
Isoforms of RI (a  and P) and RII (a  and P) have also been identified, as 
well as for the PKA catalytic subunit (a, p and y) which differ in their subcellular 
localisation and tissue distribution. RI isoforms are primarily found in the 
cytosolic fraction of the cell and RII isoforms in the particulate fraction
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[Reviewed; McKiiight, GS. 1991, Doskeland, SO., et. al. 1993]. The a - and P- 
forms of the catalytic subunit are highly homologous (93% at the amino acid 
level). They are both widely distributed throughout most tissues, the a-form 
generally being the predominant species. However, neither of these have so far 
shown any difference in specificity for proteins they phosphorylate. Distribution 
of the y-form, however, is much more restricted and has so far only been identified 
in primate testes [Beebe, S., et. a l 1990] and is only 83% homologous to the a- 
and p-forms.
1.2.5.1. cAMP response elements
Activated PKA modulates the function of nuclear factors that bind to DNA 
sequences present in the promoter region of cAMP-inducible genes. Most of these 
genes contain one or more cAMP response elements (CREs). The consensus CRE 
is constituted by the palindromic sequence TGACGTCA [Borrelli, E., ei. al.
1992]. The first protein found to bind to a CRE was CRE-binding protein (CREB) 
[Hoeffler, JP., 1988]. Following the discovery of CREB, a number of other 
binding proteins have been identified which can be classified into a number of 
groups. They all belong to the basic region / leucine zipper (bZip) transcription 
class of proteins, in which the DNA-binding domain is composed of a conserved 
region of about 30 amino acids, rich in basic residues [Landschuitz, WH., et. a l
1988]. Immediately C-terminal to this region is a region with a heptad leucine 
repeat, which forms an amphipathic a-helix with the leucines aligned along one 
ridge. Two of these helices can associate in a coiled-coil conformation
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[Landschuitz, WH., et. al. 1988], allowing dimérisation of the CRE-binding 
factor, thus forming a Y-shaped structure, the arms of which represent the DNA- 
binding domains [Vinson, CR., et. al. 1989, O’Neil, KT., et. al. 1990].
The CRE-binding factors can be divided into activators and repressors. 
Examples of activators are CREB, CREMt and ATF-1 [Meyer, TE. and Habener, 
JF. [1993] and repressors, CREMa, CREMp and CREMy [Laoide, BM., et. al.
1993]. Phosphorylation by PKA, in the case of transcriptional activators, leads to 
DNA binding and transcriptional activation [Gonzalez, GA. and Montminy, MR. 
1989, de Groot, RP., et. al. 1993]. Conversely, dephosphorylation by protein 
phosphatase-1 leads to transcriptional attenuation of a CRE-driven gene [Nichols, 
M., et. al. 1992]. Transcriptional repressors are also phosphorylated by PKA and 
consequently bind to the CRE. However they lack twoglutamine-rich domains, 
found in the transcriptional activators, which are essential for transcriptional 
activation [Foulkes, NS., et. a l 1991].
1.2.5.2. Protein kinase A anchoring proteins
Phosphorylation of target substrates by PKA mediates certain hormonal 
responses by altering the biological activity of key enzymes and structural 
proteins. PKA is a multifunctional kinase with broad substrate specificity and yet 
it can trigger discrete physiological responses even in the same cell [Reviewed; 
Scott, JD. 1991]. For example, phosphorylation of membrane-bound 
neurotransmitter receptor channels modulates the flow of ions into the cell [Wang, 
LY., et. al. 1991], while phosphorylation of nuclear transcription factors alters the
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activity of certain genes [Meyer, TE. and Habener, JF. 1993]. Work performed by 
Barsony and Marx using microwave fixing techniques has shown that specific 
hormones can increase cAMP concentrations in subcellular compartments in 
epithelial and fibroblast cell lines [Barsony, J. and Marx, SJ. 1990]. For example, 
isoprenaline and prostaglandin E2  promote cAMP accumulation close to the 
plasma membrane, whereas calcitonin causes perinuclear accumulation of cAMP.
Prolonged treatment with forskolin causes nuclear accumulation of cAMP. One 
hypothesis to account for the selectivity of PKA action is individual effectors 
activate particular pools of the kinase which are compartmentalised to intracellular 
sites which are close to preferred substrates [Harper, JF., el. al. 1985, Scott, JD. 
and Carr, DW. 1992].
Localisation of PKA is determined by the regulatory (R) subunits, of 
which there are two forms, RI being cytosolic and RII particulate. Up to 75% of 
the cellular pool of RII is associated with the plasma membrane, cy to skeletal 
components, endoplasmic reticulum or nuclei [Corbin, JD., et. al. 1975, Leiser, 
M., et. al. 1986, Nigg, EA., et. al. 1985, Nigg, EA., et. al. 1985a, Joachim, S. and 
Schwock, G. 1990]. Type II PKA compartmentalisation is determined by 
association of RII with specific A-kinase anchoring proteins (AKAPs) [Lohmami, 
SM., et. al. 1984, Leiser, M., et. al. 1986, Bregman, DB., et. al. 1989, Carr, DW., 
et. al. 1992]. A number of AKAPs have been identified, each localising PKA to 
specific subcellular regions and often showing tissue specific expression. They are 
named simple by virtue of their molecular weights. AKAPlOO, which is 
predominantly expressed in cardiac and skeletal muscle and localises RII to the
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sarcoplasmic reticulum [McCartney, S., et. al. 1995]. AKAP79, which is 
expressed to the highest levels in the cerebral cortex and localises to the 
postsynaptic densities [Carr, DW., et. al. 1992]. AKAP95 is found in the nucleus 
of most tissues and is involved in targeting RII for cAMP responsive nuclear 
events [Coghlan, VM., et. al. 1994]. AKAP75 associates with the dendritic 
microtubules of the cytoskeleton in neuronal tissue [Glantz, SB., Li, Y. and Rubin, 
CS. 1993] and AKAP150 is found associated with the microtubules in the 
neurones of the cerebral cortex and hippocampus and various other neurones 
tliroughout the forebrain.
RII dimérisation is required for AKAP binding [Scott, JD., et. al. 1990]. 
More specifically, the first 5 amino acids of each RII unit, especially the 
isoleucines at positions 3 and 5, have been shown to be required for the interaction 
[Hausken, ZE., et. al. 1994]. The site of interaction for the RII subunit on the 
AKAP consists o f an amphipathic helix of 14-18 amino acids which must be 
maintained in the correct conformation to bind [Carr, DW., et. al. 1992].
1.2.6. Action of cGMP
The mechanisms of action o f cGMP are tliree-fold. Firstly it serves to 
regulate cGMP-gated ion channels, secondly, it activates cGMP-dependent protein 
kinase (PKG) and thirdly, it regulates a number of phosphodiesterases. Regulation 
of phosphodiesterases will be discussed in section 1.3.
Chapter 1 : Introduction 13
1.2.6.1. Regulation o f cGMP-gated ion channels
Light stimulation of the vertebrate rod photoreceptor cell leads to cGMP 
hydrolysis with the consequent closing of a plasma membrane cGMP-gated cation 
channel. The net effect of which is transient hyperpolarisation of the cell and a 
neural response. A similar cGMP-gated ion channel exists in cone photoreceptor 
cells, although it is encoded by a different gene [Kaupp, UB., et. al. 1989, Bonigk, 
W., et. a l 1993]. In the olfactory sensory system, a channel with a high affinity 
for cGMP and a 74% amino acid homology to the retinal cGMP-gated channel has 
been described [Kaupp, UB., 1991]. The mechanism of cGMP regulation of 
photoreceptor ion channels is discussed further in section 1.3.7.
1.2.6.2. Activation o f  cGMP dependent protein kinases
Currently, two major types of vertebrate cGMP dependent protein kinase,
the soluble type I (PKG-I) and the membrane bound type II (PKG-II) have been
recognised. PKG-I has been shown to exist in two isoforms designated a  and p
[Lincoln, TM., et. al. 1988, Wolfe, L., et. al 1989]. The protein sequences of both
forms being almost identical in their cGMP binding and catalytic regions but only
36% homology in their N-terminal ends and they have since been identified as
splice products of a single gene [reviewed, Butt, E., et. al. 1993]. PKG-I exists as
a homo dimer, whereas PKG-II exists as a monomer. The dimérisation domain of
PKG-I is in the N-terminal region, a region that also contains binding sites for
cGMP and autophosphorylation sites (Ser-50, Ser 72, Thr-58, Thr-84 in PKG-I a),
to
the function of which i^increase the rate of cGMP dissociation from the high
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affinity cGMP binding site, thus down-regulating activity following stimulation 
[Hofmann, F., et al. 1985].
Not only do the PKG isoforms differ in their monomeric or dimeric 
composition but they also have a very specific tissue distribution. The highest 
concentration of PKG-I are in cerebella Purkinje cells, smooth muscle cells and 
platelets, whereas PKG-II is predominantly located in the epithelial brush border 
of the small intestine [deJonge, HR., 1981, reviewed Butt, E., et. a l 1993].
1.3. CYCLIC NUCLEOTIDE PHOSPHODIESTERASES
1.3.1. General background
Cyclic nucleotide phosphodiesterases (PDEs) provide the sole means of 
removing cAMP and cGMP from cells by hydrolysing the 3’-phosphate diester 
bond to give the corresponding 5’-nucleoside monophosphate. This terminates 
PKA activation as cAMP can no longer bind to and activate PKA. A number of 
highly distinct PDEs exist within the cell. These are currently categorised into 
eight families by virtue of their substrate specificity, regarding cAMP and cGMP, 
their sensitivity to inhibitors and their sequence homology (Table 1.1.). PDEl 
isoforms hydrolyse both cAMP and cGMP is stimulated by Ca^^ / calmodulin, for 
which is there is a distinct recognition site [Wu, Z., et. a l 1992]. PDE2 isoforms 
hydrolyse both cAMP and cAMP but their activity is stimulated by micromolar 
concentrations of cGMP, due to binding of cGMP to a distinct regulatory site 
[Stroop, SD. and Beavo, JA. 1992, Mercy, P-F., et. al. 1995, Pyne, NJ., et. al. 
1986]. PDE3s also hydrolyse both cAMP and cGMP, but here the activity is
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Table 1.1. Summary of PDE families and their properties
Family Number K,„ Inhibitors (KJ References
Name of Genes cAMP cGMP
PDEl 3 21-35pM 1.2-5pM nicardipine 
(l-3pM ) 
IMBX (6-7pM)
Wu, Z., et. al. 
1992
PDE2 1 36|liM
(-cGMP)
20pM
(+cGMP)
llp M EHNA (l-5pM ) 
IBMX 
(20pM +cGMP) 
(40pM -cGMP)
Stroop, SD. and 
Beavo, JA. 1992. 
Mercy, P-F., et.
al. 1995. 
Pyne, NJ., et. al. 
1986.
PDE3 2 0 . 1 -
0.8pM
O.l-O.gpM cilostaniide 
(O.OSpM) 
milrinone 
(0.5pM) 
IBMX (2pM) 
cGMP (0.1 pM)
Manganiello, 
VC., et. al. 1995
PDE4 4 l-SpM 310pM Rolipram (1- 
2pM) 
RO2074 (9pM) 
IBMX(15pM)
Bolger, G. 1994. 
Lobban, M., et. 
a/. 1994 
Table 1.3.
PDE5 2 500pM 4-5pM Zaprinast 
(0.3pM) 
dipyridamole 
(O.gpM) 
IBMX (8 pM)
Francis, SH., et. 
al. 1990
PDE6 3 2mM 60pM IBMX Yamazald, A.,
1992. 
Pfister, C., et. al.
1993.
PDE7 1 0.2pM None Michaeli, T., et. 
al. 1993.
PDE8 0 0 . 1  pM 1.8pM zaprinast (23 pM) 
IBMX (26pM)
Mukai, J., et. al. 
1994.
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inhibited by micromolar concentrations of cGMP [Manganiello, VC., et. al. 1995]. 
PDE4s are cAMP specific and insensitive to cGMP or Ca^^ / calmodulin. They 
are, hov^ever, specifically inhibited by the drug rolipram [Bolger, G. 1994]. PDE5 
and PDE6  both specifically hydrolyse cGMP but differ in structure and tissue 
distribution, PDE6  is found only in photoreceptor cells [Yamazald, A., 1992, 
Pfister, C., et. al. 1993, Michaeli, T., et. al. 1993]. PDE7 specifically hydrolyses 
cAMP but is insensitive to all known PDE inliibitors, including the general PDE 
iidiibitor isobutylmethylxanthine (IBMX) [Michaeli, T., et. al. 1993]. PDE8  is a 
recently discovered PDE that does not fit with any of the above groups in that it is 
insensitive to Ca^^/calmodulin and cGMP but will hydrolyse both cAMP and 
cGMP and is insensitive to specific inliibitors of PDEl, PDE2, PDE3, PDE4 and 
PDE5. Although a species suggested as PDE8  has been suggested, no cDNA has 
yet been identified [Mukai, J., et. al. 1994].
A further level of complexity exists for the majority of the PDE families. 
This is determined by, in most cases, multiple genes in each family apart from 
PDE2, PDE7 and PDE8  and multiple splice variants of the genes in all cases but 
PDE7 and PDE8 . These variants show differences in tissue and subcellular 
distribution, susceptibility to phosphorylation and sensitivity to inhibitors. Each of 
these factors will be discussed in sections 1.3.2., 1.3.3. ,1.3.4., 1.3.5., 1.3.6., 1.3.7., 
1.3.8. and 1.3.9.
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1.3.1.1. Homology
Mammalian PDEs all possess a common structural pattern. They all 
contain a conserved domain of about 270 amino acids which displays -25-40% 
homology between PDE families and at least 70% within a PDE family. This 
domain is usually found in the C-terminal portion of the enzyme, the extreme C- 
terminal and the N-terminal regions are often extremely divergent [Charbonneau,
H. 1990]. This conserved region represents the catalytic domain of PDEs [Stroop, 
S. and Beavo, JA. 1992, Stroop, SD, et. a l 1989].
1.3.1.2. Nomenclature
Due to the large and complex gene structure of PDEs and the continuing 
discovery of new genes and slice variants, nomenclature became rather confused. 
Consequently a standard system has been devised and is outlined in figure 1.3.1.
Gene Report
RNPDE4A5A
Î Î Î
Species Gene Family Splice Variant
Figure 1.3.1. PDE Nomenclature
Example shows a type 4 PDE from rat. It denotes 
gene A of the PDE4 family and splice variant 5 of 
that gene.
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1.3.2. PDEl Calcium/calmodulin stimulated PDE
Initial studies with PDE from rat brain showed that the PDE activity could 
be activated by a protein factor and calcium [Appleman, MM., et. al. 1985], this 
protein factor later being named calmodulin [Cheung, WY., 1967, 1970, 1971, 
Kakiuchi, S. and Yamazald, R., 1970, Kakiuchi, S., et. al. 1970, Teo, TS., et. al. 
1973]. It is evident today that CaM-PDEs exist as distinct isoenzymes, encoded by 
three different genes, PDEl A (-61kDa subunit), PDE IB (-63kDa subunit) and 
PDEIC (~75kDa subunit).
Initial experiments that were performed on brain CaM-PDEs showed that 
two species could be found, these being 60kDa and 63kDa [Sharma, RK., et. al. 
1980], which were then established to be subunits of different isoenzymes by a 
series of experiments [Wang, JH., et. al. 1980]. The PDEIC gene was identified in 
brain and testes [Slienolikar, S., et. al. 1985, Rossi, P., et. al. 1988]. Each of the 
PDEl genes have been shown to be alternatively spliced. For example, PDEl A 
has two splice variants, PD ElA l (~59kDa) found in the heart and PDE1A2 
(-61kDa) found in the brain. These two genes are identical in sequence apart from 
their extreme N-termini which contain unique sequences [Taira, M., et. al. 1993, 
Beltman, J., et. al. 1993]. Additionally, structurally related PDE IB splice variants 
have been identified by RNase protection assays in brain, kidney and adrenal 
medulla [Bentley, JK., et. al. 1992, Repaske, DR., et. al. 1992, Sonnenberg, WK., 
et. al. 1993].
PDE Is are found in virtually all other mammalian tissues at relatively low 
levels, with the exception of human peripheral blood lymphocytes and monocytes
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[Thompson, WJ, et. al. 1980]. Levels can be so low that a few tissues were 
originally determined not to contain PDE Is, mainly due to high levels of other 
PDE activities. However, with the development of better separation techniques 
such as anion exchange cliromatography, the PDEl activity was identified in these 
tissues, e.g. sperm [Wasco, WM. and Orr, GA., 1984]. Mammalian brain is the 
richest source of CaM-PDEs, where it is enriched in certain regions, particularly 
the large pyramidal cells of the cerebral cortex, the pyramidal cells of the 
hippocampus and olfactory nucleus and Purkinje cells of the cerebellum [Kincaid, 
RL., et. al. 1987]. Mammalian heart is the tissue where CaM-PDEs are next most 
abundant, although ten fold less than brain [La Porte, DC., et. al. 1979]. Most of 
the CaM-PDE isoforms are cytosolic, although a fraction of brain enzyme is found 
to membrane associated and indeed, PDEIC in rat sperm displays 100% 
membrane association [Wasco, WM. and Orr, GA., 1984, Chaudhry, PS. and 
Cassilas, ER. 1988].
The N-terminal region of isoforms from all tlmee PDEl genes contain a 
domain that is predicted to form a basic amphipathic helix which is homologous to 
the Ca^VCaM binding domain of other proteins [Novae, JP., et. al. 1991]. 
Although species from all three genes are activated by Ca^"^/CaM, their affinities 
for Ca^VCaM varies. For example the affinities of the 611<Da PDEIA and the 
63kDa PDEIB form are almost identical but the 59kDa PDEIA form, which 
differs from the 61kDa PDEIA form only in the N-terminal region, has a much 
higher affinity [Charbomaeau, H., et. al. 1991]. The activation of PDEl s over basal 
level by Ca^VCaM is of the order of 6-20 fold. However, large variations in these
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figures have been published. This may have been due to impure preparations of 
the PDEs, but is more likely to have been as a result of proteolysis, to which 
PDE Is are extremely sensitive. Proteolysis often results in a CaM independent 
activated form [Ho, HC., et. al. 1976].
Fui'ther regulation of PDE Is comes from protein phosphorylation, various 
isoforms are phosphorylated by PKA [Shaiina, RK, and Wang, JH. 1985] and 
others by Ca^VCaM dependent protein kinase-II [Sharma, RK, and Wang, JH. 
1986, Zhang, GY., et. al. 1990, Hashimoto, Y., et. al. 1989]. The effect of the 
phosphorylation by both enzymes is to decrease the affinity of the enzyme for 
Ca^VCaM, thus down regulating its activity. Phosphorylation by PKA can be 
blocked by Ca^VCaM [Sharma, RK, and Wang, JH. 1985]. Both phosphorylations 
can be removed by the action of Ca^VCaM-stimulated phosphatase [Zhang, GY., 
et. al. 1990], consequently both the phosphorylation and dephosphorylation 
reactions are controlled by second messengers.
1.3.3. cGMP stimulated PDEs (PDE2)
PDE2s, or cGMP-stimulated PDEs (cGS-PDEs) were initially described in 
experiments done on rat liver supernatant [Beavo, JA., et. al. 1970] and in the 
crude particulate fractions from several tissues, particularly brain [Beavo, JA., et. 
al. 1971]. The purified bovine cardiac PDE2 has been shown to exist as a 
homodimer with subunits of ~105kDa and has been completely sequenced [Trong, 
HE., et. al. 1990]. Only one gene has been identified for PDE2 and yet, both 
particulate and soluble forms are found [Pyne, NJ. et. al. 1986]. However, peptide
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maps generated fiom purified bovine brain and liver cytosolic PDE2s [Pyne, NJ. 
et, al. 1986, Tanaka, T., et. a l 1991, Mui'asliima, S., et. a l 1990], RNase 
protection assays [Sonnenberg, WK., et. al. 1991] and sequence analysis of rat 
brain PDE2 [Epstein, P., et. a l 1994] are consistent with generation of brain and 
cardiac membrane associated PDE2 isoforms by alternative splicing.
PDE2s hydrolyse both cAMP and cGMP with positively co-operative 
kinetics, thus at saturating levels of cyclic nucleotides, the hydrolysis of one can 
be stimulated by the other [Moss, J., et. a l 1977]. After treatment with 
chymotrypsin, a PDE2 fragment of ~36kDa, which did not exhibit positively co­
operative kinetics with respect to cAMP, was separated fi*om a 60kDa N-terminal 
cGMP-binding fragment [Stroop, SD, et. al. 1989, Stroop, S. and Beavo, JA. 
1991, Stroop, S. and Beavo, JA. 1992]. These studies were performed by 
photolabelling with high specific activity [^^P]cGMP and ultraviolet irradiation, 
demonstrating that the intact enzyme was labelled in a biphasic manner, with 
labelling affinities of about IpM  and 30pM. However, the two unique 
photolabelled sites could be separated by the proteolysis with chymotrypsin 
[Stroop, SD, et. al. 1989]. Binding to the 361cDa fragment could be abolished by 
pre-treatment with cAMP prior to photolabelling and since PDE2s hydrolyse 
cAMP as well as they do cGMP, this was thought to be the catalytic C-terminal 
region, which was later confirmed by sequencing. This demonstrated the existence 
of two functional domains, one C-terminal and catalytic and the other N-terminal 
and regulatory. The N-terminal region possesses a sequence of about 400 amino 
acids which contains a tandem repeat homologous to one found in the retinal rod
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PDE5 and represents a putative cGMP binding domain [Stroop, S, and Beavo, JA.,
1992]. A region between the catalytic domain and the non-catalytic cGMP- 
binding site has been identified as a bridge or hinge region [Stroop, SD, et. a l
1989] and it has been identified as a dynamic intermediate in the activation of 
PDE2 by cGMP, the allosteric changes being transmitted to the catalytic region 
via the this bridge.
1.3.4. cGMP-inhibited PDEs (PDE3)
Properties and characteristics of PDE3s have been studied with highly 
purified as well as partially purified preparations from a number of sources. The 
catalytic properties and inliibitor sensitivities of the highly purified preparations of 
PDE3s are very similar. Essentially they are considered to be cAMP specific, 
since, although the K,  ^values for cAMP and cGMP are similar, in the 0.1-0.8pM 
range, the for cAMP being 10-20 fold higher than for cGMP [Degerman, E., 
et. a l 1995, Rascon, A., et. a l 1992, Pyne, N., et. a l 1987, and reviewed 
Manganiello, VC. et. a l 1995]. Thus cGMP is hydrolysed only at a very low rate. 
Another characteristic that defines PDE3s is their sensitivity to inhibition by 
certain drugs that augment myocardial contractility, inhibit platelet aggregation 
and relax smooth muscle. Examples of such drugs are cilostamide, milrinone and 
OPC3911, with IC 5 0  values of <0.1 pM, 0.5pM and 0.1 pM respectively [reviewed 
Manganiello, VC. ei. a l 1995].
cDNAs encoding two subfamilies of PDE3s have been identified (PDE3A 
and PDE3B) and cloned from rat and human adipose and cardiac sources, with
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multiple species of RPDE3B being cloned [Taira, M., et. al. 1993]. The domain 
structure of these PDEs is similar to that of all other PDEs, with homologous C- 
terminal regions, containing the putative catalytic domain and N-terminal 
regulatory domains that contain hydrophobic, putative membrane association 
domains [Taira, M., et. al. 1993]. Within the putative catalytic region is an 
insertion of 44 amino acids that is not found in any of the other PDE families. This 
insertion differs in sequence between PDE3A and PDE3B [Meacci, E., et. al. 
1992, Taira, M., et. al. 1993]. This region has been termed the PDE3 insertion.
Incubation of intact adipocytes, hepatocytes or platelets with agents that 
activate adenylyl cyclase and elevate cAMP leads to the activation of PDE3 
[Manganiello, VC., et. al. 1995a, Beltman, J., et. al. 1993]. This activation is 
thought to be important in feedback regulation of cAMP levels and PKA 
activation state. Several studies indicate that activation is as a consequence of 
PKA phosphorylation of PDE3 [Kilgour, E., et. al. 1989, Degerman, E., et. al. 
1990, Smith, CJ., et. al. 1991]. It has been proposed that at least two
phosphorylation sites exist in rat liver dense-vesicle PDE3, one which effects
activity and the other that does not affect activity but prevents the activating 
phosphorylation from occurring [Kilgour, E., et. al. 1989]. In frog ventricle, 
however, a PDE3, that is membrane associated, is inhibited by glucagon via a 
pertussis toxin-sensitive G-protein [Brechler, V., et. al. 1992], clearly indicating 
defined functions for different PDE3 species
Incubation of rat adipocytes results in rapid phosphorylation and activation 
of PDE3B. The result of which is a reduction in cAMP, PKA activity, hormone-
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stimulated lipase activity and lipolysis [Degerman, E., et. al. 1995,]. The insulin 
sensitive kinase responsible has been partially purified and its action has been 
shown to be blocked by wortmamain, suggesting that insulin activation of 
phosphotidylinositol-3 -kinase (PI3-K) is an important upstream event in the 
activation of the adipocyte PDE3B [Rahn, T., et al. 1994]. The role of 
phosphorylation has been confirmed by incubating adipocytes with okadaic acid, a 
protein phosphatase inhibitor, resulting in activation of the kinase [Shibita, H., et 
al. 1991
1.3.5. cAMP-specific phosphodiesterases (FDE4)
1.3.5.1. Introduction
The cAMP specific PDE4 family are a diverse family of proteins that are 
important regulators of intracellular signalling and have been shown exhibit an 
extremely complex gene structure [Bolger, G. 1994]. They are encoded by four 
genes, PDE4A, PDE4B, PDE4C and PDE4D, each of which displays alternative 
splicing to generate multiple proteins from each gene [Bolger, G. 1994]. The 
family is distinguished by its high and specific affinity for cAMP and its 
sensitivity to specific inhibitors that include the antidepressant drug rolipram 
[Beavo, JA., et. a l 1994, Conti, M., et a l 1991, Beavo, JA. and Reifsnyder, DH. 
1990, Thompson, WJ. 1991]. PDE4s ai’e the closest mammalian homologues to 
the dunce gene of Drosophila melanogaster, which was isolated as a mutation 
effecting learning and memory [Qiu, Y. e t al. 1991, Qiu, Y. and Davis, R. 1993]. 
Each of the genes encode putative catalytic regions that have a high degree of
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homology and are identical within the splice variants any particular gene [Bolger, 
G. 1994]. The N-terminal regions, however, are extremely divergent, even 
amongst closely related splice variants, although, two conserved regions are found 
within the N-terminal regions and have been termed UCR-1 and UCR-2 [Bolger, 
G., et. al. 1993]. These may have a regulatory role and will be discussed later.
A variety of approaches have been used to clone members of the PDE4 
family. The first approach was to use the cDNA of the Drosophila melanogaster 
dunce gene to screen mammalian cDNA libraries [Davis, RL., et. al. 1989, 
Henkel-Tiggs, J. and Davis, RL. 1990]. A second approach was to isolate cDNAs 
that could suppress the heat shock-sensitive phenotype of Saccharomyces 
cerevisiae with mutations in the RAS-cAMP pathway. Activating mutations of 
this pathway produce their phenotype by elevating cAMP levels and the 
introduction of a PDE into these cells can lower the cAMP levels sufficiently to 
restore heat shock resistance. PDEs from rat and humans have been isolated by 
this approach [Colicelli, J., et. al. 1989, Colicelli, J., et. al. 1991, Michaeli, T., et. 
al. 1993]. PGR has also been employed, with oligonucleotide primers designed to 
amplify DNA sequences with homology to both dunce and previously isolated 
PDE4s [Bolger, G., et. al. 1994a]. A number of rat and human genes have been 
isolated and each shows a one to one homology, in that each rat gene is more 
closely related to its hmnan counterpart than to any of the other rat genes PDE4s 
[Bolger, G., et. a l 1994a].
Comparison of the amino acid sequences of Drosophila dunce and human 
PDE4s demonstrates regions of strong conservation of within their coding regions.
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Tliree regions of homology are seen, one of these is the putative catalytic region 
[Jin, SLC., et. a l 1992] which is 90% homologous in all PDE4 genes, and the 
other two are UCR-1 and UCR-2. UCR-1 and UCR-2 appear to be distinct 
features of the PDE4 family, as these regions are strongly conserved between 
organisms as evolutionary diverse as Drosophila melanogaster and humans 
[Figure 1.3.2.] but have no close homologues in any other sequence in the 
GenBanlc or EMBL databases [Bolger, G,, et. a l 1993]. UCR-1 and UCR-2 are 
distinct in that they are separated by a region of low homology and given the 
strong evolutionary conservation, they may encode distinct structural domains that 
have an essential function [Bolger, G., el a l 1993, Bolger, G., 1994], Indeed, 
parallels may be drawn to the regulatory domains of other PDE families, such as 
the cGMP binding domain of PDE Is and the Ca^Vcalmodulin binding domain of 
PDE2s which aic also N-terminal and strongly conserved between each PDE of 
the family.
1.3.5.2. PDE4A
The gene for PDE4A is localised on chromosome 19, the same 
chromosome but a different locus to PDE4C and on a different chromosome to the 
PDE4B and PDE4D genes [Milatovich, A., et. a l 1994, Horton, Y., et. al. 1995]. 
The structure of the gene is extremely complex, containing in excess of 14 exons 
and is found between the genes for TYK2 and the LDL receptor [Olsen, A., 
Sullivan, M. and Houslay, MD. unpublished data]. In rat, it is now known that the 
PDE4A gene encodes tlnee splice variants, the shortest of which is RDI
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MEPPTVPSERSLSLSLPGPREGQATLKPPPQHLWRQPRTPIRIQQRGYSD4A5 
MKKSRSVMTVMADDNVKDYFECSLSKSYSSSSNTLGID 4B1
4D3
Drosophila
SAERAERERQPHRPIERADAMDTSDRPGLRTTRMSWPSSFHGTGTGSGGA 4A5 
LWRGRRCCSGNLQLPPLSQRQSERARTPEGDGISRPTTLPLTTLPSIAIT 4B1
MMHVNNFPF 4D3
Drosophila
GGGSSRRFEAENGPTPSPGRSPLDSQASPGLVLHAGAATSQRRESFLYRS 4A5 
TVSQECFDVENGPSPGRSPLDPQASSSAGLVLHATFPGHSQRRESFLYRS 4B1 
RRHSWICFDVDNGTSAGRSPLDPMTSPGSGLILQANFVHSQRRESFLYRS 4D3
FDVENGGGARSPLEGGSPSAGLVLQNLPQRRESFLYRS Drosophila 
— UCRl ■ ■ ,1
DSDYDMSPKTMSRNSSVTSEAHAEDLIVTPFAQVLASLRSVRSNFSLLTN 4A5 
DSDYDLSPKAMSRNSSLPSEQHGDDLIVTPFAQVLASLRSVRNNFTILTN 4B1 
DSDYDLSPKSMSRNSSIASDIHGDDLIVTPFAQVLASLRTVRNNFAALTN 4D3 
DSDFEMSPKSMSRNSSIASESHGEDLIVTPGAQILASLRSVRNNLLSLTN Drosophila
VPVP-SNKRSPLGGPTPVCKATLS------ EETCQQLARETLEELDWCL 4A5
LHGT-SNKRSPAASQPPVSRVNPQ------ EESYQKLAMETLEELDWCL 4B1
LQDRAPSKRSPMCNQPSINKATIT------ EEAYQKLASETLEELDWCL 4D3
VPA— SNKRRPNQSSSASRSGNPPGAPLSQGEEAYTRATDTTIEELDWCL Drosophila
 UCR2 — - ■ ■
EQLETMQTYRSVSEMASHKFKRMLNRELTHLSEMSRSGNQVSEYISTTFL 4A5 
DQLETIQTYRSVSEMASNKFKRMLNRELTHLSEMSRSGNQVSEYISNTFL 4B1 
DQLETLQTRHSVSEMASNKFKRMLNRELTHLSEMSRSGNQVSEFISNTFL 4D3 
DQLETIQTHRSVSDMASLKFKRMLNKELSHFSESSRSGNQISEYICSTFL Drosophila
I tDKQNEVEIPSPTMKEREKQQAPRPRPSQPPPPPVPHLQP---- MSQITG 4A5
DKQNDVEIPSPTQKDREKKKKQQL--------------------MTQISG 4B1
DKQHEVEIPSPTQKEKEKKKRP---------------------- MSQISG 4D3
DKQQEFDLPSLRVEDNPELVAANAAAGQQSAGQYARSRSPRGPPMSQISGZ>ros<i/7/i//a
li     —LKKLM-HSNSLNNSNIPRFGVKTDQEELLAQELENLNKWGLNIFCVSDYA4A5
VKKLM-HSSSLNNTSISRFGVNTENEDHLAKELEDLNKWGLNIFNVAGYS 4B1
VKKLM-HSSSLTNSSIPRFGVKTEQEDVIiAKELEDVNKWGLHVFRIAELS 4D3
VKRPLSHTNSFTGERLPTFGVETPRENELGTLLGELDTWGIQIFSIGEFS Drosophila
GGRSLTCIMYMIFQERDLLKKFRIPVDTMVTYMLTLEDHYHADVAYHNSL 4A5 
HNRPLTCIMYAIFQERDLLKTFRISSDTFITYMMTLEDHYHSDVAYHNSL 4B1 
GNRPLTVIMHTIFQERDLLKTFKIPVDTLITYLMTLEDHYHADVAYHNNI 4D3 
VNRPLTCVAYTIFQSRELLTSLMIPPKTFLNFMSTLEDHYVKDNPFHNSL Drosophila
HAADVLQSTHVLLATPALDAVFTDLEILAALFAAAIHDVDHPGVSNQFLI 4A5 
HAADVAQSTHVLLSTPALDAVFTDLEILAAIFAAAIHDVDHPGVSNQFLI 4B1 
HAADWQSTHVLLSTPALEAVFTDLEILAAIFASAIHDVDHPGVSNQFLI 4D3 
HAADVTQSTNVLLNTPALEGVFTPLEVGGALFAACIHDVDHPGLTNQFLVZ>ro^O/;/lf7fl
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Highly conserved Catalytic Region NTNSELALMYNDESVLENHHLAVGFKLLQEDNCDIFQNLSKRQRQSLRKM 4A5 
NTNSELALMYNDESVLENHHLAVGFKLLQEEHCDIFMNLTKKQRQTLRKM 4B1 
NTNSELALMYNDSSVLENHHLAVGFKLLQEENCDIFQNLTKKQRQSLRKM 4D3 
NSSSELALMYNDESVLENHHLAVAFKLLQNQGCDIFCNMQKKQRQTLRKM Drosophila
VIDMVLATDMSKHMTLLADLKTMVETKKVTSSGVLLLDNYSDRIQVLRNM 4A5 
VIDMVLATDMSKHMSLLADLKTMVETKKVTSSGVLLLDNYTDRIQVLRNM 4B1
v i d i v l a t d m s k h m n l l a d l k t m v e t k k v t s s g v l l l d n y s d r i q v l q n m 4D3
VIDIVLSTDMSKHMSLLADLKTMVETKKVAGSGVLLLDNYTDRIQVLENM Drosophila
VHCADLSNPTKPLELYRQWTDRIMAEFFQQGDRERERGMEISPMCDKHTA 4A5 
VHCADLSNPTKSLELYRQWTDRIMEEFFQQGDKERERGMEISPMCDKHTA4B1 
VHCADLSNPTKPLQLYRQWTDRIMEEFFRQGDREREROIEISPMCDKHNA 4D3 
VHCADLSNPTKPLPLYKRWVALLMEEFFLQGDKERESOffi) ISPMCDKHNA Drosophila
SVEKSQVGFIDYIVHPLWETWADLVHPDAQEILDTLEDNRDWYYSAIRQS 4A5 
SVEKSQVGFIDYIVHPLWETWADLVQPDAQDILDTLEDNRNWYQSMIPQS 4B1 
SVEKSQVGFIDYIVHPLWETWADLVHPDAQDILDTLEDNREWYQSTIPQS 4D3 
TIEKSQVGFIDYIVHPLWETWASLVHPDAQDILDTLEENRDYYQSMIPRS Drosophila
=nPSPPPEEESRGPGHPPLPDKFQFELTLEEEEEEEISMA........... 4A5
PSPPLDEQNRDCQGLMEKFQFELTLDEEDSEGPEKEGE 4B1
PSPAPDDPEEGRQGQTEKFQFELTLEEDGESDTEKDSG........... 4D3
PSPSGVDENPQEDRIRFQVTLEESDQENLAELEEGDES........... Drosophila
Figure 1.3.2. Homology between PDE4 genes.
Shows the sequence homology between four distinct PDE4 forms, the human 
PDE4A species, PDE46 (HSPDE4A5), the human PDE4B species, PDE4B1, the 
human PDE4D species, PDE43 (HSPDE4D3), and the Drosophila melanogaster 
dunce gene, dnc. The C-termini of these sequences have been truncated here and 
exons one and two of dnc are not shown. The upstream conserved regions, UCRl 
and UCR2 are indicated and are in bold text, also in bold is a homologous region, 
C-terminal to the UCR regions which contains the putitive catalytic region. 
PDE4C is not shown due to concerns about clones that are 5’ truncated (section
I.3.5.4.)
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(RNPDE4A1A) which lacks the UCR-1 region and the N-terminal portion of 
UCR-2 [Davis, RL., et. a l 1989]. Whether this has significance to the function of 
RDI remains to be seen. The longer species are rpde6  (RNPDE4A5) [Bolger, G., 
et. a l 1994a, McPhee, I., et. a l 1995] and rPDE39 (RNPDE4A8) [Bolger, G., et. 
a l 1996]. A schematic diagram of their structure is given in Figure 1.3.3. Initially 
RD2 (RNPDE4A2) and RD3 (RNPDE4A3) [Davis, RL., et. a l 1989] were 
suggested as splice variants, but these are now considered to be attributable to 
cloning artefacts or errors in sequencing [Bolger, G., et. al. 1993, Bolger, G., et. 
a l 1994a].
rpde39
merRDl
PDE4A
rpde6 RDI
Consensus
UCR-1 UCR-2 Catalytic
Figure 1.3.3. Splice variant diagram for rat PDE4A.
Shows splice variants of the PDE4A gene from rat, rpdeb, :ipde39^ and RDI. 
met^^RDl is an engineered truncation that lacks any N-terminal splice regions The 
empty rectangle represents the core C-terminal catalytic region that is identical in 
each of the PDEs. The shaded areas represent alternatively spliced regions and the 
empty circles splice junctions.
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In hmnans, three PDE4A splice variants have been isolated to date. Only 
one of these hPDE46 (HSPDE4A5), the human homologue of rpdeb, is a 
catalytically active species [Bolger, G., et. a l 1993, Bolger, G., et. a l 1996]. Two 
other clones have been identified which possess both unique N- and C-terminal 
regions. The unique C-terminal regions, however, leads to the foreshortening of 
the putative catalytic region, producing proteins which fail to exhibit any catalytic 
activity [Plorton, Y., et. a l 1995, Bolger, G., el a l 1993]. The function of these 
inactive species has yet to be determined. To date, no human homologues of RDI 
or rPDE39 have been identified.
The expression patterns of the rat PDE4A splice valiants appear to be 
profoundly different. RDI is found exclusively in the brain [Bolger, G. 1994, 
Davis, RL., et. a l 1989, Bolger, G., 1994a, Shakm, Y., et. a l 1995], rPDE39 is 
found in testes [Bolger, G., et. a l 1996] and hepatocytes [Zeng, L. and Houslay, 
MD., unpublished data] and rpde6  is expressed in a number of different tissues, 
although the highest levels of expression are in the brain [Bolger, G. 1994a]. 
Although both RD1 and rpde6  are expressed in brain, their distribution thioughout 
regions of the brain is profoundly different (table 1.2.). It can be seen that while 
RDI is distributed through all regions of the brain, rpde6  is not expressed in either 
the brain stem or cerebellum. This differential expression pattern presmnably 
reflects cell specific differences in alternative splicing and perhaps the presence of 
distinct promoters.
On a subcellular level, RDI is fomid associated exclusively with 
membranes, particularly the plasma membrane, golgi apparatus and intracellulai*
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vesicles [Shakui’, Y., et. al. 1995], rpdeô is foimd distributed between the cytosol 
(74%), membrane (13%) and low speed pellet (13%) [McPhee, L, et. al. 1995]. 
rPDE39, like rpdeb, is fomid distributed between the membrane (15%) and cytosol 
(85%) but unlike rpdeô, is not found associated with the low speed pellet [Bolger, 
G., et. a l 1996]. If however, the artificially truncated PDE4A, met^^RDl (figure 
1.3.2), which lacks any splice regions and is catalytically active, is expressed in 
COS cells it is rendered entirely cytosolic [Shakur, Y., et. a l 1993]. This would 
imply that the subcellular distribution of the rat PDE4As is determined by their N~ 
terminal splice region since, in each case, their C-termini are identical.
Table 1.2. Distribution of rpde6 and RDI in brain regions
Relative distribution (percentage PDE4 activity ± SD) of these two splice variants 
was determined by immunoblotting [McPhee, I., et. a l 1995].
Region rpde6 Cytosol rpde6 Membrane RDI Membrane
Brain Stem 0 0 4+2
Cerebellum 0 0 1 0 + 1
Cortex 35+5 27+4 25+3
Hippocampus 10+3 14±3 17+2
Hypothalamus 20+3 25+4 8 + 1
Mid-Brain 5+2 6 + 2 16+2
Pituitary 0 0 0
Striatum 30+4 28+4 20+3
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Evidence to support this theory has come from studying the membrane 
association of RDI which was shown to be determined by a sequence of amino 
acids within the N-terminal splice region [Scotland, G. and Houslay, MD., 1995]. 
Analysis of the N-terminal structure was done by ^H-NMR and four structural 
components were identified; an N-terminal amphipathic helical domain, followed 
by a highly mobile hinge region, then a distorted helical region made up of seven 
residues, three of which are tryptophans that form a well ordered hydrophobic 
domain and finally a further helical region [Smith, KJ., et. al. 1996]. Given this 
structure it is unlikely that it could insert into membranes, nor could it form an 
integral transmembrane protein since met^^RDl is only 26 amino acids shorter and 
is entirely cytosolic. It is more likely, therefore, that it associates with a membrane 
bound anchoring protein
To investigate which regions of the N-terminal 23 amino acids of RDI 
confer membrane association, an in-frame chimera of these was made by fusing it 
to the N-terminus of a bacterial enzyme, chloramphenicol acetyl transferase 
(CAT). When CAT alone was expressed in COS cells, it was entirely cytosolic. 
Expression of the fusion protein, however, was entirely membrane-associated 
[Scotland, G, and Houslay, MD., 1995]. Deletion analysis of the structural 
domains of the N-terminus was also done using these CAT-chimeras and it was 
shown that the membrane association was determined by the distinct tryptophan- 
rich domain that forms a compact distorted helical structure [Smith, KJ., et. al. 
1996]. Given the structure of this domain, hydrophobic interaction might explain 
why RDI could not be washed off membranes by using high salt but could be
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solubilised with very low concentrations of the detergent Triton X-100 [McPhee, 
I., et. al. 1995].
No homology between the N-terminal regions of ipde6 and rPDE39 to 
RDI is apparent. The membrane association of these proteins would therefore 
seem likely to be conferred by a different mechanism, the nature of which remains 
to be investigated.
Another function of the N-terminal regions is their control of catalytic 
activity. met^^RD 1 encodes a highly active cytosolic PDE when expressed in COS 
cells [Shakur, Y., et. al. 1995]. However, determination of the activities o f the 
other splice variants, relative to met^^RDl gave values'of 0.5, 0.15 and 0.15 for 
RDI, rpde6 and rPDE39 respectively [McPhee, I., et. al. 1995, Bolger, G., et. al. 
1996, Shakur, Y., et. al. 1995]. The splice regions therefore attenuate the PDE 
activity, the mechanism of which is not Icnown.
Clearly the PDE4A N-terminal splice regions regulate subcellular 
localisation, catalytic activity and are expressed in a tissue specific manner. 
Exactly what elements within the N-terminal region of ipde6 and rPDE39 define 
the localisation remain to be determined as does the physiological function of 
localising PDEs to distinct subcellular regions.
1.3.5.3. PDE4B
As with the PDE4A gene, a number of splice variants of the PDE4B gene 
have been identified, although it is still not clear how many of these represent 
endogenously expressed species. At the time this thesis commenced, the most 
Values are Vmax relative to the Vmax for met^^RDl.
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likely candidates for full length clones were DPD (RNPDE4B1) [Collicelii, J., et. 
al. 1989] and rPDE4 (RNPDE4B2A) [Swinnen, JV., et. al. 1991]. A human 
equivalent of rPDE4, HSPDE4B2A, has been cloned [McLaughlin, MM., et. a l
1993] However, the discovery of a ' human homologue of DPD, TM72 
(HSPDE4B1) which is extended at the N-terminus has supported the hypothesis 
that both PDE4B1 clones are not full length [Bolger, G., e l a l 1993]. Absolute 
identity of sequence is seen between rPDE4 and the current DPD clone, except for 
an N-terminal extension of 48 amino acids in rPDE4 [Monaco, L., et. a l 1994]. 
More recently, a further human clone has been identified, PDE4B3 [Owens, R. 
and Houslay, MD. personal communication], which is identical to DPD along 
DPD’s entire length. However, like PDE4B2, PDE4B3 has an N-terminal 
extension. This data would indicate that the point at which DPD was proposed to 
start represents a splice j miction, onto which unique N-terminal domains are 
added, as seen in each of the human clones.
The distribution of rPDE4 and DPD has been well characterised in rat 
brain [Lobban, M., et. a l 1994]. It should be noted that at the time of this work, 
DPD was considered M l length. The species characterised by Lobban [Lobban, 
M., et. al. 1994] might now be considered either to be a proteolytic degradation 
product, possibly truncated rPDE4, or an as yet unidentified splice variant. DPD 
and rPDE4 display very different subcellular localisations, DPD being entirely 
cytosolic and rPDE4 entirely membrane associated, indicating that the N-terminal 
region of rPDE4 is responsible for the membrane attachment [Lobban, M., et. a l
1994]. Distribution of the two isoforms tliroughout various brain regions does
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however reveal differences in their expression [Lobban, M., et. al. 1994]. The 
pituitary contained no immunoreactive material for either DPD or rPDE4, the 
cerebellum, brain stem and mid brain contained no DPD but expressed rPDE4 
whereas the striatum, hypothalamus, hippocampus and cortex expressed both 
species. This does not however rule out the possibility that DPD represents 
proteolysed rPDE4 since the preparations from cerebellum, brain stem and mid 
brain may simply have been less proteolysed. It is intriguing that DPD was found 
to contribute 13-35% of the total PDE4 activity in brain cytosol and rPDE4, 40- 
50% of the PDE4 activity in the membranes in all brain regions apart from the 
mid-brain where it only represented 20% [Lobban, M., et. al. 1994]. This means 
that PDE4Bs, regardless of the species, must play a significant role in cAMP 
metabolism in the brain.
The rat PDE4B mRNAs expressed in the Sertoli cell are derived from the 
assembly of 11 exons, exons 5-10 encoding the catalytic region [Monaco, L., et. 
al. 1994]. This leaves the remaining six exons to code for ‘regulatory’ regions that 
have the potential for alternative splicing. Furthermore, Monaco and colleagues 
[Monaco, L., et. al. 1994] report that rPDE4 mRNA is likely to be expressed in 
brain containing additional 5’-exons, since the 5’-untranslated sequence has nine 
AUG codons in tliree reading frames. However, each of these is followed by stop 
codons, determining the presence o f short open reading frames which have been 
hypothesised to reduce the translatability of the mRNA, slowing the translation 
rate [Kozac, M. 1991].
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Clearly the debate is still open as to the exact nature of PDE4Bs and 
longer, alternatively spliced species may still be found.
1.3.5.4. PDE4C
In contrast to the other PDE4 genes, little is known about the PDE4C gene. 
Until very recently no full length clones had been identified for PDE4C, although 
two partial coding sequences were identified in the rat, rPDEl (RNPDE4C1A) 
[Swinnen, JV., et. al. 1989] and rPDE36 (RNPDE4C1B) [Bolger, G., et. al 
1994a] and one partial human clone, DPDEl (HSPDE4C1), [Bolger, G,, et. al
1993]. Recently a full length human clone has been reported [Engels, P. et. al
1995], which, unlike the other PDE4 genes, is not expressed at all in the immune 
system [Engels, P. et. a l 1995] and in stark contrast to the rat, is detected in the 
brain. Rat PDE4C is detected only to extremely low levels in the brain, perhaps 
indicating a species specific expression pattern.
1.3.5.5. PDE4D
The PDE4D gene is perhaps the best characterised, with the greatest 
number of splice variants identified of any of the other PDE4 genes, with five 
human variants identified. Each of these splice variants possess identical C- 
terminal catalytic regions and have uniquely spliced N-terminal domains [Nemoz, 
G., et. a l 1995, Bolger, G., et. al 1996a] (Figure 1.3.4.). The structure can be seen 
to be remarkably similar to the PDE4 gene, as with the case of RDI 
(RNPDE4A1), there are two PDE4D splice variants, PDE4D1 and PDE4D2, 
which have the UCR-1 region spliced out [Bolger, G., et. a l 1993], the functional
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significance of which is not Icnown. The only difference between these two genes 
is an insertion of 79 amino acids in the N-terminal region of PDE4D1, the 
function of which is not Imown. Three further splice variants have been identified, 
PDE4D3 [Sette, C., et. a l 1994, Baecker, PG., et. a l 1994], PDE4D4 [Bolger, G., 
et. a l 1993] and PDE4D5 [Bolger, G., et. a l 1996a].
Each of the PDE4D splice variants shows different tissue and subcellular 
distributions. At a subcellular level, PDE4D1 and PDE4D2 are entirely cytosolic, 
whilst the other splice variants show a distribution of 20-30% associated with the 
membrane, a fuither 1 0 % with the low speed pellet and the remainder in the 
cytoplasm [Bolger, G., et. a l 1996a]. This is not dissimilar to the PDE4A gene 
and
D5
D4L
D 3 i
UCR-1 UCR-2 Catalytic
]  PDE4D
Consensus
Figure 1.3.4. PDE4D splice variants.
Shows splice variants of the human PDE4D gene. The empty rectangle represents 
the core, catalytic region common to all species. The shaded areas are unique, 
alternatively spliced, regions and the circles splice junctions
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again, suggests that this differential distribution is conferred by the N-terminal 
splice regions.
A functional attribute of one of these PDE4D splice variants is that PKA 
can phosphorylate PDE4D3 within its N-terminal region [Sette, et. al. 1994]. No 
phosphorylation has been reported with the other PDE4D splice variants. This 
phosphorylation also occurred in intact cells expressing three isoforms as a result 
of incubation with dihutyryl cAMP. Two effects of this phosphorylation are seen. 
Firstly, there is an increase in enzyme activity which may be of importance in 
regulating cAMP levels that have been increased tlu'ough hormonal activation. For 
example, thyroid stimulating hormone (TSH) stimulation of rat thyroid FRTL 
cells causes and elevation of cAMP levels and results in a PKA mediated 
phosphorylation of PDE4D3. Secondly, sensitivity to PDE4 specific inhibitors, 
RS-25334 and RS-33793 is dramatically increased, 100 and 330 fold respectively 
[Avarez, R., et. al. 1995]. There are two consensus sites for PKA mediated 
phosphorylation of PDE4D3, Ser^  ^ and Ser^ "^ , both of which are phosphorylated, 
but it has been suggested that only Ser^ "^  is involved in activation of the enzyme. 
Ser^ "^  lies within UCR-1 [Sette, C. and Conti, M. 1995], perhaps this indicating 
one of the functions of the evolutionary conserved regions. UCR-1 however lies in 
a region that is shared by PDE4D3, PDE4D4, PDE4D5 and none of these have 
been formd to be phosphorylated by PKA [Sette, C. and Conti, M. 1996], as well 
as PDE4A, PDE4B and PDE4C which preliminary reports [Sette, C. and Conti, 
M. 1996] show cannot be activated by PKA dependent phosphorylation of Ser^ "^ . 
This might imply that Ser^ "^  maybe phosphorylated in all species but the kinases
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maybe different in each case, perhaps a fimction determined by the unique regions 
within the species.
It is evident that the PDE4D gene encodes a number of different splice 
variants that are differentially regulated by virtue of their N-terminal domains. 
One splice variant has been shown to be regulated by phosphorylation, however 
details of their suhcellular distribution remains to be determined.
1.3.5.6. Therapeutic use ofPDE4 inhibitors
The initial therapeutic possibilities of PDE4 inliibitors goes back 20 years 
to the discovery of a compound called rolipram [Schwabe, U., et. al. 1976]. 
Several studies on partially purified PDE4 preparations from smooth muscle and 
heart indicated that it serves as a competitive, non-stereo-selective PDE4 inhibitor 
(low pM) [Reeves, ML., et. a l 1987, Torphy, TJ. and Cieslinski, LB 1990]. 
Recent work, however, has demonstrated that rolipram has an IC 5 0  in the sub pM 
range [Souness, JE. and Scott, LC. 1993, Somiess, JE., et. al. 1995, Alvarez, R., 
et. a l 1995]. Rolipram has been shown to serve as an antidepressant. This may 
reflect the high concentration of PDE4 isoforms in brain and consistent with this 
role for PDE4s in CNS function, the PDE4 related dunce PDE influences learning 
and memory in Drosophila melanogaster [Davis, RL., et. a l 1989] and cAMP 
exerts similar' influences in mouse.
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More recently the therapeutic focus of PDE4 inhibitors has focused on 
their inliibitory effects on the ftinctions of several immunocompetent / 
inflammatory cells [Reviewed, Palffeyman, MN. and Souness, JE. 1996] and a 
number of more potent compoimds than rolipram have been identified (Table
1.3.). A great deal of interest has focused on the anti-astlima potential of PDE4 
inliibitors and their ability to potently suppress tumoiu necrosis factor-alpha 
(TNFa) production from mononuclear phagocytes. This has enabled studies into 
their potential treatment for a number of other disorders which are associated with 
over secretion of TNFa [Schade, FU. and Schudt, C. 1993]. Examples are auto­
immune diseases such as arthritis and multiple sclerosis [Tracey, KJ. and Cerami, 
A. 1993, Feuerstein, GZ., et. al. 1994], viral diseases such as AIDS and bacterial 
or parasitic infections like septic shock and cerebral ischaemia [Sekut, L. et. al. 
1995, reviewed Souness, JE. and Rao, S. 1996]. Indeed PDE4 inhibitors have also 
been shown to alleviate arthritis in animal models [Sekut, L. et. al. 1995]. This 
considerable potential for PDE4 inliibitors has been hampered by the side effects 
of the drugs, mainly nausea and vomiting [Palffeyman, MN. and Souness, JE. 
1996].
The IC5 0  of rolipram for PDE4 usually lies within the range of 0.1-2pM, as 
measured for crude subcellular fractions [Souness, JE., et. al. 1996], partially 
purified preparations [Reeves, ML., et. al. 1987], or recombinant protein 
expressed in mammalian cells [Livi, GP., et. al. 1990]. Little variation was seen 
between each of the PDE4 genes, although rolipram was reported to be 10-foid 
less potent against PDE4C [Bolger, G., et. al. 1993], but this perhaps relates to the
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Table 1.3. Potencies of FDE4 inhibitors against crude monocyte
FDE4.
measured at IpM  cAMP [Souness, JE. and Rao, S., 1996]
Compound ICso (pM)
Rolipram 0.3
WAY PDA 641 0.3
Ro 20-1724 2.4
Ibudilast 1.3
Denbufylline 0 . 2
RP 73401 0 . 0 0 1 2
GDP 840 0.007
Trequinsin 0.4
discrepancy over the nature of the full length PDE4C species. The only other 
varaitions that have been seen are that cytosolic rpdc6  (RNPDE4A5) was 1 0 -fold 
more sensitive to rolipram compared to the membrane associated form. Also, the 
phosphorylated form of PDE4D3 was 60-300 fold more sensitive to the PDE4 
inhibitors, RS-25334 and RS-33793, than the dephosphorylated form [Alvarez, R., 
et. al. 1995], whereas the potency of trequensin was uneffected. Studies with brain 
membrane and cytosol fractions have reported high-afflnity rolipram binding, with 
a Kd ~2nM [Schneider, HH., et. al. 1986]. High-affinity rolipram binding displays 
stereoselectivity, with the R-(-)-enantiomer being 10-20 fold more potent than the 
S-(+)-enantiomer [Schneider, HH., et. al. 1986, Scluniechen, R., et. al. 1990]. This
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high-affinity binding stereoselectivity contrasts with the only slight 
stereoselectivity of the binding reported in the low pM range. Evidence has been 
provided for a high-affinity rolipram-binding site (HARBS) on HSPDE4A and 
HSPDE4B [Torphy, TJ., et. al. 1992, McLaughlin, MM., et. al. 1993]. Studies on 
recombinant PDE4 suggest that the HARBS is distinct from the catalytic region 
for two reasons. (1) The affinity of rolipram for the HARBS on HSPDE4A is 
approximately 100-fold greater than for inliibition of catalytic activity [Torphy, 
TJ., et. al. 1992]. (2) The rank order of potency of structurally dissimilar 
compounds in displacing [^H]-rolipram Bom the high-affinity site does not 
correlate with their inhibition of cAMP hydrolysis [Torphy, TJ., et. al. 1992].
The physiological effects of PDE4 inhibitors are divided according to 
whether they are caused by inliibitor binding to the HARBS or are as a result of 
inhibition of catalytic activity. For example an excellent correlation between 
suppression of histamine-induced broncho constriction and PDE4 inliibitor 
displacement of [^H]-rolipram from the high-affinity site was seen in brain 
membranes [Harris, AL., et. al. 1989]. However, in human monocytes, PDE 
inliibitor suppression of lipopolysaccharide induced TNFa release and 
potentiation of PGE2 -induced cAMP accumulation correlated poorly with HARBS 
binding and a much better relationship is observed with inliibition of monocyte 
PDE4 [Souness, JE., et. al. 1996].
Pharmaceutical companies are now paying a great deal of attention to 
developing compounds which specifically inliibit PDE4 but have lower affinities 
for the HARBS. An example is SB 207499 which is equipotent with rolipram in
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eliciting functional responses in several inflammatory cells but is far less effective 
at stimulating acid production in parietal cells, thus reducing nausea [Barnette, 
MS., et. al. 1994]. The reason for this may be that this compound is 3-fold more 
potent than rolipram at inhibiting HSPDE4A but 28-fold less effect at dissociating 
[^H]-rolipram from the high-affrnity site.
1.3.6. cGMP specific phosphodiesterases (PDE5)
PDE5s contain two distinct binding sites for cGMP. One of these is the 
catalytic site where cGMP is enzymatically cleaved to 5’-GMP but the other site 
exhibits no catalytic activity at all. In this respect, they resemble PDE2s, PDE3s 
and PDE6 s. PDE5 differs from the others, however, in its almost complete 
inability to hydrolyse cAMP, cGMP is hydrolysed at a rate that is -100 times 
faster than cAMP. Binding of cGMP to the non-catalytic site of PDE5 induces a 
conformational change in an N-terminal domain of about 142 amino acids, the 
result of which is that Ser-92 becomes a target for phosphorylation by PKG 
[Fransis, SH., et. al. 1990, Thomas, MK., et. al. 1990, Thomas, MIC., et. a l 
1990a]. The functional significance of these cGMP induced changes has yet to be 
worked out.
Zn^ "*" has been shown [Francis, SH., el a l 1994] to support PDE5 catalytic 
activity, through a specific, high affinity interaction with the enzyme. PDE5 
contains at least two sites for Z i f  binding and two Zn^^ binding consensus 
motifs, that resemble those found in thermolysin, have been identified in the 
primary sequence of the catalytic domain. These sites are conserved in the
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catalytic domains of all mammalian PDEs [Francis, SH., e t a l 1994]. The role of 
these Zn^^ binding domains in catalysis remains to be determined, although it 
seems likely that they are required for catalysis [Francis, SH., et. a l 1994].
PDE5 was first identified in the hmg [Hamet, P. and Coquil, J-F. 1978, 
Fransis, SH., el a l 1980] and platelets [Hamet, P. and Coquil, J-F. 1978, Hamet, 
V., et. a l 1984]. Since then it has also been identified in a number of other tissues, 
including rat spleen [Coquil, J-F. 1983], vascular smooth muscle [Hamet, P., et. 
a l 1984, Coquil, J-F. 1983] and sea urchin sperm [Fransis, SH., et. a l 1980]. The 
subunit molecular weight of PDE5 is ~93kDa and the native species, -178kDa, 
suggesting that PDE5 exists as a homodimer [Fransis, SH. and Corbin, JD. 1988, 
Thomas, MK., et. a l 1988, Thomas, MK., et. a l 1988a].
1.3.7. Photoreceptor cGMP specific phosphodiesterases (PDE6)
Visual excitation in the vertebrate rod photoreceptor cell involves a light 
activated cGMP enzyme cascade in the outer rod segment. Absorption of a photon 
by the receptor, rhodopsin, leads to activation of PDE6 , via a G-protein, 
transducin. The effect is a rapid and transient decrease in cellular cGMP levels 
which results in the closure of a Na"^  channel, normal kept open by cGMP, and the 
membrane becomes hyperpolarised [Fresenlco, EE., et. a l 1985].
PDE6  is a latent enzyme complex which is composed of three subunits, 
PDE6 -a , PDE6 -P and PDE6 -y in the ratio of 1:1:2 respectively [Tuteja, N., e l al 
1988, Baehi’, W., et. a l 1979] . PDE6 -a  and PDE6 -p contain separate catalytic 
sites that are inliibited by the binding of PDE6 -y. Transducin is activated, like all
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G-proteins, by the exchange of GDP for GTP on its a-snbnnit and dissociation of 
the a-snbnnit from its Py-counterparts. The a-snbnnit then releases the catalytic 
constraint of the PDE6 -y subunit on catalytic activity of the PDE6 -a  and PDE6 -P 
subunits and cGMP is hydrolysed.
The catalytic, PDE6 -a  and PDE6 -p, subunits show a 72% sequence 
homology, each possessing putative catalytic domains within their C-terminal 
regions that show a degree of homology to all other PDEs [Li, T., et. al. 1990]. 
Additionally two N-terminal, non-catalytic, cGMP-binding sites, with dissociation 
constants of 0.2-2pM for cGMP are also present on PDE6 -a  and PDE6 -P [Li, T., 
et. al. 1990]. These binding sites are involved in allosteric modulation of activity 
[Stroop, S. and Beavo, JA., 1992]. The PDE6 -y subunit is a highly conserved 
protein tluough all vertebrate species [Talcemoto, IT, et. al. 1984]. Its role in the 
inhibition of activity of the other two subunits was originally suggested by 
experiments that used trypsin to degrade the y-subunit and consequently activating 
the a - and p-subunits [Mild, N., et. al. 1975]. The ability of the a-subunit of 
transducin to interact with the PDE6 -y subunit is reported to be further regulated 
by the binding of cGMP to the non-catalytic sites of PDE6 -a  and p [Arshavsky, 
VY., et. al. 1992].
1.3.8. IBMX Insensitive phosphodiesterases (PDE7)
The PDE7 gene was cloned from a human glioblastoma cell line [Michaeli, 
T., et. al. 1993] by a method similar to that used to clone DPD [Colicelli, J., et. al. 
1989], which utilised a yeast temperature sensitive mutation to raise
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intracellular cAMP levels. The method used to identify PDE7 simply deleted the 
two endogenous Saccharomyces cerevisiae PDEs, PDEl and PDE2 instead of the 
ras2'^^^^  ^mutation.
The human PDE7 cloned (HCP-1) showed considerable homology to other 
cAMP PDEs, including the putative catalytic region. High levels of PDE7 RNA 
have been found in human skeletal muscle and lower levels of expression have 
been detected in a number of tissues, including brain and heart [Michaeli, T., et. 
al. 1993]. Biochemical analysis demonstrated that PDE7 has a very high affinity 
for cAMP (0.2|aM) and is not affected by Ca^VCaM or cGMP, in which respect it 
resembles the PDE4 family. However, it is not susceptible to inhibition by IBMX 
or any known PDE4 inliibitors. HCPl does not appear to be full length so it is 
possible that the pharmacological properties may be altered with the discovery of 
a full length clone. This is unlikely to change its designation since the sequence is 
distinct from any other PDE family, so it is likely that PDE7 will remain as a 
distinct family of PDE isoenzymes.
1.3.9. PDE8
PDES has been suggested [Mukai, J., et. al. 1994] as the most recently
discovered PDE isoenzyme family. However, beyond its separation and
biochemical characterisation, no further data is available, so its acceptance as a i
separate family has yet to be confirmed. PDES was isolated by Mukai [Mukai, J., I
et. al. 1994] by a process of Mono-Q anion exchange chromatography on 
cytosolic rat brain cerebrum. A unique peak of activity was detected that was
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insensitive to Ca^^/CaM or cGMP and would hydrolyse cAMP and cGMP with 
Km values of 0.1 pM and 1.8pM respectively. PDEl, PDE2, PDE3, PDE4 and 
PDE5 inhibitors had no effect on the activity unless at high concentrations where 
they become non-specifie. It would appear therefore that Mukai and colleagues 
have identified a PDE with novel characteristics, however, no further 
characterisation has been published to date.
1.4. PROTEIN-PROTEIN INTERACTIONS
Many signalling processes are controlled by sending amplified signals to 
targets. Often these signals are maintained in macromolecular form, rather than 
being passed to small molecules such as cAMP. Such signal transducers generally 
affect a small number of target molecules and usually have their catalytic function 
separated from their binding regions, which can bring substrates to catalytic 
centres, link the signal transducers to upstream proteins and localise protein 
complexes to particular subcellulai" regions. The binding regions are often modular 
ones that are constructed with a common core recognition ability, coupled to a fine 
specificity control. A number of protein-protein interaction domains are known, 
Src homology (SH2 and SH3) domains [Koch, CA., et. al. 1991], pleckstrin 
homology (PH) domains [Mayer, BJ., et. al. 1993], WW domains [Bork, P. and 
Sudol, M., 1994] and phosphotyrosine binding (PTB) domains [Kavanaugh, WM. 
and Williams, LT., 1994]. Each of these have a few common featui'es in that they 
are all modular domains that maintain their structure and binding abilities in
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isolation and have closely apposed N- and C-termini so that can be ‘plugged in’ to 
the surface of proteins.
1.4.1. phosphotyrosine binding (PTB) domains
PTB domains are regions of about 100-150 residues in the insulin receptor 
substrates 1 and 2 (1RS 1 and 1RS 2) and in the adapter protein She [Kavanaugh, 
WM. and Williams, LT., 1994]. These proteins bind to autophosphorylation sites 
on the insulin and epidermal growth factor (EGF) receptors, respectively. The 
amino acid sequences of the 1RS 1 and 1RS 2PTB domains ar e closely related to 
each other, but have no identifiable similarity to the sequence of the PTB domain 
from She [Kavanaugh, WM. and Williams, LT., 1994]. They have, however, been 
shown hy NMR [Zhou, MM., et. al. 1996] and crystallographic [Eck, ML, et. al. 
1996] studies to have closely related tluee dimensional structures. Both the 1RS 
and She PTBs recognise the sequence NPxY where Y represents a phosphorylated 
tyrosine [Wolf, G., et. al. 1995], which bears no resemblance to the seqences 
recognised by SH2 domains [See below]
1.4.2. WW domains
WW domains are protein motifs of about 40 amino acids, first identified in 
the Yes associated protein (YAP) and dystrophin and since then in a number of 
other proteins [Bork, P. and Sudol, M., 1994, Sudol, M., et. al. 1995]. The domain 
contained four well conserved aromatic residues, two of which were tryptophans, 
hence the name WW domain [Bork, P. and Sudol, M., 1994]. Initial studies 
showed that the YAP WW domain bound to a proline-rich sequence within the
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SH3 domain of Yes [Sudol, M., 1994]. The proline-rich sequences that WW 
domains bind to have the sequence PPPPY [Chen, HI. and Sudol, M., 1995]. This 
sequence has been shown not bind to SH3 domains, which also recognise proline- 
rich sequences [Section 1.4.6.] and is consequently reported to be a distinct motif 
[Chen, HI. and Sudol, M., 1995].
1.4.3. Pleckstrin homology (PH) domains
PH domains are units of about 100 amino acids that were first identified in 
the pleckstrin protein [Haslam, R., e t a l 1993, Mayer, BJ., et a l 1993] which has 
two such units. The sequence homology between PH domains fiom different 
proteins, like PTB domains, is low [Musacchio, A., et. a l 1994] but the structural 
similai'ity, as determined by NMR, is high both between PH domains and with 
PTB domains [Downing, AK, et. a l 1994]. PH domains have been shown to bind 
to phosphoinositides [Ferguson, Km., et. al. 1995, Hyvonen, M., et. a l 1995], so 
although PTB and PH domains share similar structure, they have evolved distinct 
mechanisims for phospholigand recognition.
1.4.4. Src-homology domains
Tyrosine kinase activity, exhibited by receptors and oncogenes, can 
stimulate cell growth and proliferation. One means of achieving this is through the 
activation of MAP kinase via a sequence of phosphorylation and recruitment 
effects. The specific recruitment effects involved depend upon defined protein- 
protein interactions and insight into the molecular basis that defined them came 
initially from studies done on sequence homology of various Src family tyrosine
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kinases. These studies identified tlu'ee regions called Src homology 1 (SHI), Src 
homolgy 2 (SH2) and Src homology 3 (SH3). SHI represented the catalytic ATP- 
binding domain, whereas SH2 and SH3 reflected distinct globular' domains that 
could mediate protein-protein interactions and were essential for Src to function 
[Koch, CA., et. al. 1991].
SH2 and SH3 domains have little in common. They are both true protein 
domains, as far as they form compact globular’ domains and maintain their 
structure in isolation. The have closely apposed N~ and C-termini so that they can 
be ‘plugged-in’ to the surface of proteins. Both are found in a wide variety of 
proteins; protein kinases, lipid kinases, protein phosphatases, phospholipases, Ras- 
controlling proteins and transcription factors. They are also found in adapter 
proteins such as Crk and Grb2 which have no enzymatic function but simply serve 
to complex proteins. SH3 domains are also found in cytoskeletal elements where 
they mediate the action of signal transduction pathways on cellular architecture 
and cell movement [Koch, CA., et. al. 1991, Mayer, BJ. and Baltimore, D. 1993, 
Pawson, T. and Schlessinger, J. 1993, Musacchio, A., et. al. 1994].
1.4.5. SH2 domains
Cellular response to growth and differentiation factors involves 
dimérisation and autophosphorylation of the receptor protein tyrosine kinase 
(RTK). In response to autophosphorylation, a number of proteins become 
associated with the RTK. It was shown that these proteins contain SH2 domains 
and that they would not associate with unphosphorylated receptor [Mayer, BJ. and
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Baltimore, D. 1993]. Indeed, SH2 domains specifically bind to phospliorylated 
tryrosyl residues in proteins. The binding of SH2 domains to phosphorylated 
tyrosine residues can potentially have two effects. It may alter the subcellular 
localisation of a protein, thus bringing it closer to its substrate, or it may alter the 
conformation of either the SH2 domain-containing protein itself or the protein 
containing the P-Tyr, or another protein in the complex, thus modulating their 
activities to transduce a signal.
An example of activation by subcellular localisation is the RTK-mediated 
Ras activation pathway [Pawson, T. and Schlessinger, J. 1993]. Ras is a GTPase 
which is found associated with the plasma membrane. Ras is activated by the 
guanine nucleotide exchange factor SOS, which, even in quiescent cells is found 
in the cytoplasm, associated with an adapter protein Grb2. Grb2 has no catalytic 
function, it is composed simply of two SH3 domains and one SH2 domain, 
association with SOS is via its SH3 domains. Activation and autophosphorylation 
o f the epidermal growth factor receptor creates binding sites for the SH2 domain 
o f Grb2, the consequence of which is the localisation of the Grb2-SOS complex to 
the plasma membrane. Once at the plasma membrane, SOS is close to its substrate 
Ras, which is subsequently activated. SOS has been shown to be active in both the 
cytoplasm and at the plasma membrane so transduction of the signal from the 
receptor to Ras is entirely dependent on the recruitment of SOS to the plasma 
membrane via Grb2 and its SH2 domain [Li, N., et. al. 1993].
If the only requirement for SH2 interaction was phosphotyrosine then there 
would be no cellular control over which protein interacts with what so SH2
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domains contain a finther recognition site, usually for the tliree amino acids which 
are immediately carboxyl to the phosphorylated tyrosine residue (P-Tyr) and it is 
these residues that confer specificity. For example phosphotidylinositol 3’-kinase 
(PI3K) contains two SH2 domains and the consensus sequence for binding of 
these domains is P-Tyr-(Val/Met)-X-Met. If the platelet derived growth factor 
(PDGF) receptor is mutated at these sites then PI3K no longer binds to it. 
However the binding of Grb2, which has a different specificity, to the PDGF 
receptor is unaffected [Cantly, LG., et. al. 1991, Kazlauskas, A., et. al. 1992, 
Pawson, T. and Schlessinger, J. 1993].
A systematic approach was used to determine the optimal peptide ligand 
for specific SH2 domains. This involved the generation of an eight amino acid 
phosphotyrosyl peptide library that was randomised at positions P-Tyr- 
(+l)(+2)(+3) [Songyang, Z., et. al. 1993, Songyang, Z., et. al. 1994]. Of the 22 
SF12 domains that were tested, each selected specific peptide sequences, apart 
from the SH2 domains from src family tyrosine kinases which all selected the 
sequence YEEI (table 1.4.). These specificities are not absolute however, there 
may be more than one SH2 domain within a cell with a high affinity for a 
particular ligand. Consequently, in vivo, the ability of an SH2 domain to engage a 
particular phosphoprotein may depend on the local concentration of proteins as 
well as the modulating effect of other domains found on interacting proteins.
Little is known about the allosteric activation via with SH2 domains. Syp 
phosphatase is activated 50-fold upon binding of its SFI2 domain to 
phosphopeptides [Sugimoto, S., cf al. 1994]. How this activation is transmitted to
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the catalytic domain is unclear since very little conformation change occurs in the 
SH2 domain itself upon binding [Lee, C., et. al. 1994]. One possible explanation 
for this is that in a non-activated state, i.e. absence of P-Tyr, the SH2  domain 
interacts with another region of the protein. The best example of this occurring is 
in the case of Src, where a P-Tyr in the carboxyl tail of Src itself loops back to 
bind the SH2 domain and negatively regulate the kinase [Superti-Furga, G., et. al.
1993].
1,4.6. SH3 domains
A key step in deciphering the basis of the interaction of SH3 domains 
came with the discovery of two SF13 binding peptides, 3BP1 and 3BP2, by 
screening an cDNA expression library with the SH3 domain of Abl [Cicchetti, P., 
et. al. 1992]. The location of the possible binding regions of 3BP1 and 3BP2 was 
narrowed down to regions of -10  amino acids that were rich in prolines [Ren, R., 
et. al. 1993] and since then a number of in vivo ligands have been identified and 
their binding regions mapped to proline-rich peptide sequences [Finan, P., et. al. 
1994, Musacchio, A., et. a l 1994]. Of all the Proline-rich peptides identified to 
date, the basic core requirement for SH3 domain interaction is PxxP. However, a 
preference is displayed for arginine residues within 5 amino acids of the proline 
and often, further, nearby prolines aid interaction [Ren, R., et. a l 1993, Yu, H,, et. 
a l 1994, Feng, S., a l 1994]. More specifically, the Src SH3 domain is reported 
to prefer the proline-rich sequence RXLPPLRPO, where X represents any amino 
acid except cysteine and 0  represents a hydrophobic residue [Yu, H., et. a l 1994].
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Table 1.4. Peptide ligands for SH2 domains
Shows the preferred amino acids at positions +1, +2 and +3 from the 
phosphorylated tyrosyl residue (pY) for a number of SH2 domains. [Songyang, Z., 
et, a l 1993].
Domain pY pY+1 pY+2 pY+3
Src Family SH2 pY E D I END IVML
Abl SH2 pY ETM NED PYL
Crk SH2 pY DK I-IFN PER
p85 N-SH2 pY MVIE X M
p85 C-SH2 pY X X M
Phospholipase Cy C-SH2 pY VI IE PIV
Phospholipase Cy N-SH2 pY LIV ED LIV
Csk SH2 pY TAS KRQN MIV
R
Grb2 SH2 pY QYV N YQV
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This peptide fails into class I sequences, classified by the presence of an RXL 
motif. A second class of ligands class II, exist that lack this motif [Yu, H., et. al. 
1994, Alexandropoulos, K., et. al. 1995]. A more extensive characterisation of 
peptide ligands has recently been performed for various SH3 domains using a 
phage display library [Sparks, AB., et. al. 1996], the results are summarised in 
table 1.5. A criticism of these studies may be that all the binding studies were 
performed using short peptides which does not account for any tliree dimensional 
structural contribution. A three dimensional requirement for a left-handed 
polyproline type II helix is, however, reported [Yu, H., et. a l 1994]. Additional 
prolines, N- and C-terminal to the basic PxxP motif are reported to greatly 
stabilise such a structure [Yu, PI., et. a l 1994] and it has been recently reported 
that the binding surface of Nef for the SH3 domain of Hck, a trosine protein 
kinase, consists of a non-contiguous amino acid sequence [Grzesiek, S., et. al
1996]. [Lee, C H , et. a l  1996]
The importance of SH3 domains in cellular signalling was first highlighted 
by the mutation of the SH3 domain of v-Crk, which abolished its transforming 
potential. Additionally, the mutation of the SH3 domains of the non-receptor 
tyrosine kinases, Abl and Src, activates the transforming potential of the proto­
oncogene products [reviewed Cohen, GB., et. a l 1995]. Thus, SH3 domains may 
serve to organise protein complexes within the cell, bringing substrates to 
enzymes and regulate enzymic activities within the cell.
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Table 1.5. Proline-rich peptide ligand consensus for various SH3 domains 
identified by phage display library screening [Sparks, AB., e t al, 1996].
‘X ’ represents any amino acid, ‘+ ’ basic, 'T ' aliphatic and aromatic.
SH3 Domain Ligand Consensus
Src L X X R P L P X vp P
Yes Y X X R P L P X L P
Cortactin + P P P X K P X w L
Crk T P T L P vp K
Grb2 N-term 0 D X P L P X L P
PLCy P P V P p R P X X T L
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Compartmentalisation plays an important role in the regulation of signal 
transduction processes. Many of the signalling proteins that localise to the plasma 
membrane or cy to skeleton contain SH3 domains, suggesting that SH3 domains 
mediate localisation to these regions [Mayer, BJ. and Baltimore, D. 1993] Using 
micro-injection, it was shown that the SH3 domain of phospholipase C y is 
responsible for targeting it to cytoskeletal microfilaments , while both the SH3 
domains of Grb2, but not its SH2 domain are required for its localisation to 
membrane ruffles [Bar-Sagi, D., et. al. 1993], There are also many examples of 
SH3 domains influencing signalling pathways involving G-proteins, such as the 
Grb2-S0S complex modulating Ras GTPase activity (section 1.4.1.) and the 
interaction of the C-terminal SH3 domain of Grb2 with Vav, a hematopoietic- 
specific guanine-nucleotide exchange factor [Ye, Z-S. and Baltimore, D. 1995].
1.4.3. Interactions between SH2 and SH3 domains
Given the fact that SH2 and SH3 domains are found together on a number 
of proteins, it is not surprising to discover evidence that their activities may be 
coordinated. For example Src kinase can be negatively regulated by interactions 
between its SFI2 domain and a P-Tyr on its C-terminal tail [Superti-Furga, G., et. 
al. 1993]. This inhibition, however, requires a functional Src SFI3 domain since 
mutation of the SH3 domain activates the kinase by maldng the SH2 domain more 
accessible to exogenous substrate [Superti-Furga, G., et. al. 1993]. Additionally, a 
phosphoprotein, p 6 8 , has been identified that will independently interact with both 
isolated Src SH3 and isolated Src SH2. However, a much higher affinity for
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binding is seen with the tandem SH2-SH3 module [Fumagelli, S., et. a l 1994, 
Taylor, SJ. and Shalloway, D., 1994]. A similar synergism is observed in the 
binding of the llOkDA actin filament-associated protein to Src’s SH2 and SH3 
domains [Flynn, DC., et. a l 1993]. Structural evidence to support SFI2-SH3 co- 
operativity was provided by crystallography of a fragment of Lck, a Src family 
tyrosine kinase, which contained the SH2 and SH3 domains [Eck, MJ., et. a l
1994]. The fragment crystallised as a dimer with extensive intermolecular SH2- 
SH3 contacts. Interestingly, an SFI2 proline was found to lie in the SH3 domain 
binding pocket in an orientation similar to that of PXXP peptide. Eck also 
crystallised the SH2-SH3 fragment in the presence of a phosphorylated peptide 
that corresponds to the C-terminal tail of Lck. As expected, the phosphorylated 
tyrosine residue bound in an orientation similar to that observed in SFI2 
complexes, however the rest of the peptide did not. It was found to lie in the 
crease of the intermoleculai’ SH2-SH3 interface. While there is no evidence for 
the existence of Src or Lck as dimers, the possibility that Src might explain why 
functional SH2 and SH3 domains on Src are required for the negative regulatory 
effect of the tyrosine phosphorylated C-terminal tail of Src.
1.5. PERSPECTIVES
In this thesis I describe a series of experiments aimed at trying to 
determine the rapid activation of PDE4B species in adipocytes by insulin and to 
define the interaction of PDE4 species with SH3 domains.
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Chapter 2
Materials and Methods
2.0. SOURCES OF REAGENTS
2.0.1.PDE clones
Clones for rpdeô rpde39, hpde46, HSPDE4D1, HSPDE4D2, HSPDE4D3, 
HSPDE4D4 and HSPDE4D5 were all kindly donated by Graeme Bolger, 
Department of Medicine & Geologic Science, Huntsman Cancer Institute, 
University of Utah, Salt Lake City, UT 84148, USA [McPhee, I., et a l 1995, 
Bolger, G , et a l 1996, Bolger, G. and Houslay, M D , unpublished data]. RDI 
was a gift from Ron Davis [Davis, RL., et a i 1989]. met^^RDl was generated in 
this laboratoiy by Yasmin Shakur [Shakur, Y., et a l 1993].
2.0.2. SH3-GST fusion protein clones
The Src SH3-GST, SH2-GST, SH2SH3-GST and full length Src-GST 
fusion protein clones were obtained from Margaret Frame, Beatson Institute for 
Cancer Research, Garscube Estate, Glasgow, 061 IBD, Scotland. The Lck SH3- 
GST, Csk SH3-GST, Grb2 SH3-SH2-SH3-GST and Crk SH3-GST fusion 
proteins were obtained from Siegmund Fisher, Laboratory of Molecular and 
Cellular Oncology, Cochin Institute for Molecular Genetics, National Institute of 
Health & Medical Research, Cochin Hospital, Paris, France. The Lyn SH3-GST, 
Fyn SH3-GST and Abl SH3-GST fusion proteins were kind gifts from David 
Baltimore, Department of Biology, Massachusetts Institute of Technology, MA 
02139, USA. The cortactin SH3-GST fusion protein was given to us by Nancy 
McGee and Thomas Parsons, UVA Medical Centre, Charlottesville, VA 22908, 
USA.
2.0.3. Cell lines
All cell lines used in these studies were originally obtained from EC ACC, 
Department of Cell Resources, Centre for Applied Microbiology and Research, 
Porton Down, Salisbury, Wiltshire. SP4 GDI
2.1. POLYACRYLAMIDE GEL ELECTROPHORESIS
2.1.1. Buffers
2.1. L 1. Resolving gel buffer (Buffer A):
2M Tris/HCl, pH
0.4% (w/v) SDS
2.1.1.2. Stacking gel buffer (Buffer B):
0.5M Tris/HCl, pH 6 .
0.4% (w/v) SDS
2.1.1.3. Acrylamide mix:
30% (’w/v) acrylamide : N,N’methylenebisacrylamide 
29:1 (3.3% cross-liiildng, Bio-Rad)
2.1.1.4. Resolving gel (8%):
13.9ml 
7.8ml 
8  mis 
300pl 
ISpl
2.1.1.5. Stacking gel:
6.8ml
distilled water
Buffer A
acrylamide mix
1 0 % ammonium persulphate
N,N,N’ ,N’ -tetramethylethylenediamine
(TEMED)
distilled water
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1.35ml Buffer B
1.7ml acrylamide mix
1 0 0 |il 1 0 % ammonium persulphate
lOpl TEMED
2. L 1.6. Laemmli buffer (2x): [Laemmli, UK, (1970) Nature 227. 680-685]:
2.5ml IM  Tris/ElCl, pH 6 . 8
5 ml glycerol
8 ml 10% (w/v) SDS
3.5ml distilled water
0.007% (w/v) bromophenol blue
1 ml B-mercaptoethanol (added prior to use)
2.1.1.7. Electrode buffer:
192mM Glycine
25mM Tris
0.15 (w/v) SDS
2.1.2. Preparation of Samples
Samples containing no more than 400pg of protein were added to an equal 
volume of 2x Laemmli buffer and boiled for five minutes.
2.1.3. Protein Molecular Weight Markers
Prestained protein moleculai' weight markers (Bio-Rad) containing the 
following proteins; myosin H chain (200kDa), phosphorylase B (97.4kDa), BSA 
(6 8 kDa), ovalbumin (43kDa), carbonic anhydrase (291cDa), B-lactalbumin (18.4
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kDa) and lysozyme (14.3kDa) were used. Its should be noted that the apparent 
molecular weights varied from batch to batch and the sizes of the proteins are 
indicated on any particular figure.
2.1.4. Casting and Running of the Gel
Following assembly of the gel apparatus, the resolving gel was poured 
between the plates and 2ml of water was layered on top. Wlien the gel had set, 
about 30 minutes, the water was removed, a comb inserted and the stacking gel 
poured. When the stacking gel had set, the comb was removed and the gel placed 
in a tanlc containing electrode buffer. The samples were loaded into the wells and 
the gels were run at 60mA per gel until the bromophenol blue reached the bottom 
of the gel.
2.1.5. Staining and Drying
Gels were fixed in 0.25% Coomassie Blue (Brilliant Blue R250) in 5:1:4, 
water : acetic acid : methanol for 1 hour at room temperature. Destaining was 
performed with 5:1:4, water : acetic acid : methanol at room temperature until the 
background was sufficiently reduced. Gels were dried onto Whatman 3MM paper 
under vacuum at 60^0 for 2 hrs.
2.1.6. Non-denaturing polyacrylamide gel eleetrophoresis
2.1.6.1. Resolving Gel:
10% (w/v) Acrylamide (of which 2%
N,N ’ methyienebisacry lamide)
375mM Tris / HCl, pH 8.9
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0.5mM Potassium persulphate
5pg/ml Riboflavin
0.1% (v/v) TEMED
2.1.6.2. Stacking Gel:
4% (w/v)
60mM 
0.5mM 
5pg/ml 
0 .1 % (v/v)
2.1.6.3. Anode Buffer:
60mM
2.1.6.4. Cathode Buffer:
46mM
40mM
2.1.6.5. Elution Buffer:
20mM
O.lmM
50mM
50mM
Acrylamide (of which 20% 
N,N ’ methylenebi sacry lamide) 
Tris / Phosphate, pH 6 . 8  
Potassium persulphate 
Riboflavin 
TEMED
T ris/H C l, pH 7.5
Glycine
Tris / HCl, pH 8.9
T ris/H C l, pH 7.4
Ethyleneglycol-bis (p-aminoethyl ether)- 
N,N,N’,N’-Tetra-acetic acid (EGTA) 
Sodium Chloride 
P-Mercaptoethanol
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0.1% (v/v) Protease inhibitor cocktail (PMSF 40mg/ml, 
benzamidine 156mg/ml, apoprotinin 
1 mg/ml, antipain 1 mg/ml, leupeptin 1 mg/ml, 
pepstatin Img/ml, dissolved in DMSO)
2.1.6.6. Casting and running o f  the gels
A  tube gel apparatus was used with an internal diameter of 5mm. Each gel 
was composed of 1.6ml resolving gel and 0.7ml stacking gel. All constituents of 
the gels, including the apparatus and buffers were cooled to 4°C prior to casting 
the gels. The gels were photo-polymerised at 4°C and set after about 10
minutes. Samples to be loaded onto the gels were supplemented with 10% (v/v) 
cathode buffer which had 25% (v/v) glycerol and 12.5 pg/ml amaranth dye added. 
Gels were run at 110 volts while the samples were in the stacking gel and 160 
volts once they had entered the resolving gel. Electrophoresis was terminated 
when the dye reached the bottom of the gel.
2.1.6.7. Elution o f  samples
The gel was removed from the glass tube by filling a syringe with cathode 
buffer and applying pressure to the top of the gel. The gel was then wrapped in 
cling-film, snap frozen in a dry-ice methanol bath and sliced into a number of 
slices, approximately 1mm thick using a sharp scalpel. Each of the slices were 
then placed in separate vials, 200pl of elution buffer added and incubated at 4”C 
overnight.
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2.2. WESTERN (IMMUNO) BLOTTING *
2.2.1. Buffers
2.2.1.1. Blotting buffer:
192mM glycine
25mM Tris
20% (v/v) methanol
80% (v/v) water
2.2.1.2. Tris buffered saline (TBS):
0.5M NaCl
20mM Tris/HCl, pH 7.4
2.2.2. Transfer to Nitrocellulose
The SDS polyacrylamide gel was placed in a cassette on top of a piece of 
nitrocellulose paper (Schleicher & Schuell), bound by two pieces of Wliatman 
3MM paper and two pieces of sponge. The cassette was soaked in blotting buffer, 
being careful to exclude any bubbles and was loaded into the transfer tanlc with the 
nitrocellulose side of the cassette towards the positive electrode. The tanlc was 
filled with blotting buffer and the proteins transfeiTed for 2 hours at lamp.
2.2.3. Immuno-deteetion using ECL from Amersham
The nitrocellulose was blocked using 5% Marvel in 100ml of TBS for at 
least 21n’s with gentle shaking. The nitrocellulose was washed 2x 5mins with TBS 
+ 0.1% Nonidet P40 (NP40) and 2x 5mins in TBS. First, antibody specific to the
^Towbiii, H., Staehelin, T. and Gordon, J. (1979) PNAS 76, 4350-4355. Burnette, WN. (1981) Anal. Biochem. 
112, 195-203.
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protein of interest was added in 10ml of TBS + 1% Marvel, sealed in a polythene 
bag and incubated at room temperatuie with vigorous shaking for 2hi's. After 
washing as described above, a second, horse radish peroxidase (HRP) conjugated, 
antibody directed against the antibody added; 40pl in 100ml TBS + 1% 
Marvel. This was then incubated for llii' at room temperature with gentle shaking 
and washed 4x 5mins with 100ml TBS.
The nitrocellulose was incubated with ECL (Amersham) reagents as per 
manufacturers instructions. X-ray film (Fuji) was exposed to the nitrocellulose for 
5 secs to lOmins depending on the intensity of the signal. The film was then 
developed.
2.3. TRANSFORMATION OF BACTERIA
2.3.1. Medium and buffers
2.3.1.1. L-broth:
170mM NaCl
0.5% (w/v) Bacto-Yeast Extract
1% (w/v) Bacto-Tryptone 
pH 7.5
2.3.1.2. LB-Agar:
170mM NaCl
0.5% (w/v) Bacto-Yeast Extract
1% (w/v) Bacto-Tryptone
2% (w/v) Agar
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2.3.1.3. Transformation buffer 1 :
lOOinM
50mM
30mM
RbCl
M11CL4H2O 
Potassium acetate
lOmM Ca.Cl2.2H2O
15% (w/v) redistilled glycerol
pH 5.8, adjusted with 0.2M acetic acid. Filter sterilise through a 0.22p filter.
2.3.1.4. Transformation buffer 2:
lOmM RbCl
lOmM 3-[N-Morpholino] propane sulphonic acid
(MOPS)
75mM CaCl2.2H20
15% (w/v) redistilled glycerol 
pH 6.8, adjusted with 0.2M NaOH. Filter sterilise through a 0.22p filter.
2.3.2. Preparation of Competent E.coli JM109
A 10ml culture of JM109 E.coli in L-broth was inoculated from a glycerol 
stock and grown overnight at 37°C with constant shaking. A 500ml L-broth 
culture was inoculated with 3mis of the overnight culture and grown at 37°C, 
shaking at 200rpm until the optical density at 550nm was between 0.5 and 0.55. 
The culture was divided equally between two sterile 250ml centrifuge bottles and 
cooled on ice for 30 minutes. They were then centrifuged at 2500rpm (950g) in a 
JA14 rotor for 15 minutes and each pellet resuspended in 20ml of ice-cold
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transformation buffer 1. The cells were incubated on ice for a further 15 minutes 
before centrifugation at 2500rpm for 10 minutes. The supernatant was removed 
and the cell pellets gently resuspended in 3.5ml of transformation buffer 2. When 
the cells were completely resuspended, they were pooled and again incubated on 
ice for 15 minutes. The competent cells were then snap-frozen in 250 j l l1 aliquots 
and stored at -80°C.
2.3.3. Transformation
An aliquot of competent cells was removed from storage in the -80°C 
freezer and allowed to thaw slowly on ice. For each transformation to be 
performed, a 50pl aliquot of competent cells was transferred to a sterile Eppendorf 
tube. To each 50pl, approximately lOOng of DNA was added and incubated on ice 
for 15mins. The cells were then heat shocked for 90 seconds at 42°C and 
incubated on ice for a frndher 1 minute. 1ml of L-broth was then added and the 
transformed cells were incubated at 37°C for 30-60 minutes with shaking. 100pi 
of the bacteria were then plated on a 10cm agar plate containing selection 
medium. Transformed colonies were picked and glycerol stocks made (section
2.3.4.)
2.3.4. Glycerol stoclcs
Single colonies were picked and used to seed a 10ml L-broth culture which 
was grown overnight at 37°C. To 750pl of the overnight culture, 250pl of 80% 
glycerol in L-broth was added and vortexed. The glycerol stock was stored at - 
80°C.
Chapter 2: M aterials and M ethods 5 9
2.4. GLUTATHIONE-S-TRANSFERASE-FUSION PROTEIN INDUCTION
A scraping taken from a frozen glycerol stock was used to seed a 10ml L- 
broth culture supplemented with amplcillin (50pg/ml) which was grown over 
night at 37°C. This was used to inoculate a 500ml L-broth culture containing 
ampicillin which was grown for 21irs at 37°C with constant shaking. Expression of 
the fusion protein was induced by adding 500pl of lOOmM isopropyl-B-D- 
thiogalactopyranoside (IPTG, Boeringer Mannheim) and the culture was 
incubated for a further 5 hours at 37°C. The bacteria were harvested by 
centrifugation and resuspended in 20ml of PBS containing a protease inhibitor 
cocktail (PMSF 40mg/ml, benzamidine 156mg/ml, apoprotinin 1 mg/ml, antipain 
1 mg/ml, leupeptin Img/ml, pepstatin 1 mg/ml, lOOOx dissolved in DMSO). They 
were then frozen at -20°C in 1ml aliquots.
2.5. PULL DOWN ASSAY FOR PHOSPHODIESTERASE-SH3 
INTERACTION^
2.5.1 Buffers
2.5.1.1. Phosphate buffered saline (PBS)
KOI 2.7mM
NaCl 137mM
Na2 FIP0 4  4mM
NaH2 P0 4  0.15mM, pH 7.4
Methed adapted from Haefner, R., et. al. 1995
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2.5.2. Interactions using phosphodiesterase from transfected COS7 cells
An aliquot of the bacteria which had been induced to express the fusion 
protein of interest were thawed and lysed by sonication. The debris was pelleted 
by centrifuging for 1 min at 16,000g in a bench top centrifuge. For every 1ml of 
supernatant, which on average yielded 400-800pg of fusion protein, 100pi of 
glutathione sepharose 4B beads (Pharmacia Biotech) equilibrated in PBS were 
added and incubated end over end for llir at room temperature. The beads were
washed three times with 1ml of PBS over 15 minutes, resuspended as a 50%
slurry and assayed for protein concentration.
As a routine, volumes of sluriy containing 400pg of beads were pelleted 
and the supernatants removed. To each of the pellets, an amount of cytosolic PDE, 
from pSV.SPORT-PDE transfected C0S7 cells, capable of hydrolysing
2000pmol/min of cAMP at 30°C was added and incubated for lOmins at 4°C. The 
beads were washed as before, the washes being retained for assay. The
determination of PDE bound to the immobilised GST fusion proteins was 
performed by Western blot, using a polyclonal antibody raised against the 
conserved C-terminal region specific to rat PDE4A, PDE4B, PDE4C, or PDE4D. 
Bound PDE activity was measured by first releasing the SFI3-PDE complex from 
the agarose beads by incubation with 100 pi of 1 OmM-glutathione in 50mM- 
TrisHCl buffer pH 8.0 for ten minutes at room temperature. This treatment was 
repeated a twice more and the supernatants pooled.
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2.5.3. Interactions using phosphodiesterases from rat tissue
For preparation of rat tissue cytosols see section 2.11.3.The method used is 
almost identical to that described for COS cell extracts, however, 100-400pg of 
brain cytosol were used and the binding performed for 30 minutes at 4°C.
2.6. IMMUNOPRECIPITATION
2.6.1. Buffers
2.6.1 J .  Immunoprécipitation Buffer
lOmM 
lOOmM 
1% (w/v) 
50mM
Ethylenediaminetetra-acetic acid (EDTA)
NaH2P0 4 .2H20
Triton X I00
N-2"Hydroxyethylpiperazine-N’-2- 
ethanesulfonic acid (Hepes), pH 7.2
2.6.1.2. Wash Buffer
lOmM Ethylenediaminetetra-acetic acid (EDTA)
lOOmM NaH 2 P0 4 .2 H2 0
1% (w/v) Triton XlOO
0.1% (w/v) Sodium dodecyl sulphate (SDS)
5 OmM N -2 -Hydroxy ethylpiperazine-N ’ -2-
ethanesulfonic acid (Hepes), pH 7.2
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2.6.2. Procedure
The sample to be immunoprecipitated from was in either TBS, PBS or 
KHEM buffer. The sample was diluted to 1ml in immunoprécipitation buffer so 
that at least 50% (v/v) was immunoprécipitation buffer. 20pl of polyclonal 
antibody were added and incubated end over end at 4°C overnight. 200pl of 
Pansorbin (Calbiochem) were added and incubated end over end at 4°C for at least 
2 hours. The Pansorbin was pelleted by spinning at 14,000g at 4°C in a bench top 
microfuge for 2 minutes and washed three times with wash buffer and once with 
PBS.
2.7. PHOSPHODIESTERASE ENZYME ASSAY
Briefly, [^H]-cyclic nucleotide (8 position of the adenine or guanine ring) 
was hydrolysed to form labelled nucleotide mono-phosphate. The nucleotide 
mono-phosphate ring was then converted to the corresponding labelled nucleoside 
by incubation with snake venom which has 5’-nucleotidase activity. The 
conditions were such that complete conversion took place within the incubation 
time. Unhydrolysed cyclic nucleotide was separated from the nucleoside by batch 
binding of the mixtuie to Dowex-1-chloride. This bound the charged nucleotides 
but not the uncharged nucleosides.
2.7.1. Buffers
2.7.L1. Assay buffer:
lOmM MgCl2
20mM Tris/HCl, pH 7.4
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2.7.2. Procedure
A 2x stock solution of cAMP was made by adding 30jul of [^H]-cAMP 
(ImCi/ml, 41.7|aM) to 10ml of 2|_iM cAMP in assay buffer. The assay volume was 
lOOpl which consisted of SOpl 2x cAMP stock and 50pl of sample, a proportion 
of which could be replaced by an effector or made up with buffer. All tubes were 
kept on ice prior to incubation at 30°C. The reaction was stopped usually after 10 
minuets by boiling for two minutes. The vials were then cooled on ice and 25pi of 
1 mg/ml snake venom (Sigma) was added and incubated for a further 10 minutes. 
After cooling, 400pl of Dowex resin was added and incubated on ice for 15 
minutes. The dowex was pelleted by spiiming in a bench top centrifuge for 3 
minutes and 150pl of the supernatant removed for scintillation counting in 2mls 
Ecoscint A.
2.7.2. Use of PDE assay to profile PDE families present in various tissues
To determine the contribution of various PDE families to the overall cyclic 
nucleotide phosphodiesterase content of a tissue, the normal PDE assay, 
supplemented with various specific inhibitors and additional factors was used, 
since each of the PDE families has its own specific catalytic and regulatory 
properties.
2.7.2.1. PDEl
The PDEl family requires Ca^^/Calmodulin for activity. To measure PDEl 
activity, the activity was measured when supplemented with Ethyleneglycol-bis 
(p-aminoethyl ether)-N,N,N’,N’-Tetra-acetic acid (EGTA) (2mM), to chelate the
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calcium which inactived the enzyme and with EOT A and an excess of CaCl2  
(5mM) and Calmodulin (10U/100(al) which fully activated it. The difference 
between these values represented the PDEl activity.
2  7.22. PDE2
The PDE2 family is activated by cGMP and inliibited by the drug EHNA. 
The difference in PDE activity when supplemented with cGMP (lOpM), 
compared to cGMP with EHNA (lOpM) represented the PDE2 activity. The 
addition of cGMP alone was not sufficient since PDE3 is inhibited by cGMP.
2.7.2.3.PDE3andPDE4
The PDE3 family is specifically inhibited by the drug cilostamide and the 
PDE4 family by rolipram. Measurement of PDE activity with and without 
cilostamide (lOpM) and with and without rolipram (lOpM) present gave the 
contribution of PDE3 and PDE4 respectively
2.7.2.4. Isobutylmethylxanthine (IBMX) insensitive.
The only other family measured was that that is insensitive to IBMX, a 
PDE inhibitor that inhibits all PDE families, apart from PDE7. The activity that 
remained afterr IBMX treatment was used to indicate PDE7 activity, although it 
had to be considered that IBMX may not have completely inliibited all other PDEs 
at the concentrations used. The IBMX insensitive fraction was represented as the 
PDE activity remaining when IBMX (lOOpM) was added to the PDE assay buffer.
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2.8. TISSUE CULTURE
2.8.1. NG108-15 cell line
NG108-15 cells are mouse neuroblastoma, rat glioma cell hybrids, formed 
by Sendai virus induced fusion of mouse and rat clones.
2.8.1.1. Growth medium for NG108-15 cells:
Growth medium was Dulbecco’s Modified Eagle’s Medium ( DMEM, 
Sigma D5671). This was supplemented with Penicillin / Streptomycin (100 
units/ml, Sigma), lOmM glutamine, 5% (v/v) HAT supplement (Sigma) and 5% 
controlled process seruiu replacement type 3 (CPSR, Sigma).
2.8.1.2. Maintenance ofNG108-15 cells
Cells were grown in an atmosphere of 95% air and 5% CO^ at 37°C in 
10ml of the medium detailed above. Cells were given fresh medium daily. When 
the cells reached about 90% confluency the cells were passaged 1:7 to fresh flasks 
and medium.
2.8.1.3. Passaging NG 108-15 cells
The cells were washed in 10ml of PBS prewarmed to 37°C and 2ml of 
trypsin were added. The cells were then returned to the incubator for 2 minutes or 
until they detached from the flask. They were then spun for 5 mins at 200g to 
pellet the cells. The medium was removed and the cells resuspend in 70ml of fresh 
medium which was distributed to seven new flasks.
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2.8.1.4. Differentiation ofNG108-15 cells using forskolin
NG108 cells grown to about 80% confluency were passaged 1:9 into 
medium detailed above but containing 1% (v/v) CPSR. The passage medium 
contained lOpM forskolin to elevate cAMP levels and induce differentiation. If 
necessary the cells medium was replaced as the medium changed to a yellow 
colour. Extreme care was taken while handling the differentiating cells because 
they did not attach very strongly to the surface of the plate. At 7-8 days after 
adding forskolin, the cells had completely differentiated.
2.8.2. NCB20 cell line
2.8.2.1. Growth medium fo r NCB20 cells:
Growth medium was Dulbecco’s Modified Eagle’s Medium ( DMEM, 
Sigma D5671). This was supplemented with Penicillin / Streptomycin (100 
units/ml, Sigma), lOmM glutamine and 10% foetal calf serum (Sigma).
2.8.2.2. Maintenance o/NCB20 cells
Cells were grown in an atmosphere of 95% air and 5% CO2  at 37°C in 
10ml of the medium detailed above. When the cells reached about 90% 
confluency the cells were passaged 1:5 to Ifesh flasks and medium.
2.8.2.3. Passaging NCB20 cells
The cells were washed in 10ml of PBS prewarmed to 37°C and 2ml of 
trypsin were added. The cells were then returned to the incubator for 2 minutes or 
until they detached from the flask. They were then spun for 5 mins at 200g to
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pellet the cells. The medium was removed and the cells resuspend in 50ml of fresh 
medium which was distributed to five new flasks.
2.8.3. COS7 cell line
C0S7 cells are a fibroblast-like cell line derived from the African green 
monkey kidney cells. These cells have been transformed by an origin defective 
mutant of SV40 which codes for wild type T-antigen. They make an excellent host 
for transfection with vectors requiring the expression of SV40 T-antigen. They 
permit replication of any plasmid caontaining an SV40 origin of replication, thus 
amplifying the expression of any genes encoded by the plasmid.
2.8.3.1. Growth medium fo r C 0S7 cells:
Growth medium was Dulbecco’s Modified Eagle’s Medium ( DMEM,
Sigma D5671). This was supplemented with Penicillin / Streptomycin (100 
units/ml, Sigma), lOmM glutamine and 10% foetal calf serum (Sigma).
2.8.3.2. Maintenance o f  COS7 cells
Cells were grown in an atmosphere of 95% air and 5% CO2  at 37°C in 
10ml of the medium detailed above. Wlien the cells reached about 90% 
confluency the cells were passaged 1:5 to fresh flasks and medium.
2.8.3.3. Passaging COS7 cells 
The cells were washed in 10ml of PBS (section 2.5.1.1.) prewarmed to
37°C and 2ml of trypsin were added. The cells were then returned to the incubator 
for 2 minutes or until they detached from the flask. They were then spun for 5
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mins at 200g to pellet the cells. The medium was removed and the cells resuspend 
in 50ml of fresh medium which was distributed to five new flasks.
2.9. COS7 CELL TRANSFECTION
2.9.1. Buffers
2.9.1.1. Transfection medium (make fresh)
Transfection medium was Dulbecco’s Modified Eagle’s Medium ( 
DMEM, Sigma D5671). This was supplemented with Penicillin / Streptomycin 
(100 units/ml, Sigma), lOmM glutamine, 10% new-born calf serum (Sigma) and 
lOOjLiM chloroquine.
2.9.1.2. TrisEDTA buffer (TE):
ImM Ethylenediaminetetra-acetic acid (EDTA)
lOmM T ris/H Cl, pH 7,5
2.9.2. Procedure
Cells were passaged to about 33% confluency 24hrs prior to transfection. 
lOpg of DNA was diluted to 250pl in TE and 200pl of DEAE Dextran (lOmg/ml 
in PBS) were added. This was incubated for 15 minutes at room temperature. 
C0S7 cell growth medium was aspirated from the cells and 5ml of transfection 
medium added. The DNA solution was added dropwise to the cells and mixed by 
swirling. The cells were returned to the incubator for 3-4hrs.
The cells were shocked by first aspirating the transfection medium and 5ml 
of 10% DMSO in PBS were added for exactly 2 minutes. The DMSO was
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aspirated and the cells washed with lOmls of PBS. The cells were returned to 
normal growth medium, placed in the incubator for tliree days and split only if 
necessary. Functional assays were then performed.
Lysis of transfected COS7 cells
KHEM buffer
TE A /K C l
50mM KCl
lOmM Ethyleneglycol-bis (p-aminoethyl ether)-
N,N,N’,N’-Tetra-acetic acid (EGTA)
5 OmM N-2-Hy droxy ethy Ipiperazine-N ’ -2-
ethanesulfonic acid (Hepes), pH 7.2 
1.92mM MgCl2
ImM Dithiothreitol (DTT), added fresh
20|Lig/ml Cytochalasin B, added fresh
Protease inliibitors (section 2.4), added fresh
lOmM Triethanolamine (TEA)
150mM KCl
pH 7.2 with HCl
Procedure
The culture medium was removed from the cells and 2ml of KHEM added. 
The cells were incubated at 4°C for 45 minutes. The KHEM was removed and 5ml 
o f TEA / KCl were added and incubated for 10 minutes at 4°C. The TEA / KCl
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was removed and the cells washed with 5ml KHEM. 1ml of KHEM was then 
added and the cells incubated for 2 minute at 4°C. The KHEM was aspirated, the 
cells scraped from the plate and homogenised with 20 strokes in a glass on glass 
dounce homogeniser. The homogenate was centrifuged at 65Og for 10 minutes to 
pellet debris. The supernatant was snap-frozen in liquid nitrogen in 100pi aliquots 
and stored at -80°C or used for membrane and cytosol preparations (section
2.11.3.). Note in preparations where the cytoskeleton was required intact, the 
cytochalasin was omitted from the KHEM buffer.
2.10. ADIPOCYTE PREPARATION
Adipocytes were prepared from the epididymal fat pads from male 
Sprague-Dawley rats of weight 200-25Og. These rats were provided by the 
University’s animal house.
2.10.1. Buffers
2.10.1 A. Low-phosphate Krebs:
114mM
4.7mM
1.18mM
50pM
25mM
25mM
3% (w/v)
IM
NaCl
KCl
M g S 0 4 .7 H 2 0  
KH2PO4 
NaHCOg 
HEPES, pH 7.4
Bovine serum albumin (BSA) (add fresh) 
CaCl2  (add fresh)
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2.10.1.2. Incubation buffer:
50pg/ml Adenosine deaminase
2mg/ml Coilagenase
500pg/ml Trypsin Inliibitor
Made up in low-phosphate Krebs
2.10.2. Procedure:
Epididymal fat pads were dissected out directly to low phosphate Krebs 
buffer at 37°C. The pads were finely chopped using scissors and rinsed in a tea- 
strainer. They were transferred to 10ml of incubation buffer in a siliconised glass 
vessel and incubated at 37°C for approximately 50 minutes in a shaking water 
bath. Cells were rinsed tlnough a nylon tea-strainer with low-phosphate Krebs to 
remove any cells that remain as clumps. Cells were centrifiiged at 600rpm (80g) 
for 2mins to float adipocytes and the buffer below the adipocytes removed. The 
adipocytes were resuspended in 30ml of low-phosphate Krebs at 37°C and spun 
again. This was repeated twice more. The cells were finally resuspended at 
approximately 15% cells in total volume of suspension. Protease inliibitors were 
added (PMSF 40mg/ml, benzamidine 156mg/ml, apoprotinin 1 mg/ml, antipain 
1 mg/ml, leupeptin 1 mg/ml, pepstatin 1 mg/ml, lOOOx dissolved in DMSO) and the 
cells gently gassed with 95% 0  ^ and 5% CO2  at 37°C in a shaking water bath for 
20 minutes before adding any drugs.
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2.11. PREPARATION OF RAT TISSUE FRACTIONS
All rats used were male Sprague-Dawley rats of weight 200-25Og, supplied 
by the University’s on site animal house.
2.11.1. Buffers
2.1 L 1.1. Homogenisation buffer:
ImM EDTA
lOmM Tris/HCl, pH 7.4
1 OOpM Dithiothreitol
Protease inhibitor cocktail
2.11.2. Preparation of a erude homogenate from brain
A brain from a 200-25Og male Sprague-Dawley rat was dissected and 
finely chopped in 20mls of ice-cold homogenisation buffer The chopped brain was 
washed through a tea-strainer with 5Omis of ice-cold homogenisation buffer and 
homogenised with eight strokes at full speed in a rotary homogeniser using a 
Teflon pestle and a glass vessel, in 5mis of homogenisation buffer. The 
homogenate was centrifuged at 650g for 10 minutes to pellet debris. The 
supernatant was snap-frozen in liquid nitrogen in lOOpl aliquots and stored at - 
80°C or used for membrane and cytosol preparations (section 2.11.3.). A similar 
method was used for preparing homogenates of heart, lung, liver and testes.
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2.11.3. Preparation of brain membrane and cytosol fractions
Rat brain homogenate was centrifuged at 245,000g and 4°C in a Beclcman 
TL-100 centrifuge for 20 minutes. The supernatant constituted the cytosol fraction 
and was snap-frozen in liquid nitrogen in lOOpl aliquots. The pellet or membrane 
fraction was resuspended in an identical volume to the cytosol fraction, snap- 
frozen in lOOpl aliquots and stored at -80°C. A similar method was used for 
preparing cytosol and membrane fractions from heart, lung, liver and testes.
2.12. PROTEIN ASSAY
2.12.1. Bradford assay
This method of protein determination is based on the Bradford method^ A 
standard curve was constructed using 0-20pg bovine serum albumin (BSA). These 
concentrations of protein were dissolved in 800pl distilled water. To this, 200pl 
Bio-Rad reagent was added, the tubes were vortexed and the absorbance was read 
against a blanlc curvette containing no protein, at a wavelength of 595mn. Protein 
concentrations of the samples were determined in a similar way, diluting 5pi of 
the sample in 800pl distilled water, adding Bio-Rad reagent and reading the 
absorbance in the spectrophotometer as before. All samples were assayed in 
duplicate. Protein concentrations were determined by plotting the standard cui’ve 
and fitting a 3rd polynomial curve to the points. The equation of the line was used 
to determine the protein concentration of the samples.
" Bradford, MM. (1976) Anal. Biochem. 72, 248-254.
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2.13. DNA MANIPULATIONS
2.13.1. Plasmid purification
All plasmids were pmified from E.coli JM109. Large cultures, 500ml were 
purified with use of Wizard Maxi-Preps (Promega) and small, 10ml cultures with 
Wizard Mini-Preps (Promega). In both instances, the manufacturers instructions 
were followed. Following purification, an extra ethanol precipitation step was 
used to further increase the purity of the plasmid (Section 2.13.2.).
2.13.2. Ethanol precipitation
To the volume of DNA to be ethanol precipitated, 10% (v/v) 3M sodium 
acetate was added and 2 volumes of 100% ethanol. The vial was mixed and 
incubated at -80°C for 30 minutes. The vial was spun at high speed in a microfuge 
for 10 minutes to pellet the DNA. The supernatant was aspirated and 1ml of 70% 
ethanol added the DNA was pelleted again by spimiing at high speed in a bench- 
top centrifuge for 5 minutes, the supernatant aspirated and the pellet allowed to 
air-dry for 5-10 minutes. The DNA was resuspended in TE buffer (section 2.9.1.2) 
and the purity of the DNA checked by UV absorption at 260nm and 280nm where 
^ 2 6 0 / ^ 2 8 0 = 1.8 for pure plasmid DNA.
2.13.4. Restriction enzyme digests
All restriction enzyme digest were performed on pure plasmid DNA using 
restriction enzymes supplies by Promega. Incubation were conditions were 37°C 
for a minimum of 1 hour using the appropriate buffer supplied by Promega. 
Following digestion DNA was cleaned-up using Wizard Clean-up kit (Promega)
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or run on an agarose gel and the required band excised, the DNA then being 
purified by the use o f Wizard PCR purification kit (Promega).
2.13.5. Ligations
Ligations were performed at 37°C overnight using T4  DNA ligase 
(Promega), using buffer and conditions as supplied by the manufacturer.
2.13.6. Polymerase chain reaction (PCR)
PCR was performed usually with 30 cycles of replication, a melting 
temperature of 94°C, an annealing temperature of about 50°C, depending on the 
primers and an elongation temperature of 72°C. Taq polymerase, Taq buffer, 3M 
magnesium chloride and dNTPs were all supplied by Promega.
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Chapter 3
Regulation of PDE4B
3.1. INTRODUCTION
As discussed in Chapter 1, the PDE4 family is encoded by four genes; 
PDE4A, PDE4B, PDE4C and PDE4D, each of which have distinct cluomosomal 
locations [Milatovich, A., et. al. 1994, Horton, Y., et. al. 1995]. For active splice 
variants within the PDE4 family, there is high homology in their C-terminal 
regions (figure 1.3.2.), whereas low homology of this region is seen between 
different PDE families. Within this C-terminal region is the catalytic domain, the 
sequence similarity presumably reflects the sensitivity of each of the splice 
variants to the PDE4 inliibitor, rolipram. The N-terminal regions show extremely 
low levels of homology, both between and within families [Bolger, G., et. al. 
1994, Conti, M., et. al. 1995]. It is these N-terminal domains which regulate the 
PDEs properties, such as catalytic activity, effector binding and subcellular 
distribution.
At the time this work commenced, only two PDE4B splice variants were 
suggested to represent full length clones and work performed by Lobban [Lobban, 
M., et. al. 1994] was the first attempt to characterise them as endogenously 
expressed species. For the purpose of this chapter, only these will be discussed in 
the introduction, the implications of recent findings will be considered in the 
conclusions. The suggested species were DPD (RNPDE4B1) [Collicelli, J., et. al. 
1989] and PDE4B2 (RNPDE4B2A) [Swinnen, JV., el. al. 1991]. HSPDE4B2A, a 
human equivalent to RNPDE4B2 has been cloned [McLaughlin, MM., et. al. 
1993] but no human equivalent to DPD has been identified. DPD was identical to 
PDE4B2 along its’ entire length, the only difference between the two form was an
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N-terminal extension of 48 amino acids in PDE4B2 (figure 3.1.1). Therefore, the 
start point of DPD appears to represent the point of a splice junction.
■DPD
PDE4B2 Common region PDE4B
Consensus
UCR-1 UCR-2 Catalytic
Figure 3.1.1. PDE4B Splice variants
Shows the PDE4B splice variants proposed [Collicelli, J., et. al. 1989, Swimien, 
JV., et. a l 1991]. The common region contains both UCR2 and the catalytic 
region and represents the entire length of DPD. The empty circle represents the 
splice junction where an additional N-terminal domain of 48 amino acids is added 
for PDE4B2.
To determine if the species cloned by Collicelli and Swinnen [Collicelli, J., 
et. al. 1989, Swinnen, JV., et. al. 1991] represented endogenously expressed 
species, their expression was investigated in rat brain using antisera directed to a 
peptide sequence found in the common C-terminal region, thus recognising both 
DPD and PDE4B2^ and antisera directed to the unique N-terminal region of 
PDE4B2 [Lobban, M., et. a l 1994]. Both DPD and PDE4B2 were reported to be 
expressed, each with a different subcellular distribution; PDE4B2 was entirely
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membrane associated, while DPD was cytosolic. Since the only difference 
between the two splice variants is a unique 48 amino acid N-terminal domain in 
PDE4B2, membrane association must be determined by these amino acids.
DPD and PDE4B2 also displayed a very different expression pattern 
between various regions of the brain, the organ in which they were reported to be 
expressed to the highest levels [Lobban, M., et. al. 1994]. The cerebellum, brain 
stem and mid brain expressed PDE4B2 but not DPD, the striatum, hypothalamus, 
hippocampus and cortex expressed both species while the pituitary was shown not 
to express either species. The most striking finding [Lobban, M., et. al. 1994] was 
that DPD was found to contribute 13-35% of the total PDE4 activity in brain 
cytosol and PDE4B2, 40-50% of the total PDE4 activity in the membranes. These 
figures indicated that the two PDE4B enzymes play a significant role in brain 
cAMP metabolism.
It has been shown that PDE4B mRNAs expressed in the Sertoli cell are 
derived from the assembly of 11 exons, with exons 5-10 encoding the catalytic 
region [Monaco, L., et. al. 1994]. This means that five exons code for N-terminal 
regions which have the potential for alternative splicing and a final exon codes for 
the C-terminal tail (Figure 3.1.2.). Monaco and colleagues further hypothesised 
that the niRNA of PDB4B2 is likely to be expressed in brain with an additional 5’ 
exon since exon lb, found in the Sertoli cell is missing in brain. It is possible 
therefore that either the splice variants DPD and/or PDE4B2 do not represent full 
length species and that the species detected and characterised [Collicelli, J., et. al. 
1989, Swimien, JV., et. al. 1991, Lobban, M., et. al. 1994] represent proteolytic
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products of larger proteins. They may, however, have represented true species and 
further splice variants may be discovered.
la lb 2 4 5 6 7 8 9 10 11H -l
Catalytic
Region
Figure 3.1.2. Proposed gene structure of the FDE4B gene.
Shows the exons as filled boxes, numbered, and the introns as connecting lines of 
the PDE4B gene. The hatched box represents the coding region derived from the 
Sertoli cell intron start site, a region which is absent in brain. The box marked la  
represents the upstream exons utilised in brain mRNA. Its presence was inferred 
by PCR amplification data on brain mRNA and by comparison with the 
Drosophila dunce gene. [From Monaco, et a l 1994].
Insulin is known to reduce cAMP levels in hepatocytes by the activation of 
phosphodiesterases [Loten, EG. and Sneyd, JGT. 1970]. This is due to the 
activation of at least three phosphodiesterases. One of these appears to be a PDE4 
form, another of these is a PDE3 species that can also be stimulated by glucagon 
[Heyworth, CM., et. al. 1983]. Activation of a PDE3 species by insulin has also 
been demonstrated in adipocytes and this occurs via a serine phosphorylation 
[Degerman, E., et. a l 1990]. An additional PDE species is also thought to be
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activated, althought its identity is not loiown [Degerman, E., et. al. 1990]. 
Preliminary data in this laboratory had indicated that a PDE4 species from 
adipocytes could be activated in response to insulin and that this might be a 
PDE4B form. This chapter describes work which investigates this.
3.2. RESULTS AND DISCUSSION
3.2.1. Detection of DPD by immunoblotting using polyclonal antibodies.
Three batches of antisera, were available that had been made in tluee 
separate rabbits, using the same peptide which was chosen to represent the 
sequence ‘A*'’*-T-E-D-K-S-L-I-D-T’‘’’ found in the C-terminus o f both PDE4B2 
and DPD but no other PDE species. The efficiency of these antibodies was tested 
using DPD expressed in COS cells (figure 3.2.1.). It was evident that each of the 
tluee antisera recognised DPD. Both the antisera 653 and 652 recognised a single 
band with no antigenicity seen with their pre-immune serum, whereas antisera 
2296 gave good recognition of DPD but also recognised a lower band of ~381d9a. 
This 38kDa band was, however, also seen in non-transfected COS cells and was 
not considered to be a PDE since no PDE activity could be imniunoprecipitated 
from these cells without transfection with a plasmid designed to express DPD.
3.2.2. Immunoblotting for PDE4B in adipocytes and hepatocytes
Work performed previously in the lab showed that DPD was expressed in 
both hepatocytes and adipocytes. However, difficulties were experienced in this 
work when immunoblotting adipocytes and hepatocytes with polyclonal 
antibodies generated from a peptide sequence found in the C-terminal region of
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Figure 3.2.1. PDE4B antibodies
Shows the specificity of three polyclonal antisera directed a peptide sequence in 
the C-terminal region of PDE4B2 and DPD. Antisera 2396 recognised an 
immunoreactive species of ~59kDa present in COS cells transfected with a 
plasmid designed to express DPD (lanes ‘T’) but also detected a non-specific band 
present in non-transfected COS cells (lane ‘NT’). The 2"  ^ bleeds o f antisera 652 
and 653 recognised the same immunoreactive species of ~59kDa present in COS 
cells transfected with a plasmid designed to express DPD (lanes ‘2"^’), with no 
detection with the pre-immune serum from the rabbits (lanes ‘Pre’).
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both PDE4B2 and DPD. A number of immunoblots on both crude, membrane and 
cytosol fractions from both adipocytes and hepatocytes, separated on 8% 
polyacrylamide SDS gels did not detect any immunoreactive species. It was, 
however, shown that PDE activity could be immunoprecipitated using this antisera 
(see below) and that the antibody recognised COS cell expressed DPD (see 
below). Immunoblotting of immunoprecipitated DPD was unsuccessful since the 
immunoglobulin G (IgG) band of the antisera used to iimiiunoprecipitate DPD co­
migrated with DPD. The antisera used for detection was the same as used for 
immunoprécipitation. Consequently the enzyme-linlced second antisera also 
recognised the immunoprecipitating IgG which was visible as a large band on the 
blot, masking DPD.
It was loiown that PDEs were susceptible to proteolysis [Davis, RL. 1990, 
Conti, M., et. al. 1991] and although protease inhibitors were present at all stages 
of preparing cellular fractions from both rat hepatocytes and epididymal 
adipocytes, a point o f concern was that DPD might have been degraded during the 
lengthy preparative procedure. In order to try and minimise this problem, both 
liver and fat pads were dissected directly into boiling 2% SDS in PBS, rapidly 
minced, homogenised and centrifuged at 650g for 10 minutes to pellet the debris. 
To the supernatant, an equal volume of Laemmli buffer added the samples 
subjected to SDS-PAGE and immunoblotted (figure 3.2.2.). Immunoreactive 
bands, consistent with the size of DPD (59kDa), were seen in both hepatocytes 
and adipocytes, although levels of detection were weak.
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Figure 3.2.2. DPD in adipocytes and hepatocytes
Shows an immunoblot using antisera 653 of rat adipocytes from epididymal fat 
pads and hepatocytes homogenised directly in boiling 2% SDS. Lane ‘1’ 
hepatocytes, lane ‘2’ hepatocytes diluted 1:10, lane ‘3’ hepatocytes diluted 1:100, 
lane ‘4’ adipocytes, lane ‘5’ adipocytes diluted 1:10. The bands seen on the 
immunoblot are ~59kDa, the same molecular weight as DPD.
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3.2.3. Effect of hormones on PDE activity of PDE4B in adipocytes
3.2.3.1. Effect o f  insulin and isoprenaline
Insulin has been shown to activate a PDE3 in adipocytes [Degerman, E., 
et. al. 1990]. It had been suggested, given the action of insulin in hepatocytes on 
PDE4 and the lack of correlation between PDE3 phosphorylation and total PDE 
activation in adipocytes that another PDE was involved in this activation 
[Beltman, J., et. a l 1993]. Preliminary data in the lab also suggested that a PDE4B 
may be activated by insulin in adipocytes. For this reason the action of insulin on 
intact rat adipocytes was investigated. Isoprenaline was also used to see if PDE4B 
was activated in response to elevated cAMP levels.
Intact adipocytes were incubated for 10 minutes with lOOiiM insulin, IpM  
isoprenaline or both together, in the presence of a protease inhibitor cocktail and 
the protein phosphatase inhibitors okadaic acid [Cohen, P., et. a l  1990] and 
sodium orthovanadate [Swarup, G., et. a l 1982]. The phosphatase inhibitors were 
present to maintain any activation that might have occurred via a phosphorylation. 
Following incubation, the adipocytes were lysed and PDE4B was 
immunoprecipitated using antisera 653. The immunoprecipitated PDE4B activity 
was then measui'ed by PDE assay and it was evident that a two-fold activation was 
seen with insulin which was shown with a Students /-test to be statistically 
significant (p<0.05). This activation was consistent over tliree experiments (figure
3.2.3.). Although a smaller activation was also seen with isoprenaline, this 
activation was not statistically significant. Treatment of the adipocytes with 
isoprenaline and insulin together had no effect on the immunoprecipitated PDE4B
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activity. While isoprenaline alone had no significant effect, it clearly attenuated 
the effect of insulin on the adipocyte PDE4B activity.
The method of activation of PDE4B by insulin was not likely to be via 
increased production of protein since the time-scale of the experiment was only 1 0  
minutes. Activation must have been either by a phosphorylation or by an allosteric 
interaction. No phosphotyrosine could be detected on either stimulated or 
unstimulated adipocyte PDE4B by immunoblotting with an anti-phosphotyrosyl 
monoclonal antibody, this does not entirely rule out the possibility that a tyrosine 
phosphorylation occurred but indicates that it is more likely to be either a serine / 
threonine phosphorylation or another interaction.
3.2.3.2. Time course o f  activation ofPDE4B in adipocytes by insulin.
In order to determine how rapidly the PDE4B from adipocytes was 
activated by insulin, a time-course was performed (figure 3.2.4.). DPD (PDE4B) 
could be seen to be activated very rapidly, an increase in activity seen after only 
one minute and maximal activity at two minutes, after which a gradual reduction 
of activity occurred. If the activation was via a phosphorylation, then the 
activation would be expected to be maintained since phosphatase inliibitors were 
present thioughout. However, an independent desensitisation mechanism may be 
inactivating DPD following activation or, indeed, the activation may not be 
mediated via a phosphorylation. The activation of DPD did not reflect the 
activation of the total PDE4 activity which occuired more slowly, peaking at 10
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Figure 3.2.3. Effect of insulin and isoprenaline on PDE4B from adipocytes.
Adipocytes prepared from rat epididymal fat pads and equilibrated in low 
phosphate Krebs buffer for 20mins were treated with insulin (lOOnM) and 
isoprenaline (1|,lM ) in the presence of phosphatase inliibitors okadaic acid (IqM ) 
and ortho vanadate (lOOpM) for lOmiiis. The cells were lysed on ice and PDE4B 
immunoprecipitated. Graph shows the PDE activity, measured as given in the 
methods at IpM  cAMP and 30^C, associated with identical protein concentrations 
of immunoprecipitated enzyme. ‘Control’ Shows samples incubated with okadaic 
acid and orthovanadate only. Values are activation over control ± standard error 
for three separate experiments.
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Figure 3.2.4. Time course for insulin activation of FDE4B
Shows the activation of PDE activity, at IpM  cAMP and 30°C of 
immunoprecipitated PDE4B, all PDE4 activity (measured by adding rolipram 
(lOqM), a PDE4 specific inhibitor, to the PDE assay) and total adipocyte PDE 
activity. Adipocytes were treated with lOOnM insulin at 37°C for the times 
indicated. Values are expressed as relative to ‘control’ which represents untreated 
cells ± standard error for three experiments.
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minutes, perhaps indicting that DPD was not the only PDE4 that is regulated by
insulin in adipocytes. Very little overall effect of insulin was seen on total PDE
activity. However, DPD constituted <2% of the total PDE activity and given that
the total PDE activity was very high, the visible effect of insulin on DPD would
efitect
have been negligible overall. The net^of insulin on total PDE activity would have 
been expected to be higher due to the reported effect of insulin on PDE3 
[Degerman, E., et a l 1990], the reasons remain unknown.
3.2.4. Difficulties with hormonal activation of DPD
Following the initial set of experiments (above), where insulin was shown 
to increase the catalytic activity of DPD in intact epididymal fat pads of Sprague 
Dawley rats, a number of problems were encountered. The most significant of 
these was the complete loss insulin stimulation of DPD, even though adipocytes 
were prepared and treated identically to previously. A number of explanations 
were possible; rats supplied may have been under varying degrees of stress or 
simply fed state, the adipocytes may not have been supplied with adequate 
conditions duiing incubation, or problems with infections in the University’s 
Animal Flouse at the time may have had adverse effects on tissue prepared from 
the rats.
3.2.4.1. Possible solutions
In order to investigate the change in insulin sensitivity of DPD, the first 
additional measure that taken was starving the rats overnight in an attempt to 
regulate their hormonal condition at the time the fat pads were dissected. This had 
no effect. The next steps were to supplement the incubation medium for the
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adipocytes with various nutrients. Thioughout a large number of experiments, the 
incubation medium was supplemented with combinations of glucose (2mM), 
adenosine (200nM), adenosine deaminase (lU/ml) and (-)-N^“(2-phenylisopropyl) 
adenosine (3iiM) (PIA) which is an analogue of adenosine that camiot be 
metabolised. None of these supplements had any effect and the insulin response 
curve remained completely flat (figure 3.2.5.).
It would appear that after originally demonstrating that DPD could be 
activated by insulin, it was shown that insulin did not have any effect on DPD 
from intact adipocytes, thus giving two completely opposed sets of data. 
Consequently, it was not possible to draw any conclusions about the activation of 
DPD by insulin. Problems with infection in the University’s Animal House 
continued and it was decided to look for expression of DPD in cell lines in order 
for its regulation by insulin to be characterised.
3.2.5. Expression of DPD in cell lines
Given that difficulties were incurred in studies with enzyme from Sprague 
Dawley rats, a series of cell lines were examined for expression of DPD.
3.2.5.1. Expression in 3T3L1 fibroblasts and adipocytes.
The 3T3L1 cells are fibroblasts that can be differentiated in adipocytes. 
Flasks of 3T3L1 fibroblasts and adipocytes were kindly donated by G'wymi Gould 
(Department of Biochemistry, University of Glasgow). The cells were scraped 
from the flasks directly into Laemmli buffer when they had reached 90% 
confluency and immediately boiled to avoid proteolysis. They were then subjected
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Figure 3.2.5. No activation of DPD by insulin
Adipocytes prepared from rat epididymal fat pads and equilibrated in low 
phosphate Ki'ebs buffer supplemented with glucose (2mM) and PIA (2nM) for 
20mins were treated with insulin (lOOnM) and isoprenaline (IpM ) in the presence 
o f phosphatase inhibitors okadaic acid (IpM ) and orthovanadate (lOOqM) for 
lOmins. The cells were lysed on ice and PDE4B immunoprecipitated with antisera 
653. Graph shows the PDE activity associated with identical amounts of 
immunoprecipitated enzyme. ‘Control’ Shows samples incubated with okadaic 
acid (IpM ) and ortho vanadate (lOOpM) only. Values are expressed relative to 
control ± standard error for three experiments.
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Figure 3.2.6. Immunoblot with anti-PDE4B on 3T3L1 fibroblasts and 
adipocytes
Cells from a single 90% confluent flask of either 3T3L1 fibroblasts (lanes ‘2’ and 
‘3’) or 3T3L1 adipocytes (lane 4) were scraped into 300pl of Laemmli buffer and 
boiled for 5mins. 50pl were then loaded onto an 8% polyacrylamide gel which 
was probed with antisera 653. Lane ‘1’ represents 200pg of a crude homogenised 
Sprague Dawleyrat brain preparation used as a positive control.
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to SDS-PAGE and immunoblotted with antisera 653 (figure 3.2.6.). The 3T3L1 
fibroblasts showed species of ~59kDa and 152kDa, the 59kDa species was likely 
to be DPD since it had the same apparent molecular weight. 3T3L1 adipocytes, 
however, showed no such immunoreactive species, perhaps indicating that 
expression of DPD was changed with differentiation of this cell line. The natum of 
the additional species that also seen in the fibroblasts with an apparent molecular 
weight of about 150-153kDa was not determined since no attempt was made to 
immunoprecipitate PDE activity with antisera 653 from 3T3L1 fibroblasts. Rat 
brain was used as a positive control on this immunoblot since it was reported to 
express DPD to high levels (13-35% cytosolic PDE4 activity) [Lobban, M., et. al.
1994] and intriguingly, no species corresponding to the reported size of 59kDa for 
DPD was seen. Tlnee bands were however visualised, each with much larger 
molecular weights than expected for DPD, -75, -141 and ~167kDa. These sizes 
were consistent tlrrough four separate inimunoblots. It is possible that the smaller 
band of 75kDa may have been PDE4B2, although the reported apparent molecular 
weight is 64kDa [Lobban, M., et. al. 1994]. Possible explanations for these 
inconsistencies will be discussed in the following sections.
3.2.5.2. Expression in NCB20 and NGJ 08 cell lines.
Cells from NCB20s and NGlOSs, a mouse neuroblastoma rat glioma 
hybrid cell line, were scraped directly from the flask into Laemmli buffer and 
boiled to avoid any potential proteolysis. Three immunoreactive bands were seen 
(figure 3.2.7.) for each of the cell lines. One of these corresponded to the apparent 
molecular weight of DPD (59kDa), the other two were much larger in size, being
Chapter 3 : R egulation o f  PD E 4B  \ Q 4
NG108 cells
NCB20 cells
lOSi
70.81
ÿ 4 % I' 4 k
109 kDa 
lOlkDa
#  59kDa
%E#
■ • I  I
il05
i70.8
■43.6
Figure 3.2.7. Immunoblots for PDE4B with NG108 and NCB20 cell lines.
Cells from a single 90% confluent flask of either NG108 or NCB20 cells were 
scraped into 300pl of Laemmli buffer and boiled for 5mins. 50pl were then loaded 
onto an 8% polyacrylamide gel which was probed with a antisera 653 to recognise 
PDE4B species.
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approximately lOlkDa and 109kDa. Evidently these were different in size to those 
seen in either rat brain or 3T3L1 fibroblasts.
3.2.53. Evidence for multiple splice variants?
It was obvious that a number of immunoreactive species were being 
detected by immunoblotting various cell lines with antisera directed to a peptide 
sequence within the C-terminal region of PDE4B species. One might hypothesise 
that these are ‘real’ splice variants of the PDE4B gene, perhaps generated by 
alternative splicing of the 5’region of the gene, as predicted by Monaco [Monaco, 
L., et. al 1994] (see introduction and conclusions). Perhaps the most striking 
finding was the lack of any immmioreactive band from rat brain that would 
represent either DPD or PDE4B2 but instead the existence of thiee much larger 
species. These suggestions will be discussed in view of more recently published 
data on the nature of PDE4B splice variants in the conclusions at the end of this 
chapter.
3.2.6. Dose response to rolipram of Immunoprecipitated PDE4B from NG108 
cells.
In order to ascertain whether or not the species recognised by the anti- 
PDE4B antisera, 653, were PDE4 species, they were iimmmoprecipitated from 
NG108 cells and a dose response to rolipram, the PDE4 specific inliibitor, 
performed (figure 3.2.8.). It was evident that the immimoprecipitated PDE activity 
was extremely sensitive to rolipram, a specific PDE4 inliibitor, as the ICgq was 
approximately 0.1 pM, which was lower than the figure published for PDE4B, 
IpM. Although figure 3.2.8, represents only a single experiment and to obtain an
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accurate IC5 0 , the range of rolipram concentrations needed to be lowered, a 
nmnber of further experiments on material immunoprecipitated from NGl 08 cells 
showed the PDE activity immunoprecipitated by the PDE4B antibody to be 
completely inhibited by rolipram at lOpM, a concentration at which rolipram 
inhibits all PDE4s but no other PDE family [Reeves, ML., et. al. 1987, Toiphy, 
TJ. and Cieslinski, LB. 1990, Soimess, JE. and Scott, EC. 1993].
3.2.7. Separation of the PDE4 species expressed in NG108 cells by non­
denaturing polyacrylamide gel electrophoresis.
It has been demonstrated that N G l08 cells expressed a PDE activity that 
was recognised by the PDE4B antisera 653 and was sensitive to the PDE4 
inhibitor, rolipram. However, it was not laiow if  this activity was solely as a result 
of the species of 59kDa that corresponded to DPD on immunoblots or if this 
activity was also contributed to by the other two much larger species of about 1 0 1  
and 1091cDa. In an attempt to resolve these activities, cytosolic fractions from 
N G l08 cells were subjected to non-denaturing PAGE as described in methods. 
Each non-denaturing gel was snap-frozen, sliced into thin slices and the PDE 
activity eluted overnight at 4”C. The PDE activity eluted from each of the slices 
was measured with and without the PDE4 inhibitor rolipram (figure 3.2.9.). 
Unfortunately, using the given conditions, no PDE species migrated very far into 
the gel and consequently the activities were not resolved. In order to get around 
this problem, either the gel would have had to be run for a much longer period of 
time, perhaps with a different dye as indicator or the acrylamide concentrations
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Figure 3.2.8. Dose response of NG108 PDE4B to rolipram
Shows a single experiment with PDE4B immunoprecipitated from N G l08 cells on 
which a PDE assay was performed for 10 minutes at 30°C at IpM  cAMP, in the 
presence of varying concentrations of the PDE4 specific inliibitor rolipram. 
Values are % of activity with no added rolipram ± standard error triplicate values 
within the experiment.
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could have been changed to get better resolution. The pH was at its maximal limits 
for such a gel so changing the pH was not a feasible solution.
Immunoblotting of the two peaks that were rich in PDE4 activity 
demonstrated that the peak that ran the farthest into the gel contained all tln'ee 
species detected by PDE4B antisera 653 on SDS-PAGE. It also contained rpde6  
and RDI, which are PDE4A species so the experiment failed to resolve the three 
immunoreactive species detected by antisera 653 into fractions that would enable 
their biochemical characterisation.
3.3. CONCLUSIONS
A number of difficulties were experienced with PDE4B., Recent data, 
however, casts some light onto these. A human homologue to DPD has been 
identified, TM72 (HSPDE4B1). However, this is greatly extended at its N~ 
terminus and is still not reported to be a frill length clone (figure 3.3.1.) [Bolger, 
G., et. al. 1993]. A further species was then identified that, like TM72 and 
PDE4B2 (RNPDE4B2), was identical to DPD apart from a unique N-terminal 
extension, PDE4B3 [Owens, R., and Houslay, MD., personal communication]. 
This data indicates that the point at which DPD was reported to start represents a 
common splice junction in PDE4Bs and it would seem likely that the species 
identified as DPD on immunoblots in this thesis was either a proteolytic fiagment 
of larger species or PDE4B2. The human B1 and B3 clones identified have 
apparent molecular weights of 1031cDa and 102kDa respectively, on immunoblots 
[Huston, E. and Houslay, MD., unpublished data]. These sizes are not too
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Figure 3.2.9. Non-denaturing PAGE of FDEs expressed in NG108 cells
Panel (a) shows the PDE activity of the slices of the gel ± rolipram. 600pg of 
cytosol from N G l08 cells were loaded onto the gel which was run until the dye- 
front (Amaranth) reached the bottom of the gel. The PDE activity was elute from 
the gel slices prior to assay. Panel (b) shows the PDE4 activity of the slices, 
represented as the total PDE activity minus the activity with lOpM rolipram.
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dissimilar to the bands seen in NG108 and NCB20cells of lOllcDa and 109kDa. 
On this basis, the species detected may have represented true rat PDE4B splice 
variants.
PDE4B1 (TM72-human)
1
(human and rat)
1
1 l^ UllllllUll PDE4B
PDE4B3 (human)
Consensus
UCR-1 UCR-2 Catalytic
Figure 3.3.1. Schematic representation of human PDE4B species
Shows the current PDE4B species from rat and human. The rat splice variant DPD 
is identical to all species from the common splice junction (empty circle). Variable 
domains are shown as shaded rectangles. The positions of UCRl, UCR2 and the 
putative catalytic region are indicated.
The work of Lobban [Lobban, M., et. a l 1994] only detected low MW 
species in immunoblots of rat brain. However, it should be noted that PDE4B2 
was found entirely membrane associated and DPD cytosolic, implicating the 
region of PDE4B2 that is not found in DPD as being responsible for membrane 
attaclnnent. In the work performed by Lobban, PDE4B2 was detected by two 
separate antisera, one directed to a peptide found in its unique N-terminal region
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and one made with a peptide in the C-terminal region common in all PDE4B 
splice variants. DPD was however only detected by the C-terminal antisera, which 
also recognised PDE4B2. It is possible therefore that the species characterised as 
DPD was a proteolysed form of PDE4B2. The fact that DPD was cytosolic and 
PDE4B2 membrane associated can be explained simply by the fact that the N- 
terminal region of PDE4B2, determining membrane association was clipped off, 
leaving a fully active cytosolic PDE4B species.
The activation of PDE4B by insulin remains questionable, due to the 
conflicting data given. A possible mechanism to explain the properties seen is that 
insulin has been shown to activate the MAP kinase cascade [reviewed White, 
MF. and Kalm, CR. 1994] which may have led to the phosphorylation and 
consequent activation of PDE4B within the time scale given, Isoprenaline elevates 
cAMP levels [Keely, SL. 1979], activating PKA, one of the targets for which is 
Raf. Phosphorylation of Raf by PKA inactivates it and since Raf is required for 
the insulin activation of the MAPK cascade [Denton, RM. and Tavare, JM. 1995, 
White, MF. and Kalin, CR. 1994], this might explain why isoprenaline attenuated 
the activation of PDE4B by insulin. However, insulin activation of PDE4B was 
not consistent.
Due to the difficulties experienced at the time, study of PDE4B was 
abandoned and the following chapters investigate the role of the unique N- 
terminal splice regions of other PDE4 species in regulating subcellular distribution 
and protein-protein interactions.
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Chapter 4
SH3 Domain Interaction of PDE4A
4.1. INTRODUCTION
The PDE4 family is encoded by four genes, PDE4A, PDE4B, PDE4C and 
PDE4D. The PDE4A gene lies between the genes for TYK2 and the LDL receptor 
on chromosome 19 and is extremely complex, having in excess of 14 exons 
[Olsen, A., Sullivan, M. and Houslay, MD. unpublished data]. Alternative splicing 
of the PDE4A gene leads, predominantly, to 5’ domain swaps, which produces a 
number of splice variants, each with unique N-terminal domains [Bolger, G. et. a l 
1994, Conti, M., et. al. 1995]. In the rat, there ai’e three splice variants o f the 
PDE4A gene, RDI [Davis, RL., et. al. 1989], rpdeô [Bolger, G., el. a l 1994a, 
McPhee, 1., et. a l 1995] and rpde39 [Bolger, G., et. a l 1996], Figure 4.1.1. In 
humans tliree PDE4A splice variants have been isolated to date. O f these, only 
one, hPDE46, the human homologue of rpdeb, has been characterised [Bolger, G., 
et. a l 1993, Bolger, G., et. a l 1996]. All active PDE4A splice variants do 
however have identical ‘core’-catalytic units, a phenomenon which is displayed by 
each of the PDE4 genes. There are however two additional splice variants that 
possess unique N- and C- terminal regions. These, however, encode catalytically 
inactive species due to alternative splicing, leading to premature truncation within 
the putative catalytic region [Horton, Y., et. a l 1995, Bolger, G., et. a l 1993]. The 
functional significance of these proteins with no phosphodiesterase activity has yet 
to be determined.
Each of the rat PDE4A splice variants has a profoundly different 
expression pattern. RDI is found exclusively in the brain [Bolger, G. 1994, Davis, 
RL., et. a l 1989, Bolger, G., 1994a, Shakiu, Y., et. a l 1995], rpde39 is found in
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the testes [Bolger, G., et. a l 1996] and hepatocytes [Zeng, L. and Houslay, MD., 
unpublished data] and rpde6  is expressed at its’ highest level the brain [Bolger, G., 
1994a]. Even though rpde6  and RDI are both expressed in brain, their expression 
patterns differ throughout the brain regions [Bolger, G., 1994a, Shakur, Y., et. a l 
1995, Section 1.3.5.2.], which might imply that they have unique functional roles.
rPDE39
UCR-1 UCR-2
mer'RDl
PDE4A
rPDE6 RDI
Consensus
Catalytic
Figure 4.1.1. Splice variant diagram for rat PDE4A.
Shows splice variants of the PDE4A gene fi'om rat, rpdc6 , rpde39 and RDI. 
met^^RDl is an engineered truncation that lacks any N-terminal splice region. The 
empty rectangle represents the core C-terminal catalytic region that is identical in 
each of the rat PDE4As. The shaded areas represent alternatively spliced regions 
and the empty circles splice junctions. The positions of UCRl, UCR2 and the 
putative catalytic region are indicated.
Each of the rat PDE4A splice variants have unique subcellular 
distributions. RDI is found to be 100% membrane associated when found in brain 
[Shakur, Y., et. a l 1995] and when transiently expressed in both COSl and C0S7 
cells [McPhee, I., et. a l 1995, Shakur, Y., et. al 1993]. met^*^RDl, however, is 
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found as a fully active enzyme which is expressed 100% in the cytosol [McPhee, 
I., et. al. 1995]. This has led to the proposal that the membrane association of RDI 
is conferred by its N-terminal splice region [Scotland, G. and Houslay, M.D. 
1995]. This was confirmed by the generation of a chimera of the N-terminal 
region of RDI fused to the N-terminus of a cytosolic bacterial enzyme, 
chloramphenicol acetyl transferase (CAT). This chimera was found to be 100% 
membrane associated when expressed in COS cells [Scotland, G. and Plouslay, 
M.D. 1995].
The subcellular distribution of rpde6  and ipde39, however, is not as clear 
cut. In contrast with RDI, which is 100% membrane associated, rpde39 is 
approximately 15% associated with the membrane fraction and the remainder 
found in the cytosolic fraction [Bolger, G., et. al. 1996]. Similarly, rpde6  is found 
distributed between the cytosol, membrane (P2 pellet) and also the low speed 
pellet (PI pellet); 74%, 13% and 13% respectively [McPhee, I., et. al. 1995]. RDI, 
can be removed from the membrane by washing with very low concentrations of 
the detergent Triton X-100 [Scotland, G. and Houslay, M.D. 1995]. However, 
rpde6  and rpde39 cannot be removed by using a combination of IM NaCl and 4% 
Triton X-100 [McPhee, I., et. al. 1995, Bolger, G., et. al. 1996]. It would be 
expected that any association with integral membrane proteins would be disrupted 
under such conditions. This might imply that rpde6  and rpde39 are associated with 
cytoskeletal structures that are associated with membranes and that such remnants 
are not disrupted by high salt and detergent [Slusarewicz, P., et. al. 1994, Jackson, 
SP., et. al. 1994]. There is no sequence homology between the N-terminal region 
of rpdc6  or ipde39 and the membrane targeting domain of RDI [McPhee, I., et. al.
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1995], which suggests that there is a fundamental difference in the method of 
membrane association between RDI and rpde6/39.
The extreme N-terminal sequence of rpde6  which is unique to that of 
rpde39 (figure 4.1.1.) contains a number or proline rich peptide sequences (figure
4.1.2.).
m e P P a a P s e r s l s l s l P g P r e g o a t l k P P P o h l w r g P r t P  
ir io o r g y P d s a e r s e t e r s P h r P ie r a d a v d t g d r P g l r t
Figure 4.1.2. The unique N-terminal region of rpde6.
Prolines are indicated by large bold text and argenines by bold text. 
Consensus sequences for binding to SPI3 domains are underlined.
These proline-rich sequences fit with consensus CLASS II Src homology 
domain 3 (SH3) binding sites [Alexandropoulos, K., et. al. 1995]. SH3 domains or 
Src homology domain 3, are distinct globular units of proteins that mediate 
interaction with proteins containing proline-rich sequences. SH3 domains are 
found in many proteins, including tyrosyl kinases, adapter proteins and 
cytoskeletal elements [reviewed Cohen, GB., et. al. 1995]. They function to 
recruit proteins to form functional complexes and to compartmentalise cellular 
signalling [Mayer, BJ. and Baltimore, D. 1993, Mayer, BJ., et. al. 1993, Booker, 
GW., et. al. 1993, Guruprasad, L., et. al. 1995, Pawson, T. and Gish, GD. 1992].
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In this chapter the potential of rpde6  to interact with SH3 domains is 
investigated. A protocol using SH3 domains fused to glutathione-S-transferase 
(GST) was adopted. This protocol involved the production of the fusion protein in 
bacteria. Once the bacteria were lysed, the fusion protein was purified on 
sepharose beads that had glutathione chemically linked to them. The beads, with 
the SH3-GST fusion protein complexed to them, could then be incubated with 
rpde6  and binding measured by immunodetection or enzyme assay. This method 
has been used by a number of other investigators [Haefner, R., et. al. 1995, 
Ramos-Morales, F., et. al. 1994, Alexandropoulos, K., et. al. 1995]. It allows 
rapid and effective purification of the SH3 domain (Section 2.5.).
4.2. RESULTS AND DISCUSSION
4.2.1. Expression of g!utalhione-S-transferase-SH3 fusion proteins in E.coli.
Glutathione-S-transferase (GST) flision proteins were expressed to high 
levels in E.coli JM109 bacteria using an isopropyl-b-D-thiogalactopyranoside 
(IPTG) sensitive promoter as described in section 2.4. Expression was induced 
with lOOpM IPTG for 4-6 hours at 37°C. Figuie 4.2.1a shows typical examples of 
such an induction. The fusion proteins were expressed to levels higher than any of 
the endogenous bacterial proteins. Figure 4.2.1b shows an example of how the 
fusion protein was purified from the bacterial extract with the glutathione 
sepharose beads.
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Figure 4.2.1. Induction of GST fusion proteins
Panel (a) shows the induction of GST fusion proteins in E.coli JM109 by 
lOOpM IPTG at 37°C for 5hrs. The fusion proteins can be seen as the bands, 
indicated with the numbers of their lane. Lane ‘M’ markers; ‘1’ GST (~25kDa); 
‘2’ Not induced; ‘3’ Src SH3-GST (~30kDa); ‘4’ Src SH2-SH3-GST (~40kDa); 
‘5’ Fyn SH3-GST (~29kDa). The gel is a 12% polyacrylamide gel stained with 
Coomassie Blue. Panel (b) shows the purification of GST. Lane (a) Purified GST 
on glutathione beads, (b) Markers, Bacteria not induced (c) and induced (d) to 
express GST.
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4.2.2. rpde6 binds to the SH3 domain of v-Src.
Using rpde6  from the cytosolic fraction of transfected C0S7 cells, 
preliminary results showed, using a PDE4A-specific polyclonal antisera for 
detection, that rpde6  can associate with the SH3 domain of v-Src (figure 4.2.2. 
lane 8 ). This binding was specific in that rpde6  did not bind to either glutathione 
beads alone or to glutathione beads with native GST bound to them (figure 4.2.2 
lanes 4 and 6 ). It was therefore evident that the prerequisite for ipde6  to bind was 
the presence of the SH3 domain of v-Src. Furthermore, washing the GST-Src SH3 
beads, with rpde6  attached, with 0.5% Triton X-100 and 0.5M sodium chloride 
only produced a small reduction in the amount of rpde6  bound, 5-22% as 
measured by densitometry scanning of four such immunoblots. This is 
characteristic of the rpde6  that is found associated with pellet fraction of brain and 
transfected COS cells which could not be removed with either high salt or 
detergent either [McPhee, I., et. al. 1995]. This might suggest that the method of 
attaclnnent is via an SH3 interaction.
4.2.2.1. All o f  the cytosolic rpde6 expressed in COS cells will bind to Src SH3
When cytosolic ipde6  from COS cells was presented to the SH3 domains 
for binding, a number of other COS cell cytosolic proteins will have been present 
also. Within these will have been proteins that contain SH3 domains that ipde6  
could potentially interact with and a number of proteins that potentially could 
have interacted with the SFI3 domain of Src. Thus when cytosolic ipde6  is 
presented with the Src SH3 domain a degree of competition will have existed for
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Figure 4.2.2. Binding of rpde6 to the v-Src SH3 domain expressed as a GST 
fusion protein.
This shows a typical immunoblot using a rat PDE4A specific anti-peptide 
antiserum that recognises the C-terminus of rpde6 . It demonstrates the binding of 
rpdeb to the SH3 domain of v-Src expressed as a fusion protein. Track 1, 
membranes (25pg) from rpde6  expressing C0S7 cells; track 2 , cytosol (25pg) 
from expressing C0S7 cells; track 3, washed glutathione agarose beads after 
exposure to rpde6 ; track 4, as track 3 but washed with 0.5M-NaCl + 0.5%-Triton 
X-100; track 5, blank ; track 6 , washed glutathione agarose beads with attached 
GST (lOOpg) after exposure to rpdeb; track 7, as track 6  but washed with 0.5M- 
NaCl + 0.5%-Triton X-100; track 8 , washed glutathione agarose beads with 
attached GST-v-Src-SH3 (lOOpg) after exposure to rpde6 ; track 9, as track 8  but 
washed with 0.5M-NaCl + 0.5%-Triton X-100; track 10, supernatant from the 
GST-v-Src-SH3 glutathione agarose beads after exposure to rpde6 .
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rPDE6 Gst
Figure 4.2.3. All of the cytosolic rpdc6 from COS cells will bind Src SH3.
Demonstrates that the GST-v-Src-SH3 fusion protein can adsorb all of the rpde6 . 
Here is shown an immunoblot using a rat PDE4A specific antiserum. 'rpde6 ‘ 
shows soluble C0S7-cell expressed rpde6 ; 'Gsf shows GST-containing agarose 
beads (400pg) exposed to rpde6  and then pelleted and washed; in tracks 1, 2 and 3 
are the results of probing agarose beads with attached GST-v-Src-SH3 domain 
(400pg each) which had been exposed to soluble rpde6 , harvested and washed. In 
this experiment GST-v-Src-SH3 agarose was added to rpde6  and the beads 
isolated (track 1 ) as well as a supernatant which was treated again with beads to 
yield a further pellet (track 2) which was repeated again to yield a pellet (track 3) 
and a final, clear supernatant (track 4). The band seen was approximately 111 kDa. 
This data represents a typical experiment of one done at least tliree times
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binding. However, figure 4.2.3 shows that all of the cytosolic COS cell rpde6  had 
the potential to bind to the SH3 domain of Src. This was done by presenting 25 pg 
of cytosolic COS cell rpde6  with three consecutive batches of 400pg Src SH3- 
GST immobilised on glutathione beads. In order to compaie affinities of different 
SH3 domains for rpde6 , quantities of SH3 domain were used such that only a 
proportion of the rpde6  interacted, in all future experiments.
4.2.3. Measurement of binding by phosphodiesterase enzyme assay
In section 4.2.2., rpdeb was found to interact with the SH3 domain of Src 
using immunoblotting as the detection method. However, it was not loiown if 
rpde6  catalytic activity was affected by binding to the SH3 domain of Src. 
Measurement of the PDE activity that associated with the SH3 domain of Src 
required the development of a method to measure PDE activity associated with the 
GST-Src SH3 beads.
4.2.3.1. Measurement o f  the proportion o f rpde6 that bound to the Src SH3 
domain by PDE assay
A method was devised that involved binding 25pg of COS cell cytosol 
expressing rpde6  to lOOpg of the Src SH3 domain, identically to the method for 
binding used for assay by immunoblotting. After washing of the beads, instead of 
resuspending the beads in Laemmli buffer for SDS-PAGE, they were resuspended 
in lOOpl of PDE assay buffer. 15-25pi of the resuspended beads were then added 
directly to a PDE assay which was performed as described in methods. Table 4.1. 
shows a typical PDE assay. Only about 3% of the rpde6  activity added to the
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Table 4.1. Measurement of rpde6 binding to Src-SH3-GST by PDE assay
Shows the proportion of PDE activity that associated with lOOpg of the SI-13 
domain of Src, relative to the quantity of 25pg of rpde6  transfected COS cell 
cytosol added. Values are expressed as pmols cAMP hydrolysed per minute per 
25 pg cytosol ± standard error for a single experiment.
pmols/min/25pg % of added
PDE activity added to SH3 beads 1870± 120 1 0 0
PDE activity bound to SH3 beads 60 + 14 3.2
PDE activity recovered Le. unbound 494+ 1.3 26.4
PDE activity unaccounted for 1316 70.4
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beads actually bound to the SH3 domain. Furthermore, if the PDE activity of the 
supernatant, i. e. the fraction containing the PDE that did not become associated, 
was measured, then discrepancies in the activity figures were found. 3% bound, 
26% recovered in the supernatant, which meant that approximately 70% of the 
activity added was apparently ‘lost’.
Possible explanations were that either rpde6  was inactivated upon binding 
to the src SH3 domain, a large proportion of the PDE activity was loosely 
associated with the beads after binding but removed in the washes or that the PDE 
bound to the immobilised SH3 domain, formed a pellet in the assay tube which 
prevented it from getting access to the substrate.
4.23.2. Determination o f  activity lost in washes
It was reasoned that, if  the PDE activity ‘lost’ when bindings were 
performed with GST alone was considered as the activity lost through washing 
and this accounted for in the binding to Src-SH3-GST, the activity bound, 
unbound and lost should have added up to the total presented for binding. Unless, 
that is, rpdeb was inactivated upon binding or another factor was contributing to 
the error, table 4.2. shows that, although a considerable amount of activity was 
lost in washing GST, considerably more was lost in the washing of Src-SU3-GST 
beads, indicating that this was not the only factor contributing. A second 
experiment to confirm this was simply not to wash the beads at all, assuming that 
a similar quantity of non-specific binding occurred with GST alone, binding could 
be measured as GST subtracted from Src (table 4.3.). While neither figures added 
up, GST alone was only missing 9% but about 23% of the activity added was still
Chapter 4: SH3 D om ain Interaction o f  P D E 4A  ^ 2 5
Table 4.2. Measurement of PDE activity lost in washing in the binding of
rpde6 to Src-SH3-GST
Shows the proportion of PDE activity that associated with lOOpg of the SH3 
domain of Src and GST alone, relative to the quantity of 25pg of rpde6  transfected 
COS cell cytosol added. Values are expressed as pmols cAMP hydrolysed per 
minute per 25pg cytosol ± standard error for a single experiment.
pmols/min/25pg % of added
Activity added 1293 ±38 1 0 0
Activity bound to Src SH3 25 + 2 2
Activity bound to GST 3.5 ± 3 0
Activity in Src SH3 supernatant 195 + 30 15
Activity in GST supernatant 785 ±18 61
Activity ‘lost’ in Src SH3 1073 83
Activity lost in GST washes 504 39
Actual activity ‘lost’ in Src SH3 569 44
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Table 4.3. Assessment of activity lost when no washes were used
Shows the proportion of PDE activity that associated with lOOpg of the SH3 
domain of Src and GST alone, relative to the quantity of 25pg of rpde6  transfected 
COS cell cytosol added, when the beads are not washed to remove non- 
specifically bound PDE. Values are expressed as pmols cAMP hydrolysed per 
minute per 25 pg cytosol ± standard error for a single experiment.
GST Src SH3
pmol/min/25pg % Added pmol/min/25pg % Added
Activity added 2059 ± 32 1 0 0 2059 ± 32 1 0 0
Activity on beads 301 ± 10 14 353 ± 6 17
Activity unbound 1603 ±61 77 1255 ±55 61
Activity missing 155 9 451 2 2
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missing with Src SH3 domain. These results might have indicated that, perhaps, 
rpde6  was inactivated upon binding. However, one further possibility existed, and 
that was, with the rpde6-SH3-GST complex linlced to SH3 beads, it formed a 
pellet at the bottom of the vials very rapidly, which might have prevented catalysis 
simply by hindering access to substrate.
4.2.33. PDE assay following release o f  fusion protein complex from  heads
A simple way of preventing the problem of the beads settling to the bottom 
of the vial in the PDE assay was to release the GST-SH3-rpde6 complex fi'om the 
glutatliione-sepharose beads using glutathione. One potential problem was 
that any bound PDE was diluted considerably. In order to compensate for the 
lower PDE activity, the incubation time of the PDE assay was increased to 30 
minutes over which period it still remained linear. Such a procedure was also used 
to assay the activity contained within various washes, where PDE was also very 
dilute. Table 4.4 shows a typical experiment. Using this procedure, it was shown 
that the PDE activity, both bound and unbound, added up to the total presented for 
binding. This demonstrated that rpde6  was not inactivated upon binding to the 
SH3 domain of Src. Thus the major factors which had led to discrepancies in the 
assay was due to bead immobilisation preventing the enzyme from having free 
aeeess to substrate and activity being lost in the washes.
4.2.4. Time course for binding of rpde6 to the SH3 domain of v-Src
Binding of rpde6  to the SH3 domain of v-Src was shown to be a rapid 
event, even at 4°C. It can be seen from figure 4.2.4. that maximal binding
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Table 4.4. PDE assay with GST-SH3 complex released from beads
Shows the proportion of PDE activity that associated with lOOpg of the SH3 
domain of Src and GST alone, as a percentage the activity in 25pg of rpde6  
transfected COS cell cytosol added. Shows activity released from the beads with 3 
washes of lOOpl of lOmM glutathione in lOmM Tris, pH 8.0, that that was not 
released from the beads and the activity that remained in the supernatant or was 
washed of the beads following binding. Values are expressed as pmols cAMP 
hydrolysed per minute per 25 pg cytosol ± standard error for a single experiment.
GST GST-Src SH3
Activity left on beads 0 . 8 1
Activity released from beads 0.9 + 0.05 6.2 ±0.07
Activity in supernatant 92.8 ±9.1 88.3 ± 6 . 8
(including washes)
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Figure 4.2.4. Time course for the binding of rpde6 to the Src SH3 domain.
In this experiment conditions were chosen (25pg rpde6  transfected COST- 
cell cytosol; 200pg v-Src-SHS-GST fusion protein) such that not all of the rpde6  
protein would become bound to the GST-v-Src-SH3 fusion protein and the time- 
course of binding followed by following PDE activity. Binding was done at 4°C 
Values are given as pmols cAMP hydrolysed/min/25 pg of rpdeb added ± standard 
error. This shows a typical experiment o f one done thi'ee times.
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occurred within five minutes. This demonstrated that not only could the 
competition for binding be overcome but that this could occur rapidly, perhaps 
giving some indication as to the affinity of rpde6  for the Src SH3 domain. 
Previously bindings had been performed for 60 minutes at 4°C but, in light of this 
data, it was decided that all subsequent bindings be performed for only 1 0  
minutes.
4.2.6. The relationship between binding and amount of SH3 domain used was 
linear
In previous experiments, only 3-7% of the rpde6  added bound to the SH3 
domain. If, however, the quantity of SH3 domain was increased then the 
proportion of ipde6  that bound increased with a linear fashion (figure 4.2.5.), 
demonstrating that if the amount o f SIT3 domain were increased still further, then 
was likely that all o f the rpde6  could be bound, confirming data given in section 
4.2.2.1., where all the rpde6  bound to four sequential batches of the Src SH3 
domain.
4.2.5. Kinetic properties of rpde6 when bound to Src SH3
It has been demonstrated that the activity of rpde6  was not altered upon 
binding to the SH3 domain of Src. It has, however, been shown that the IC5 0  for 
rolipram at (lOpM cAMP substrate) differed by an order of magnitude between 
the membrane-bound and cytosolic forms of rpde6 , namely 1.2pM and 0.16pM 
respectively [McPhee, I., et. al. 1995]. Experiments were performed to investigate 
if the or rolipram inhibition of rpde6  were altered upon binding to SH3 
domains.
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Figure 4.2.5. Relationship between binding and amount of SH3 domain.
Shows the percentage ± standard error for two separate experiments of the rpde6  
added in 25).Lg of COS cytosol that bound to various amounts of the Src SH3 
domain linlced to glutathione beads. Bindings were performed for 10 minutes at 
4°C and the SH3-PDE complex release from the beads for assay.
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I
y = m1*mO/(m2+mO)
Value Error
tn1 29.28 1.1199
m2 7.6762 0.62257
Chisq 1.4648 NA
0.99634 NA
10 15
[cAMP] (fiM)
20 25
Figure 4.2.6. determination for rpde6 bound to the Src SH3 domain
Shows a plot of concentration of cAMP against the rate of catalysis expressed as 
pmols cAMP hydrolysed per minute. The inset box shows the kinetic and 
statistical analysis ‘m 2’ represents and ‘m l’ the Shows an experiment 
identical to one done three times.
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4.2.5.1. Determination ofKjfi and Vjfiaxfor rpde6 bound to Src SH3
To determine the K,„ of rpdeô bound to the Src SH3 domain, catalytic 
activity was measured at a number of cAMP concentrations, with assays done at 
30°C. The bound PDE-SH3 complex was released from the glutathione beads 
prior to assay. Figure 4.2.6. shows a typical experiment which gives and 
apparent values that are almost identical to those published for both cytosolic 
and membrane associated rpde6  [McPhee, I., et. al. 1995]. Clearly the kinetic 
properties with respect to cAMP hydrolysis were unaffected by binding to the SH3 
domain of Src.
4.2.5.2 Determination o f  rolipram IC5Q values fo r  rpdeô when bound to Src SH3
To investigate if the IC5 0  values for rolipram corresponded to the values 
for membrane (1.2pM) or cytosolic (0.16pM) rpde6 , the inhibition of rpdeô bound 
to Src SFI3 was measured at O.lSpM and 1.5pM rolipram, similar to the IC 5 0  
values for cytosolic and membrane bound, respectively. Table 4.5. demonstrates 
that 0.15pM rolipram gave approximately 50% inliibition of the activity of rpdeô 
bound to Src SH3. This suggests that rpdeô when bound to the Src SH3 domain 
alone, resembles its cytosolic form.
4.2.7. Other PDE4A splice variants do not bind.
To address the question of which region of rpdeô is responsible for binding 
to the SH3 domain of Src, the binding of rpde39 and met^^^RDl were investigated. 
met^^RD 1 lacks any N-terminal splice regions (figure 4.1.1.) and it can be seen
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Table 4.5. Inhibition of rpdeô bound to Src SH3 by rolipram
Shows the inliibition of rpdeô by rolipram at two concentrations. Assays were 
done on rpdeô that had been bound to 400pg of Src SH3 on glutathione beads at 
4®C for 10 minutes and the complex then released with lOmM glutathione or 5pg 
of either cytosolic of membrane associated rpdeô. Figures are given ± standard 
error for thi'ee experiments.
Activity 
(pmol/min/25pg rpdeô) % Inhibition
rpdeô - Src SH3 2441 ±32
rpdeô - Src SH3 
+ O.lSpM rolipram
1220 ± 17 50 ±1
rpdeô - Sre SH3 
+ l.SpM rolipram
445 ± 43 82 ± 2
rpdeô -cytosolie (5pg) Ô259± 188
rpdeô - cytosolic (5pg) 
+ O.lSpM rolipram
3352 ±00 4Ô
rpdeô - cytosolic (Spg) 
+ l.SpM rolipram
911 ± 19 85
rpdeô - membrane (Spg) 1822 ±70
rpdeô - membrane (Spg) 
+ O.lSpM rolipram
152ô± ôl 1Ô
rpdeô - membrane (Spg) 
+ l.SpM rolipram
779 ± 23 57
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(a)
t m ê
Figure 4.2.7. met^^RDl and rpde39 do not interact with SH3 domains.
(b) GST Src Lyn
C b s/n b s/n b s/n
Panel (a) shows experiments done using met^^RDl (met26) and mock (vector 
only) extracts of C0S7 cells (mock) as the enzyme source. The data show 
immunoblots using the rat PDE4A specific antiserum. In track 1 is shown the 
soluble extract of C0S7 cells used in the experiments. The pelleted beads 
harvested after incubation with either GST-agarose (track 2) or with GST-v-Src- 
SH3 agarose (track 3) were iimnunoblotted as was the supernatant fraction from 
the GST-v-Src-SPI3 agarose (track 4) experiment. This experiment is typical of 
one done three times. The upper segment shows an identical set of experiments to 
those described above for the lower segment except that cytosol from mock 
(vector only) transfected COS-7 cells was used. This shows that the 
immunoreactive species detected by the PDE4A specific antisera are dependent 
upon transfection and expression of RPDE6. This data represents a typical 
experiment of one done at least three times
Panel (b) shows experiments done using rpde39 with GST alone and with GST 
fusion proteins formed with the SH3 domains of Src and Lyn as indicated in the 
figure panel, ‘b ’ represents lanes containing bound PDE and ‘s/n’ represents lanes 
showing unbound PDE. Lane ‘C’ shows COS cell expressed rpde39. rpde39 was 
detected using a PDE4A specific polyclonal antibody. This data represents a 
typical experiment of one done at least thi'ee times.
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from figure 4.2.7a. that it did not interact at all with the SH3 domain of Src. 
Therefore, the N-terminal region of rpde6 is required for binding to SH3 domains.
The N-terminal splice region of rpdc6 is 256 amino acids, 154 of which are 
shared with ipde39 (figuie 4.1.1.). When, however, the binding of rpde39 to Src 
SH3 domain was investigated, again, as with met^^RDl no binding was seen, 
figure 4.2.7b. This demonstrated that the extreme N-terminus of ipde6, which is 
unique, was required for binding to the v-Src SH3 domain and that the longer 
common region between rpde6 and rpde39 is not responsible. It maybe that this is 
the reason for their different subcellular distributions. The SH3 domain interaction 
may determine association with the low speed pellet and the common region 
between rpde6 and rpde39 might be involved with membrane association.
4.2.8. The use of dot blots to screen a number of SH3 domains for interaction.
It has been shown above, that rpde6 interacts with the SH3 domain of v- 
Src. In order to try and speed up the assay to facilitate the investigation of binding 
to a number of other SH3 domains from a variety of sources, a ‘dot blot’ 
procedure was developed. The hypothesis was that if SH3 domains were 
immobilised onto nitrocellulose then ipde6 could be overlaid and interaction 
detected using antibody directed to the PDE.
4.2.8.1. rpdeô used fo r overlay.
Experiments were designed such that lO^g, 20pg and 40 pg of SPI3 
domains from Src, p85, Ick, crk, csk and grb2 were loaded onto nitrocellulose. A 
vacuum system was used to load the protein onto a small area of 3 mm in diameter, 
thus enabling 96 samples to be loaded onto a single piece of nitrocellulose. The 
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SH3 domains to be loaded were purified on glutathione beads and then released 
from the beads into lOmM glutathione in 50mM Tris, pIT 8.0, as described in 
section 2.5.2. (figure 4.2.1.). The nitrocellulose was then blocked with 5% marvel 
in TBS and overlaid with lOOpg of cytosol from rpde6 transfected COS cells for 
2hrs at room temperature. It was then probed with a PDE4A specific polyclonal 
antisera, followed by a anti-rabbit HRP conjugated second antibody, essentially 
treated identically to an immunoblot (Section 2.2.3.).
Figure 4.2.8. shows an example of such a ‘dot blot’. Unfortunately this 
method did not prove effective for screening for interactions. The use of the 
vacuum system for loading proteins onto the nitrocellulose caused small 
indentations, into which the ECL reagent used for detection settled. This made it 
impossible to get comparative data and ECL from positive dots often ran into 
negative ones, giving false positives, for example the lOpg Grb2 SH3 domain in 
figure 4.2.8.
4.2.8.2. Biotinylated N-terminal rpdeô used for overlay.
In parallel with the method used in 4.2.4.1., the nitrocellulose was overlaid 
with lOOpg of a biotinylated peptide encoding the unique N-terminal region of 
rpdeô [O’Comiell, JC., et. al. 1996] instead of COS cell expressed rpdeô. This 
allowed for one step detection using HRP-conjugated streptavadin (SAPU) which 
bound to the biotin on the peptide. Unfortunately this method failed to be effective 
for screening SH3 domains for exactly the same reasons as section 4.2.4.1.
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Figure 4.2.8. A ‘dot blot’, used for screening of rpde6-SH3 interactions.
lOpg, 20|ig and 40|ag of the various SH3 domains were loaded onto the 
nitrocellulose which was then blocked with 5% marvel in TBS. The nitrocellulose 
was overlaid with lOOpg of cytosol from rpdeô transfected COS cells for 2hrs at 
room temperature. Detection of rpdeô was via PDE4A specific polyclonal 
antisera.
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4.2.9. Screening a number of SH3 domains for interaction with rpdeô.
domains could not be easily developed, binding was performed as described in 
section 4,2.2. SH3 domains have previously been shown to display selectivity for 
interaction with target species [Tersawa, H., et. al. 1994, Ramos-Morales, F., 
1994]. This same selectivity can be seen for their interaction with rpdeô, as 
measured by immunoblotting, in figure 4.2.9. The binding of rpdeô to SH3 
domains was measured both by densitometry scanning of immunoblots and by
by immunoblotting, table 4.2.Ô., it was evident that the SH3 domains with the 
highest affinity were those of Lyn and Fyn, which are tyrosyl kinases related to 
Src [Bolen, JB. 1993, Courtneidge, SA., et. al. 1993]. In contrast, another Src- 
family tyrosyl kinase, Ick [Bolen, JB. 1993, Courtneidge, SA., et. al. 1993] 
showed only a very low binding. Additionally, it should be noted that while Lyn- 
SH3 showed an 8.8 fold increase in binding to rpdeô over Src-SH3, it still did not
Since a rapid method for studying the interaction of rpdeô with SH3
i
assaying PDE activity associated with the SH3-GST beads and is tabulated in ' | |
table 4.2.Ô. :f
If the relative affinities of rpdeô for various SH3 domains were compared
.interact with the other PDE4A splice variant, rpde39 (figure 4.2.7b.). This :g|
supports the theory that the association of rpdeô with SH3 domains was conferred 
by its unique N-terminal region that contained the proline rich sequences.
Using an immunoblotting procedure [McPhee, I., et. al. 1995] to determine 
the relative activities of soluble and particulate forms of rpdeô, it was shown that 
the PDE activity of rpdeô, when bound to the SFI3 domain of Src, was changed by
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Figure 4.2.9. Selectivity for the binding of rpdeô to various SH3 domains 
expressed as GST fusion proteins.
Experiments were performed using 400pg of SH3 domain linked to glutathione 
sepharose beads and 15pg of cytosolic rpdeô from COS cells. Any rpdeô that 
became immobilised on the SH3 beads can be seen in lanes ‘b ’. That PDE that did 
not interact can be seen in lanes ‘s/n’. Lane ‘C’ represents COS cell cytosolic 
rpdeô. Detection was via a polyclonal antibody to PDE4A. These immunoblots are 
typical of ones done at least thi'ee times.
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Table 4.2.6. Assessment of the binding of rpdeô to SH3 domains
Detection of the amount of associated PDE was done by following 
immunoreactive protein and also by following PDE activity. For comparison, 
these data are shown relative to those found for v-src SH3 (set equal to 1), Errors 
are SD on the indicated number of experiments (n).
PD E4A
species
G ST fusion protein species relative
binding
relative
activity
(n)
rpdeô S1-C-SH3 (1) (1) (25)
rpdeô GST alone 0.05 ±  0.03 0.04 ±  0.03 (25)
rpdeô Src-SH3 + (1 -256  N T-R PD E6/biotin) 0.08 ± 0 .ô 0.1 ± 0 .5 (3)
rpde39 GST alone 0.04 ±  0.04 0.07 ± 0 .0 5 (4)
rpde39 Src-SH3 0.05 ±  0.04 0.05 ±  0.03 (4)
rpde39 Lyn-SH3 0.09 ± 0 .0 5 0.08 ±  0.05 (4)
rpdeô Lck-SH3 0.39 ±  0.09 0.07 ±  0.04 (6)
rpdeô Crk-SH3 0.40 ± 0 .1 2 0.05 ±  0 .04 (6)
rpdeô Csk-SH3 0.25 ± 0 .0 6 O.OÔ ±  0.05 (6)
rpdeô Abl-SH 3 0.58 ± 0 .1 4 0.48 ±  0.09 (6)
rpdeô Fyn-SH3 2.1 ±  1.1 3.1 ±  1.2 (4)
rpdeô Lyn-SH3 8.8 ± 1 .5 9.1 ±  1.7 (4)
rpdeô G rb2-(SH 3-SH 2-SH 3) 0.08 ±  0.05 0.07 ± 0 .0 4 (3)
rpdeô Src kinase 7.8 ±  1.2 7.0 ±  0.9 (4)
rpdeô Src-SH2 0.04 ± 0.04 0,05 ± 0 .0 3 (4)
rpdeô Src-(SH 2+SH 3) 8.1 ± 0 . 8 7.9 ± 0 . 5 (4)
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less than 7% (n=6 ). If, however, the relative affinities of rpdeô for various SH3 
domains were compared by measuring the PDE activity versus immimoblotting, 
then a slightly different pattern was evident. Binding to the SH3 domains of Lyn, 
Fyn and Abl were similar by both immunoblotting and PDE activity. However, 
the SH3 domains that displayed weaker affinity Crk, Csk and Lck, had virtually 
no PDE activity associated with them, which would not have been expected by if 
the levels of protein on an immunoblot are considered. It would appear that 
although binding to these domains was weak, the PDE that associated with them 
displayed a marked diminution of activity.
From the analyses done, the strongest interactions with rpdeô were those of 
the SH3 domains of Src, Fyn and Lyn. However, SH3 domains from these 
proteins need not necessarily be the actual proteins that rpdeô interacts with in 
vivo, since in intact cells, interaction will depend on availability of suitable SH3 
domain containing proteins and competition with other species for the interaction. 
A potential for modulation of PDE catalytic activity was demonstrated on 
association with the SH3 domains of Crk, Lck and Csk. It may be that other SH3 
domains can interact with a higher affinity and modulate activity.
4.2.10. Binding of rpdeô to full length Src
It has been well documented that SH3 domains, when generated as distinct 
species, fold into active conformations [Tersawa, H., e t a l 1994, Goudreau, N., 
et. a l 1994, Booker, GW., et. a l 1993, Borchert, TV., et. a l 1994, Yu, FI., et. a l 
1993, Guruprasad, L., et. a l 1995]. It was decided to confirm the interaction of 
rpdeô with an intact protein containing an SFI3 domain. It was shown that rpdeô
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could interact with a full length Src tyrosyl kinase expressed as a GST fiision 
construct, figure 4.2.10. Indeed, when the cytosol from v-Src transfected COS 
cells was mixed with cytosol from rpdeô transfected COS cells, rpdeô could be co- 
immunoprecipitated with Src using anti Src antisera, figure 4.2.12. This data 
demonstrated that intact Src and intact ipdeô would interact when mixed together.
4.2.11. rpdeô does not interact with the SH2 domain of Src.
Src also has an SH2 domain, it was shown which binds to phosphorylated 
tyrosine residues in proteins. However, using the SH2 domain of Src, expressed as 
a GST fusion construct, it was shown (figure 4.2.10. and table 4.2.Ô.) that rpdeô 
did not interact with this species. Indeed, for rpdeô to interact with an SH2 
domain, it would have needed to be tyrosine phosphorylated and not only was it 
not possible to demonstrate any tyrosine phosphorylation of rpdeô, figure 4.2.11. 
but rpdeô does not contain a consensus tyrosine phosphorylation site within its 
coding sequence.
4.2.11.1, Increased affinity o f  the Src SH2-SH3 construct over SH3 alone.
Despite the inability of rpdeô to interact with the SH2 domain of Src, table
4.2.Ô. and figure 4.2.9 show that a GST construct with the SH2 and SH3 domains 
of Src together was much more effective in binding rpdeô than the STB domain 
alone. A similar potentiation of SH3 binding has been noted for the binding of PI- 
3 kinase to the Src SH3 domain in a construct made from the Src SH2 and SH3 
domains [Haefner, R., et. al. 1995]. This was also shown not to be due to any 
interaction with the SH2 domain of Src but was presumed to be due to a more
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Src Src Src Full Length
SH2 SH3 SH2/3 Src
s/n b b s/n b s/n b s/n b s/n
Figure 4.2.10. rpdeô binds to full length Src but not to the Src SH2 domain
Experiments were performed as described in the legend of fig. 4.2.9. but 
using GST fusion proteins of Src-SH2 domain, Src-SH3 domain, Src-(SH2+SE[3) 
domain and full length Src. The immobilised (b) and remaining soluble (s/n) 
fractions are shown. The presence of associated rpdeô was detected using 
immunoblotting with the PDE4A anti serum. Experiments are typical o f those done 
at least three times.
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Figure 4.2.11. rpdeô is not tyrosine phosphorylated
Shows immunoblots using anti-phosphotyrosine antiserum probing an 
immunoprecipitate of v-Src incubated in a buffer system which allows for the 
functional tyrosyl kinase activity of Src to be expressed. In track (1) data is shown 
for incubation of the Src immunoprecipitate alone, with the single auto- 
phosphotyrosyl phosphorylated Src protein being identified. In track (2) 
incubations were done with the addition of immunoprecipitated rpdeb. 
phosphotyrosyl immunoblotting of Src and rpdeô. No evidence of any 
phosphotyrosine associated with rpdeô was obtained. The position where rpdeô 
migrated on these gels, as detected by stripping the blots and re-probing with 
antibody for rpdeô, is shown. The immunoprecipitated Src protein kinase was 
able to phosphorylate exogenously enolase on tyrosine residues (data not shown). 
Experiments are typical of those done at least three times.
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Figure 4.2.12. rpdeô and Src can be co-immunoprecipitated
The cytosol fractions from v-Src transfected cells were mixed with those from 
COS7 cells transiently expressing rpdeô. In track (3) anti-Src antibody was added 
and the immunoprecipitate probed by Western blotting with antibody for rpdeô. In 
track (2) a non-specific antibody was used and in track (1) no antibody was added 
to the immunoprécipitation system. Experiments are typical of those done at three 
times.
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effective folding of the SH3 domain as a result of the presence of the SH2 domain 
which is normally adjacent to it in the native protein [Haefner, R., et. al. 1995]. It 
appears, therefore, that a similar phenomenon exists for Src SH3 interaction with 
rpdeô.
A Grb2 construct, however, which contained two SH3 and an SH2 domain 
failed to interact with rpdeô at all, table 4.2.ô. Thus rpdeô does not interact with 
this adapter protein, again reflecting the specificity of the interaction with SH3 
domain containing proteins.
4.3. CONCLUSIONS
I have demonstrated that COS cell expressed rpdeô appears to bind to SH3 
domains via its N-terminal splice region. This interaction is both specific and 
rapid and cannot be disrupted by high concentrations of either salt or detergent. 
The rat PDE4A splice variants, ipde39 and the ‘core’ species met^'^RDl do not 
interact with SH3 domains, which, given the differences that are seen in 
subcellular localisation, indicates that the SH3 interaction of rpdeô may be 
involved in regulating this, rpdeô is the only rat PDE4A splice variant that 
associates with the low speed pellet, whereas both rpdeô and rpde39 associate 
with the membrane and ai'e found in the cytosol [McPhee, I., et. al. 1995]. The 
only difference between rpdeô and rpde39 is their extreme N-terminal regions, 
which in the case of rpdeô contains the proline rich regions, so perhaps the SH3 
binding of rpdeô confers its association with the low speed pellet. If the IC 5 0  
values for rolipram are considered, they are identical for rpdeô bound to an SH3 
domain to those seen for the cytosol form but 1 0 -fold lower than the membrane
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bound form. Therefore, either SH3 domain interactions do not confer membrane 
association or rpdeô or another factor, such as another interacting protein, might 
alter the properties of the membrane bound form.
The following chapter goes on to investigate the binding of rpdeô to other 
SH3 domains, looks at the binding to SH3 domains of PDEs that are expressed in 
rat tissues and investigates the potential binding of other PDE isoforms.
Chapter 4: SH3 D om ain Interaction o f  PD E 4A 149
Chapter 5
SH3 Domain Interaction of PDE4D
5.1. INTRODUCTION
In chapter 4, it was shown that a PDE4A splice variant, rpde6, could 
associate with the SH3 domains of Src family tyrosyl kinases. This association 
was characterised and shown to be conferred by its’ N-terminal splice region 
which contained proline rich sequences [Chapter 4, O’Connell, JC., et. a l 1996]. 
Such sequences are loiow to interact with SH3 domains [Alexandropoulos, K., et. 
a l  1995]. All the investigations performed in chapter 4 used COS cell expressed 
PDEs which raised the questions ‘Can endogenously expressed rpdeb interact with 
SH3 domains?’ and ‘Do any other PDEs interact?’. The species rpdeb is 
predominately expressed in brain [Bolger, G., et. al 1996], together with RDI 
(figure 4.1.1.) and rPDE39 is expressed in testis [Bolger, G., 1994a], which are 
also PDE4A splice variants. These consequently made two good target tissues for 
investigating binding of PDE4A to SH3 domains.
PDE4s are encoded by four genes, PDE4A, PDE4B, PDE4C and PDE4D. 
The structure of the PDE4A gene is discussed in chapters 1 and 4. The PDE4D 
gene, in contrast to the PDE4A gene, has been better characterised in human tissue 
than in rat. As with the PDE4A gene, there are a number of splice variants, each 
with unique N-terminal domains [Nemoz, G., et. a l 1995, Bolger, G., et. a l 
1996a]. Figure 5.1.1. illustrates the PDE4D splice variants. These PDE4D species 
showed distinct expression patterns in a number of cell lines, indicative of distinct 
functions conferred by their N-terminal domains [Nemoz, G., et. a l 1995, Bolger, 
G., et. a l 1996a]. They also showed remarkable similarity to the PDE4A species 
in their subcellular distribution, PDE4D1 and PDE4D2 show very little, <3%,
Chapter 5: SH 3 D om ain Interaction o f  P D E 4D  t 5 1
association with the membrane, PDE4D3, PDE4D4 and PDE4D5 each display 20- 
35% membrane association, with a further 10% being associated with the low 
speed pellet [Bolger, G., et. al. 1996a]. Given that the shorter species, PDE4D1 
and PDE4D2 showed little membrane association then it is likely that subcellular 
targeting was conferred by the N-terminal splice regions of the other species.
D51
D4l1...........
D1 f1 1 1 1 1 1
D2
UCR-l UCR-2
PDE4D
Consensus
Catalytic
Figure 5.1.1. PDE4D splice variants.
Shows splice variants of the human PDE4D gene. The empty rectangle represents 
the core, catalytic region common to all species. The shaded areas are unique, 
alternatively spliced, regions and the circles splice junctions. The positions of the 
homologous regions, UCRl and UCR2 are indicated.
In this chapter, the binding of endogenously expressed rpde6 
(RNPDE4A5) to SH3 domains is investigated. It also demonstrates that another 
PDE, the PDE4D4 isoform, interacts with SH3 domains.
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5.2. RESULTS AND DISCUSSION
5.2.1. Generation of a fodrin SH3-GST fusion protein.
It has been shown in chapter 4 that rpdeb preferentially binds to SH3 
domains of Src family tyrosyl kinases, having very little or no affinity for the SH3 
domains of adapter proteins Grb2 and Crk. Another class of proteins that SH3 
domains are commonly found in are cytoskeletal proteins. Association of rpde6 
with SH3 domains of such proteins might help to explain the distribution pattern 
of rpde6 between the cytosol, membrane and low speed pellet [McPhee, I., et. al. 
1995, Section 1.3.5.2.]. A cytoskeletal protein that contains an SH3 domain is 
fodrin [Moon, RT., and McMahon, AP. 1990]. In order to investigate binding of 
PDEs to this protein, a GST fusion protein was made with the SH3 domain so that 
it could be expressed and purified from E.coli.
5.2.1.1. Design o f  primers to amplify the fodrin SH3 domain
The complete coding sequence of fodrin (nonerytlii’oid alpha-spectrin) was 
obtained from GeiiBanlc (accession number J05243). Sequence homology with the 
SH3 domain of Src and information from the SwissProt database indicated that 
amino acids 974-1021, from the initiating methionine, form the SH3 domain. The 
expression vector that the SH3 domain was to be cloned into was pGEX-5X-l 
from Promega. This vector allowed for induction of the GST-SH3 fusion protein 
with IPTG, as described in methods. The multiple cloning site of this vector is 
immediately downstream of the GST protein, to allow an N-terminal in-frame 
fiision protein to be generated (figure 5.2.1.).
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Figure 5.2.1.(a) Multiple cloning site of pGEX-5X-l
Shows the amino acid and nucleotide sequence of the multiple cloning site of 
pGEX-5X-l. The unique restriction sites are indicated.
975 Leu Tyr Asp Asp Gin Glu Lys Ser Pro Arg Glu Val Thr Met Lys Lys
3025 CTC TAC GAC TAT CAG GAG AAG AGT CCC CGA GAC GTC ACC ATG AAG AAG
Gly Asp l i e Leu Thr Leu Leu Asn Ser Thr Asn Lys Asp Trp Trp Lys
GGA GAT ATC CTT ACC TTA CTC AAC AGC ACC AAC AAG GAT TGG TGG AAA
Val Glu Val Asn Asp Arg Gin Gly Phe Val Pro Ala Ala Tyr Val Lys 1022
GTG GAA GTG AAC GAT CGT CAG GGT TTT GTG CCG GCT GCG TAC GTG AAG AA 3 1 7 0
Figure 5.2.1.(b) DNA and Protein sequence of the fodrin SH3 domain
Show the protein and DNA sequence of the fodrin SH3 domain that was cloned 
into pGEX-5X-l. The residue numbers from the initiating methionine or AT G are 
indicated.
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PCR primers were designed to amplify the SH3 domain of fodrin given in 
figure 5.2.1.(b) and add restriction sites to the fragment for EcoRl and BamHl to 
allow insertion into the vector. The sequences of the primers used are given 
below.
N-terminal: 5 ’-CTGGTCGGATCCCTCTACGACTATCAGGAGAAG-3 ’ 
C-terminal: 5 ’-GGGTCCGAATTCTTCACGTACGCAGCCGGCAC-3 ’
First strand cDNA was made using RNA from Jurkats cells (human T-cell 
line) with a kit from Pharmacia. PCR was performed with 30 cycles, using 
26pmols of each of the primers.
5.2.1.2. Cloning o f the fodrin SH3 domain
Both the PCR fragment and the vector were digested with EcoRl and 
BamHl and purified using Promega’s Wizard kit. They were then ligated 
overnight with T4 DNA ligase and competent E.coli transformed. Transformed 
bacteria showed resistance to ampicillin and six colonies were picked, grown and 
mini-preps of their plasmid DNA made. When each of the colonies 1-6 were 
grown and induced with lOOpM IPTG for Slii's, a protein species was produced 
that could be visualised on Coomassie-stained 12% SDS-PAGE (Figure 5.2.2.). 
However clone F0D5 produce a band that was smaller than the others, 
approximately 25kDa, the same size as GST alone. The other clones produced 
proteins of about 30kDa, the predicted size of an SFI3-GST fusion. Restriction
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Figure 5.2.2. Coomassie stained SDS-PAGE of fodrin SH3 domain 
indications
Shows 12% SDS-PAGE of six bacterial clones transformed with the fodrin SH3- 
GST fusion protein, induced with lOOpM IPTG and stained with Coomassie blue 
(lanes 1-6). Lane ‘M’ contains molecular weight markers, lane ‘U’ uninduced 
bacteria and lane ‘GST’ induced vector alone transformed bacteria.
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digests using EcoRV, which cut the vector once and the insertonce, confirmed that 
clone F0D 4 contained the fodrin SH3 domain and F0D5 contained vector alone,
5.2.2. rpde6 but not rPDE39 from rat tissue binds the Src SH3 domain
In order to investigate if any endogenous rpde6 (RNPDE4A5) could
interact with SH3 domains, a cytosolic fraction from rat brain was used since
rpde6 is Icnown to be expressed in brain [McPhee, I., et. al. 1995]. Similarly
rPDE39 is expressed in the testis [Bolger, G., et. al. 1996] so rat testis was used to
investigate the binding of rPDE39, a PDE4A which lacks the proline-rich regions
found in rpde6 (figure 4.1.1.). As with the COS cell expressed rpde6, experiments
were performed using immobilised GST-Src SH3 fusion protein, the difference
being only that brain or testis cytosol was used instead of COS cell cytosol. The
whichPDEs were detected using polyclonal antiserE^recognised all rat PDE4A species 
and a typical immunoblot is given in figure 5.2.3. It is clear that native rpde6 did 
associate with the SH3 domain of Src and that native rPDE39 did not. Thus 
endogenous PDE4A species showed a similar selectivity in binding SH3 domains 
as did the COS cell expressed species. The lower band seen in testis, as detected 
with an anti-PDE4A antibody, was of unlaiown origin. It is not known to date if 
this represents a novel PDE4A species, however, it did not associate with the SH3 
domain of Src.
5.2.3. PDE activity can be bound from rat brain ,
Given that rpde6 from rat brain was shown, by immunodetection, to bind |*
to SH3 domains, the next step was to see if catalytically active PDE could be 
extracted from rat brain cytosol using various SH3 domains. Figure 5.2.4.
Chapter 5: SH3 D om ain  Interaction o f  P D E 4D  \ 57
■ ■
Brain
GST Src
(u) (b) (u) (b)
Testis
GST Src
(u) (b) (u) (b)
1-PDE6
lllk D a  
|=!rPDE39
Figure 5.2.3. rpde6 from brain but not rPDE39 from testis binds to Src SH3
Figure shows binding of lOOpg of brain or testis cytosol to 400pg of Src-GST 
fusion protein. GST alone is included as a control. Lanes (u) represent 
immunoreactive PDE that did not bind and lanes (b) represent PDE that did bind. 
Detection was via a polyclonal antisera that will recognise all rat PDE4A species.
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demonstrates that PDE activity from brain cytosol bound to the SH3 domains of 
Src and Fyn, but not the SH3 domains of either the cytoskeletal protein, fodrin, or 
the N~ or C-terminal SH3 domains of the adapter protein, Grb2. This specificity 
for the SH3 domains of the Src family tyrosine kinases reflects the same 
specificity that was seen with the COS cell expressed rpde6 in chapter 4. It is 
worth noting that while the SH2 domain of Grb2 showed no affinity for any PDEs, 
the SFI2 domain of src displayed some affinity for PDE activity. This however 
was very variable between experiments, as reflected by the error bars. If, indeed, 
any PDE binds then it is unlikely to be rpde6 as it was shown not to interact with 
the SH2 domain of Src when expressed in COS cells [Chapter 4]. Furthermore, the 
primary sequence of rpdc6 does not contain any consensus sites for tyrosine 
phosphorylation which would be required since SH2 domains bind to 
phosphorylated tyrosine residues (Chapter 1). It does not however rule out the 
possibility that another PDE was interacting with the Src SH2 domain, although 
by immunodetection, no PDE4A species was found to bind to the Src SH2 
domain. The variation seen may have been effected by the phosphorylation state 
of the enzyme in the preparation, which was perhaps related to the lack of protein 
phosphatase inhibitors when preparing brain cytosol.
4.2.4. Estimation of the proportion of PDE4 from brain cytosol that could 
bind to SH3 domains
By measuring the total PDE activity in rat brain cytosol that was inhibited 
by rolipram, a PDE4 specific inhibitor, an estimation was made as to the total 
amount of PDE4 activity that was present. Consequently the amount of PDE4
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Figure 5.2.4. PDE Activity Bound to SH3 Domains from Rat Brain
Shows the total PDE activity that bound to 400|Lig of various SH3 domains from 
100|LLg of rat brain cytosol. ‘Fod’ represents fodrin, ‘Grb2-N SH3’ represents the 
N-terminal Grb2 SH3 domain and ‘Grb2-C SH3’ represents the C-terminal Grb2 
SH3 domain Values are expressed relative to those for the Src SH3 domain ± 
standard error for tlii'ee experiments.
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activity that bound to SH3 domains could be calculated as a percentage of the total 
PDE4 activity (figure 5.2.5.). It should be noted that not all o f the PDE4 activity is 
contributed by rpde6 (RNPDE4A5), in fact rpde6 is reported to represent only 8- 
14% of the PDE4 activity in the cytosol [McPhee, I., et. a l 1995]. Consequently, 
one would not have expected to achieve 100% binding, nor at this stage was it 
known if rpde6 was the only PDE4 that was capable of interacting with SH3 
domains. The data in figure 5.2.5. showed a high level of variation between 
experiments, with the proportion of PDE4 bound ranging between 20 and 50%. 
While the reasons for the variation remain unlaiown, it is possible that any 
endogenous associations of PDE4s may have changed with the age of the brain 
preparation, thus effecting the pool of PDE4 that is free for binding exogenous 
SH3 domain. Regar dless of variation, figures anywhere within the range, represent 
a significant proportion of cytosolic brain PDE4s and in fact are much higher than 
the proportion constituted by rpde6 [McPhee, I., et. a l 1995]. It is likely therefore 
than other PDE4 species from brain might be capable of interacting with SH3 
domains.
5.2.5. Assessment of the interaction of other PDE families from various 
tissues with SH3 domains.
Having already shown that PDE4 activity can be bound to SH3 domains 
from rat brain using SH3 domains as GST-fusion proteins, linked to glutathione 
sepharose beads, the next step was to determine if PDE activity could be bound 
from any other tissues. Additionally it is not a forgone conclusion that because all 
the activity found to bind to SH3 domains in section 5.2.4. could be inliibited by
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Figure 5.2.5. Percent of total brain PDE4 activity that binds to various SH3 
domains.
Shows the proportion of brain cytosolic PDE4s that can interact with SH3 
domains. Expressed as a percentage of the total brain cytosolic PDE4 activity in 
lOOpg that bound to 400pg SH3 domain ± standard error for three experiments. 
PDE4 activity was measured using 1 OpM rolipram as an inhibitor.
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Figure 5.2.6.(a) Assessment of cytosolic PDEl activity associating with the 
SH3 domains of Fyn and Grb2.
Shows PDEl activity from lOOpg of tissue cytosols that was pulled down by 
400pg of either the Fyn SH3 domain or the N-terminal Grb2 SH3 domain with the 
GST controls subtracted. The PDEl activity was measured as that which was 
activated by Ca^^ (5mM) and calmodulin (lOU/lOOpl). Values are given as 
percent of total PDEl activity (Table5.1) ± standard error for tliree measurements 
per tissue.
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Figure 5.2.6.(b) Assessment of cytosolic PDE2 activity that associated with the 
SH3 domains of Fyn and Grb2.
Shows PDE2 activity from lOOpg of tissue cytosols that was ‘pulled down’ by 
400|LLg of either the Fyn SH3 domain or the N-terminal Grb2 SH3 domain with the 
GST controls subtracted. The PDE2 activity was measured as that which was 
inhibited by EFINA following stimulation by cGMP. Values are given as percent 
of total PDE2 activity (Table 5.1.) ± standard error for tliree measurements per 
tissue.
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Figure 5.2.6.(c) Assessment of cytosolic PDE3 activity that associated with the 
SH3 domain of Fyn and Grb2.
Shows PDE3 activity from lOOpg of tissue cytosols that was ‘pulled down’ by 
400pg of either the Fyn SH3 domain or the N-terminal Grb2 SH3 domain with the 
GST controls subtracted. The PDE3 activity was measured as that which was 
inliibited by cilostaniide. Values are given as percent of total PDE3 activity (Table
5.1.) ± standard error for tlmee measurements per tissue.
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Figure 5.2.6.(d) Assessment of cytosolic PDE4 activity that associated with the 
SH3 domain of Fyn and Grb2.
Shows FDE4 activity horn lOOpg of tissue cytosols that was ‘pulled down’ by 
400pg of either the Fyn SH3 domain or the N-terminal Grb2 SH3 domain with the 
GST controls subtracted. The PDE4 activity was measured as that which was 
inliibited by rolipram. Values are given as percent of total PDE4 activity (Table
5.1.) ± standard error for tliree measurements per tissue.
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Table 5.1. Total PDE activities in tissues used for binding profiles
Shows the total cytosolic PDE activity for the tissues used in figures 5.2.6.(a-d). 
PDE activity is expressed as pmols cAMP hydrolysed per minute per unit of 
sample used at IpM  cAMP for the SH3-binding studies ± the standard error for 
tliree measurements per tissue.
Brain Heart Lung Liver Testes Kidney
PDEl 18640 713 855 3900 2990 3390
±4320 ±50 ±65 ±760 ±230 ±530
PDE2 4940 2337 330 11110 1150 1900
±1470 ±65 ± 165 ± 1095 ± 180 ±630
PDE3 5530 535 580 3320 520 4430
± 1690 ± 8 ±35 ±920 ±280 ±68
PDE4 3820 525 2035 2320 6700 6760
±300 ±38 ±260 ±720 ±60 ± 1190
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rolipram, the only PDEs that bind SH3 domains are PDE4s. For instance PDEl 
activity would not be detected without adding Ca^^/Calmodulin to activate it and 
PDE2 activity may not be detected without the presence of cGMP. In order to 
evaluate this, cytosolic fractions were taken from a number of tissues, namely 
brain, heart, lung, liver, kidney and testis and over a number of experiments 
probed with the SH3 domains of Fyn and Grb2, with GST alone as a control, and 
assayed for the presence of the vaiious PDE families (figures 5.2.6.(a), (b), (c) and 
(d) ). Figure 5.2.6.(d) shows that significant proportions of PDE4 activity bound 
from both brain and heart to the SH3 domain of Fyn, with no binding seen from 
the other tissues. The PDE4A species, rpde6 is expressed at high levels in the 
brain [Bolger, G., 1994a], which might explain this level of binding. The identity 
of PDE4 species in heart has not heen reported, so it is not laiown if ipde6 was 
present. However, the levels of total PDE4 activity in heart were very low (table
5.1.), so such a low level of expression might account for the 15% of total activity 
that associated with the SH3 domain. However, in a manner that was very 
different to that in brain, binding of heart PDE4 activity to the Gi*b2 SH3 domains 
occurred. This might indicate that a different PDE4 form is expressed in heart 
which can bind to Grb2, unlike in brain where rpde6 has a negligible affinity for 
the Grb2 SH3 domains (chapter 4). A potential candidate might be PDE4B3, 
which has been shown to be expressed in heart by PCR and a low level expression 
detected by immunoblotting [Huston, E. and Houslay, MD., mipublished data]. In 
the sequence of PDE4B3 [Owens, R. and Houslay, MD. personal communication] 
can be seen two PxxP motifs within its unique N-terminal region (figure 5.2.7.). 
Although one PxxP motif is also found in both PDE4B1 and PDE4B2, the
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4B1 MKKSRSVMTVMADDNVKDYFECSLSKSYSSSSNTLGIDLWRGRRCCSGNL
4B2 MKEHGG----------   TFSSTGISGG----------------------SGDS
4B3 MTAKDSSKELTASEPEV C l — KTFKEQ--------- MHL------------------- EL
4B1 QLPPLSQRQSERARTPEGDGISRPTTLPLTTLPSIAIT---------- TVSQECF
4B2 AMDSLQ----------------------------------------------------------------------------------------------
4B3 ELPRLPGNRPTSPKISPRSSPRNSPCFFRKLLVNKSIRQRRRFTVAHTCF
4B1 DVENGPSPGRSPLDPQASSSAGLVLHATFPGHSQRRESFLYRSDSDYDLS
4B3 DVENGPSPGRSPLDPQASSSAGLVLHATFPGHSQRRESFLYRSDSDYDLS
4B1 PKAMSRNSSLPSEQHGDDLIVTPFAQVLASLRSVRNNFTILTNLHGTSNK
4B2 --------------------------------------MPVCLFA-----------------------------------------------------
4B3 PKAMSRNSSLPSEQHGDDLIVTPFAQVLASLRSVRNNFTILTNLHGTSNK
4B1 RSPAASQPPVSRVNPQEESYQKLAMETLEELDWCLDQLETIQTYRSVSEM
4B2 ----------------------------------EESYQKLAMETLEELDWCLDQLETIQTYRSVSEM
4B3 RSPAASQPPVSRVNPQEESYQKLAMETLEELDWCLDQLETIQTYRSVSEM
Figure 5.2.7. Alignment of the N-terminai regions of the PDE4B species.
Shows sequences o f the N-terminal regions of the PDE4B splice variants'to their 
region of homology. Proline residues are indicated in bold. Consensus SH3 
binding sequences on the basis of a PxxP motif [Ren, R., et. a l 1993, Yu, H., et. 
a l 1994, Feng, S.,e/. al. 1994] are underlined.
Owens, R and Houslay, MD., unpublished data
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sequence surrounding the other PxxP motif in PDE4B3 is rich in prolines. Such a 
proline-rich sequence can function to stabilise the formation of a poly-pro line 
helix, a structure which is reported to be required for SEI3 domain binding [Yu, 
H., e l a l 1994].
Figure 5.2.6.(c) shows binding of a PDE3 species from heart and testes to 
Fyn and a PDE3 species binding from heart but not brain to Grb2 SFÏ3. It is not 
known what PDE species may have contributed to this. However, examination of 
the sequence of PDE3A revealed that it too contains a proline-rich sequence in its 
N-terminal splice region (figure 5.2,8.). PDE3A is expressed in heart [Taira, M., 
et a l 1993] but no evidence has been published concerning its expression in
m r k d e r e r d t P a m r sP P P P P P P a t a t a a s
P P e s l r n g y v k s c v sP l r q d P P r sf ffh l c r
f c n v e P P a a s l r a g a r l s l a a l a a f v l a a l l
g a g P e r w a a a a t g l r t l l sa c sl sl sP l fsia  
c a fffl t
Figure 5.2.8. The amino acid sequence of the 
extreme N-terminus of human PDE3B.
Shows the first 130 amino acids of human PDE3A.
Prolines are indicated in large bold type. This 
sequence has no homology to any other PDE3 
species.
I
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testis. A proline-rich sequence was not found within the coding sequence of any 
known PDE3B splice variants, so the difference in affinity of the PDE3 species 
between the two tissues for the SH3 domains of Grb2 and Fyn might indicate the 
presence of further splice variants that have yet to be discovered or that a 
modification occurs in some tissues that prevents association with SH3 domains. 
It should be noted that, although a large proportion of total PDE3 activity bound 
from these tissues, the total PDE3 activity was low. For example in testes, PDE3 
activity was 13-fold lower than PDE4 activity (table 5.1). This meant that, 
although ~10% of the PDE3 activity in testis associated with the SH3 domain of 
Fyn, the actual activity associated with the beads was only one fifth of the PDE4 
activity that associated from brain. Low levels of activity would have made further 
characterisation difficult.
Figures 5.2.6 (a) and (b) demonstrate that no detectable PDEl or PDE2 
activity associated with the SH3 domains of Fyn or Grb2. Negative values in the 
case of PDEl are likely to have been because, although Ca^ "^  is used to stimulate 
PDEl, it also inhibits PDE4 [Wilkinson, IR. and Houslay, MD., unpublished 
data], so a drop in activity upon the addition of Ca^^ is consistent with the 
presence of bound PDE4 activity.
5.2.6. Two PDE4 splice variants from rat brain become associated with the 
Src SH3 domain
Since the PDE4 activity that associated with SH3 domains was the highest 
in terms of total activity, irrespective of percentage of total PDE4, when rat brain 
was used, the next stage was to determine which PDE4 species were responsible
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ifor this activity. It has already been shown in section 5.2.2. that rpde6 binds, but
,
this need not have been the only species. To determine if any other PDE4 species 
contributed to the activity associated with the SH3 domains, rat brain cytosol was 
probed with immobilised SH3 domains and which were then loaded onto SDS
m
gels and analysed with antisera specific to PDE4A, PDE4B, PDE4C and PDE4D.
.No PDEs were detected on immunoblots with either the PDE4B or the 
PDE4C antisera, indicating that no PDE4B or PDE4C species from rat brain were 
capable of interacting with SPI3 domains.
Figure 5.2.9. shows such a PDE4D immunoblot. It is clearly evident that a 
PDE4D species also possessed the ability to associate with SH3 domains. The
Ti . -PDE4D species that interacted was likely to be PDE4D4, as it comigrated with the 
PDE4D4 transfected COS cell cytosol. Rat brain could be seen to express species 
that comigrated with PDE4D3, PDE4D4 and PDE4D5, PDE4D3 apparently being 
expressed higher levels than the other two. The interaction of PDE4D4 with the 
SH3 domains was therefore specific since neither of the other two species 
expressed displayed any binding capabilities at all. Furthermore, the specificity for 
particular SH3 domains was also high since PDE4D4 interacted with the SH3 
domains of Src and Fyn but not with that of fodrin.
Given that PDE4D4 interacted with Src family tyrosine kinases and that | |
■|
neither PDE4D5 or PDE4D3 interacted, then the interaction must have been 
conferred by its N-terminal splice region, since the C-terminal regions are 
identical (figure 5.1.1.). When the sequence of the extreme N-terminal region of \
PDE4D4 was studied, a large proline-rich region was seen (figure 5.2.10.). It is
-T'i
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PDE4D1
-216kDa
i lllkDa
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Figure 5.2.9. PDE4D4 binds to SH3 domains
A typical immunoblot with a PDE4D specific monoclonal antibody. It shows that 
only PDE4D4 of the PDE4D species expressed in rat brain bound to SH3 
domains. COS cell expressed PDE4D splice variants are indicated in the figure. 
PDEs that bound to 400pg of SH3 domain from lOOpg of rat brain cytosol are 
indicated in lanes (a)-(f): (a) GST control. (400pg) (b) Src SH3-GST. (400pg) (c) 
Src SH2SH3-GST. (400pg) (d) Fyn SH3-GST. (400pg) (e) Fodrin SH3-GST. 
(400pg) (f) 25pg of rat brain cytosol.
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proline-rich sequences that confer interaction with SH3 domains (chapters 1 and
4).
As can be seen from figure 5.2.10., the N-terminal region of PDE4D4 is 
extremely rich in prolines, 74% proline, within a stretch of 31 amino acids. Thus, 
PDE4D4 is remarkably similar to rpde6 (RNPDE4A5) in that it possesses an N- 
terminal region that enables it to interact with SH3 domains and that both species 
are able to interact with SH3 domains from Src family tyrosyl kinases.
m e a e g s s a P a r a g sg e g sd sa g g a t l ic a P k h l w r
heqhhqyP lrqP qfrllhP hhulP P P P P P sP qP
qP qcP lqP P P P P P lP P P P P P P gaargryassg
a t g r v r h r g y s d t e r y l y c r a m d r t s y a v e t g h r P
g l k k sr m sw P ssfq g l r r
Figure 5.2.10. The N-terminal sequence of PDE4D4.
Shows the amino acid sequence of the first 150 amino acids 
of the unique N-terminal region of PDE4D4. Each proline 
is indicated as a large bold ‘P \
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5.2.7. PDE4D4 interacts with SH3 domains
In section 5.2.6. it was demonstrated that a protein from rat brain cytosol 
could be detected on an immimoblot, with a PDE4D specific antibody, that bound 
to the SH3 domains of Src and Fyn and comigrated with PDE4D4 transfected 
COS cell cytosol. Consequently, it was assumed that this was in fact PDE4D4. To 
confirm this, a range of PDE4D species were expressed In COS cells and the 
cytosolic extracts pooled together before being probed with SH3 domains (figure 
5.2.12.). It can be seen that only PDE4D4 bound to the SH3 domains and in the 
cases of Src and Fyn, virtually all the PDE4D4 that was available for binding was 
found associated with the SH3 domain. The specificity was exactly the same as 
with the PDE4D4 from rat brain, with binding to the SH3 domains of Src and Fyn 
but not to the SH3 domain of fodrin.
5.2.8. PDE4D4 binds in an active form
As PDE4D4 could be detected as associating with SH3 domains by 
immunoblotting, it was necessary to determine if PDE activity could be detected 
associated with SH3 domains. To check this, bindings to the SH3 domains of Fyn, 
Src and fodrin were performed with both PDE4D4 and also with PDE4D1, a 
PDE4D species that lacks the proline-rich region seen in PDE4D4 (figure 5.2.11.). 
As would have been expected, PDE4D4 activity could be detected associated with 
the SH3 domains of Src and Fyn but not to fodrin and no PDE4D1 activity 
associated at all, thus confirming the immunoblotting data.
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5.2.9. PDE4D4 shows a different specificity for SH3 interaction to rpde6 
(RNPDE4A5) and rpde6 is inactivated upon binding to fodrin and cortactin.
It has already been shown that PDE4D4 does not interact with the SH3 
domain of fodrin, as detected on an immunoblot (figures 5.2.9. and 5.2.12) and if 
the activity data for rpde6 (RNPDE4A5) (figures 5.2.4. and 5.2.5.) is studied, then 
it appears that rpde6 did not bind to fodrin either. When, however, samples of 
rpde6 were incubated with the SH3 domains of fodrin and cortactin and binding 
assayed by immunoblotting, then binding was evident (figure 5.2.13.). The 
PDE4A species, rpde6 must therefore have been catalytically inactivated upon 
binding to the SH3 domains of fodrin and cortactin. Significantly, also, the 
interaction of PDE4D4 with these SH3 domains displayed differences in 
specificity. While PDE4D4 showed similar affinity for the SH3 domains of Src ;;|
family tyrosyl kinases, little or no affinity was seen for the cytoskeletal SH3 
domains, either by measuring PDE activity or by immunodetection. Evidently, 
although both PDEs belong to the same family and interact with SH3 domains, 
they differ in selectivity for SH3 domains and properties once bound. This 
demonstrated that PDE4D4 and rpde6 are likely to have unique and finely defined 
functional roles within the cell.
5.3. CONCLUSIONS
It has now been conclusively shown that two PDE4 species interacted with 
SH3 domains. These PDEs were are encoded by different PDE4 genes, PDE4A 
and PDE4D, with only one splice variant of each gene possessing the ability to 
interact with SH3 domains. PDE4D4 showed a different specificity to rpdc6,
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Figure 5.2.11. Association of PDE4D4 activity with SH3 domains
Shows PDE4D4 and PDE4D1 activity that associated with 400pg of SH3 domains 
from 15|4g of COS cell cytosols. PDE activity was measured after releasing the 
GST-SH3-(PDE) complex from glutathione sepharose beads with lOmM 
glutathione. Values are expressed as PDE activity per 400pg of SH3 domain ± 
standard error for two separate experiments.
Chapter 5: SH3 D om ain  Interaction o f  PD E 4D 177
PDE4D4PDE4D5PDE4D3
PDE4D1
GST Src SH3 Src SH2/3 Fyn Fodrin
Figure 5.2.12 PDE4D4 binds to SH3 domains
Shows a typical immunoblot with a PDE4D specific monoclonal antibody. It 
demonstrates that when 15pg each of cytosolic PDE4D1, PDE4D3, PDE4D4 and 
PDE4D5 from COS cells were mixed together, and incubated with 400pg of 
various SH3 domains, only the PDE4D4 species bound to the SH3 domains. Each 
of the splice variants used are clearly marked on the figure. Lanes marked ‘b’ 
show PDEs that bound to the SH3 domain, lanes marked ‘u’ show PDEs that did 
not bind to the SH3 domain. Only 50% of the unbound fraction was loaded onto 
the gel.
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GST Grb2
N-SH3
Src
SH3 Fyn rpde6Fodrin Cortactin
1 f ’-f
GST Fodrin
Src Grb2
HPDE4D4
SH3 C-SH3 Fyn
Figure 5.2.13. Different specificity of SH3 binding between rpde6 and 
PDE4D4
Panel (a) shows a typical immunoblot with a PDE4A specific antibody. COS cell 
transfected rpde6 was incubated with glutathione beads linked to GST fusion 
proteins of the SH3 domains from the indicated proteins. The beads were loaded 
onto the gel to measure binding. Binding to the SH3 domains of Src, Fyn, Fodrin 
and Cortactin was seen. Panel (b) shows a typical immunoblot with a PDE4D 
specific antibody. COS cell transfected PDE4D4 was incubated with glutathione 
beads linked to GST fusion proteins of the SH3 domains from the indicated 
proteins. The beads were loaded onto the gel to measure binding. Binding to the 
SH3 domains of Src and Fyn was seen.
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PDE4D4 only binding to SH3 domains of the Src family tyrosyl kinases, Fyn and 
Lyn, and rpde6 binding to SH3 domains of both Src family tyrosyl kinases and the 
cytoskeletal proteins, fodrin and cortactin. The interaction of rpdeb with the SH3 
domains of fodrin and cortactin but not Src family tyrosyl kinase SH3 domains 
profoundly attenuated the catalytic activity.
In addition to the binding of PDE4D4 and rpdeb, evidence was suggested 
for the potential binding of another PDE4 species, a PDE4B, although this 
remains to be confirmed. Also, a PDE3 species was detected, associating with 
SH3 domains from heart and testes. It is likely that this is PDE3B1, since it 
contains a proline-rich region that fits with the SH3 binding peptide consensus 
[Yu, H., et. a l 1993], although again, this has yet to be confirmed.
Such interactions must clearly possess some functional role. Clearly they 
may serve to localise PDEs to particular subcellular compartments, the 
implications of which will be discussed in the next chapter.
i
I
■
. ■Y.:
I
Chapter 5: SH3 D om ain Interaction o f  PD E 4D 180
Chapter 6
A*
II
General Discussion and Conclusions
ï^î
I
i
■S
1
:î
6.1. GENERAL DISCUSSION AND CONCLUSIONS
The introduction to this thesis summarised current knowledge about the 
PDE4 family of enzymes which is encoded by four- genes, each of which is 
alternatively spliced. The tissue and subcellular distributions of very few of these 
splice variants has been documented in detail. There is also little insight into how 
the intracellular targeting of particulate associated species is determined and its 
functional significance. However, work performed recently in this laboratory has 
been fundamental in demonstrating that the N-terminal splice domains of various 
PDE4 isoforms can determine their intracellular localisation. The appreciation of a 
functional role for the N-terminal regions of certain PDE isoforms came originally 
from studies done on the membrane association of RDI [Shakur, Y., et, a l, 1994, 
Scotland, G., et. al. 1995]. I have extended this to the study of the PDE4A splice 
variant, rpde6 and the PDE4D splice variant PDE4D4, where I have demonstrated 
their ability to interact with SH3 domains. rpde6 was shown to bind to the SH3 
domains of a number of proteins, particularly those of Src family tyrosyl kinases. 
This SH3 binding was shown to be conferred by the N-terminal region since 
met^^RDl, which lacks the splice region, did not interact. Furthermore, other rat 
PDE4A splice variants, which have different N-terminal domains, were shown not 
to possess the ability to bind SH3 domains. Additionally, it was demonstrated that 
another PDE4 species, namely PDE4D4, was also able to bind to the SH3 domains 
of Src family tyrosyl kinases. As with rpdeb, the interaction involving PDE4D4 
appeared to be determined by the uniquely spliced N-terminal domain of this 
isoform. In both these instances, the N-terminal domain contains proline-rich
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sequences which are known to define interaction with SH3 domains [Ren, R., et. 
al. 1993].
Specificity for SH3 domain interaction has been shown to be conferred by 
residues surrounding a simple PxxP motif in the primary sequence [Ren, R., el. al. 
1993, Yu, H., et. al. 1994, Feng, S., et. al. 1994]. PxxP motifs are split into two 
categories, those that contain the sequence RxL immediately N-terminal to PxxP, 
(Class I) and those that don’t (Class II) [ Yu, H., et. al. 1994] as shown below.
Class I motif consensus R X L P X X P X X
Class II motif consensus X X X F X X P X,=,-3 R
Where X represents any amino acid
A number of groups have studied the interaction of proline containing 
peptides with SH3 domains so as to produce consensus SH3-binding sequences. 
Initial work, performed by Yu, H., et. al. 1994 and Rickies, RJ., et. al. 1994, used 
peptides generated by studying SH3 binding sequences in a number of natural 
ligands. In all these studies, done for Class I motifs, the constitutive PxxP motif 
was of the form PPxP, where only x was variable. Work performed more recently 
[Sparks, AB., et. al. 1996] has shown that the second proline is not a constitutive 
requirement for SH3 binding and, in most cases, can be replaced by any amino 
acid (Figure 6.1). Based upon this, I have performed an alignment of consensus 
sequences information fi*om Sparks, AB., et. al. 1996 (Figure 6.1), the 
implications
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SH3 Domain Ligand Consensus
h K K R F L F X w F
Yes^ _ X X R P L p X L p
Cortactin^ + P p Y p X K p X w L
Crk^ 4^ p Y L p T K
Grb2 N- 0 D X p L p X L p
term=
PLCy* P p V p P R p X X T L
Abl^ P P P X p P p P I p X X
Fodrin^’ P P L A L T A P P p A
rpdc6 1-11 M E P 1 A A 1 S E "s“
rpdc6 30-42 Q H L w R G 1 g T 1 I R I Q
rpdc6 54-66 s E T E R S 1 i R i I E R A
rpdc6 24-29 T L K 1 F 1 Q H L W
4D4 72-85 L Q E P F P l l h 1 p P P P
4B3 27-36 H L L E h l S h : G N R P
4B3 85-95 P S F g R S l h D F Q A S S
Figure 6.1. Proline-rich peptide ligand consensus for various SH3 domains 
aligned with proline-rich sequences from PDE4 isoforms.
Shows consensus SH3 binding regions. Prolines of the PxxP motif are in bold. 
Homology to the Src SH3 binding consensus is shaded, homology to the Grb2 
consensus is underlined. Lower part of the table shows proline-rich regions in 
PDE4 isoforms. ‘X’ represents any amino acid, ‘+’ basic, aliphatic and ‘0 ‘ 
aromatic. ‘1’ from Sparks, AB., et. al. 1996, ‘2’ from Rickies, RJ., et. al. 1994, ‘3’ 
from Rotin, D., et. al. 1994. Not consensus, simply region known to bind from 
a single protein.
Chapter 6: General D iscussion  and C onclusions 184
of which are discussed in the following paragraphs. While the consensus 
sequences for class I sequences are well documented [Yu, H., et. al. 1994 and 
Rickies, RJ., et. al. 1994, Sparks, AB., 1996] the class II sequences are less so.
1 i
■I
Alexandropoulos [Alexandropoulos, K., et. al. 1995] reports that sequences fitting
■■the general consensus PxxPx(x)(x)R or PPxxPx(x)R is sufficient for interaction
with the SH3 domains of Abl, Src, Fyn, Crk, Grb2 and Nek, where P represents
proline, x any amino acid and (x) any amino acid but may be deleted. The PDE4A
species, rpde6, contains three such sites that appear to fit with this consensus.
.These conespond to residues 4-10, 36-41 and 60-66 (Figure 6.2.). This might 
explain why rpde6 was found to interact with the SH3 domains of Src, Fyn, Abl 
and Crk
Class II consensus X/P P X X P X R
X/P P X X P X X R
X P X X P X X X R
rpde6 (residues 3-11) P P A A P s E R S
rpde6 (residues 35-43) G P R T P I R I Q
rpdc6 (residues 59-67) S P H R P I E R A
Figure 6.2. Alignment of rpde6 sequence with consensus class II SH3 domain 
binding motifs
Shows the consensus class II binding motifs for interaction with the SH3 domains 
of Src, Fyn, Abl, Crk, Grb2 and Nek [Alexandropoulos, K., et. al. 1995, Tersawa, 
H., et. al. 1994]. Proline and arginine residues, fitting with the class II consensus 
given in the table are in bold text.
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It is not clear why ipde6 preferentially bound to the SH3 domains of Src, 
Fyn and Lyn than to those of Crk and Abl. However, specificity is known to be 
determined by residues surrounding the PxxP motif [Ren, R., et. al. 1994, Yu, H., 
et. al. 1994, Feng, S., et. al. 1994]. It is likely, therefore, that specificity foi- 
interaction with Src and Fyn maybe determined by such residues, although the 
specific preferences of the SH3 domains of Src and Fyn are not known. 
Furthermore, it has been shown [Grzesiek, S., et. al. 1996]^that the binding 
sequence of the HIV protein Nef to the SH3 domain of Hck tyrosine protein 
kinase occurs tlirough a non-contiguous interaction. Therefore, it may be that 
additional amino acid residues in the sequence of rpde6 contribute to the 
interaction with the Fyn and Src SH3 domains when the three dimensional folding 
of the N-terminal region of rpde6 is considered. The requirement for such residues 
may differ between SH3 domains. Thus, it is possible that rpde6 may be prevented 
from associating with Crk and Abl, by a process of steric hindrance caused by 
other regions of this protein.
PDE4D4 appeal’s to contain no absolute consensus for either class I or 
class II SH3 domain binding motifs within its N-terminal splice region. However, 
the sequence between amino acid residues 72 and 81 is similar- to the class I 
consensus sequence, LXXRPLPXW , required for interaction with the SH3 
domain of Src (figm-e 6.1.) [Alexandropoulos, K., et. al. 1995]. The absence of 
RxL, which is reported to define class I motifs [Yu, H., et. al. 1994], suggests that 
the interaction of PDE4D4 with SH3 domains differs to those published to date.
The consensus site for Abl reported by Rickies is highly distinctive, with a 
requirement for a string of proline residues, PPPxPPPP(I/V)Pxx, [Rickies, RJ.,
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[Lee, C H , et. a l  1996]
et. a l 1994]. This is not evident in rpde6, although interaction with Abl was 
observed, albeit at a far lower level than with either Src or Fyn. The proline rich 
region in PDE4D4 does, however, resemble the preferred sequence for interaction 
with Abl more closely (figure 6.1 and 6.3.) and I would predict that it may 
preferentially bind to the Abl SH3 domain than to that of Src.
Abl consensus' P P P X P P P P Ï P X X “  
PDE4D4 (75-83) L Q P P P P P P L P P P  
Figure 6.3. Alignment of PDE4D4 with the consensus SH3-binding sequence 
for Abl
1 -Alexandropoulos, K., er. al 1995
Binding of a PDE4 species from rat heart was seen to the SH3 domain of 
Grb2 but not to Fyn. It was hypothesised in chapter 5 that this may have been a 
novel (unpublished) form of PDE4B, namely PDE4B3, since it is has been 
detected to be expressed in heart [Huston, E. and Houslay, MD., unpublished 
data]. The sequence of PDE4B3, residues 29-36 is very similar to the consensus 
binding sequence for the N-terminal SH3 domain of Grb2 (underlined in Figiu'c 
6.1. and 6.4.). This suggests that PDE4B3 may malce a good candidate for such an 
interaction.
A further level of complexity for the SH3 interaction came from the 
discovery that binding of rpde6 to the SH3 domain of fodrin significantly
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inhibited the catalytic activity of rpde6. Interaction with this domain represented a 
stark difference in the ability of rpde6 and PDE4D4 to bind to SH3 domains, since
Grb2 consensus P X X P X X R
Grb2 consensus^ P P X X P X R
Grb2 consensus^ 0 D X P L P X L P
PDE4B3 (28-39) L E L E L £ E L P G N E
Figure 6.4. Alignment of PDE4B3 with consensus binding domains for the N- 
terminal SH3 domain of Grb2
Shows the alignment of PDE4B3 residues 28-39 with two published consensus 
binding sequences for the N-terminal Grb2 SH3 domain. Homology is underlined 
in the sequence of PDE4B3. 1-Tersawa, H., et. al. 1994. 2-Sparks, AB., et. al. 
1996.
PDE4D4 failed to interact with the fodrin SH3 domain at all. The consensus 
binding sequence for the SH3 domain of fodrin is not known. However, work 
done by Rotin localised the region of the epithelial sodium channel that bound to 
the fodrin SH3 domain to a sequence that contained the following proline rich 
sequence, PPLALTAPPPA [Rotin, D., et. al. 1994]. This sequence is unique in 
that it does not contain the consensus PxxP motif, perhaps indicating that the SH3 
domain of fodrin is less selective in the distance between the two prolines. It is 
very noticeable that four of the five amino acid residues N-terminal to the tliree
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prolines, PPP, are aliphatic and hydrophobic. This may relate to the specificity for 
interaction with the SH3 domain of fodrin.
PDE46 is the human homologue of rpde6 [Bolger, G., et. al. 1993, Bolger, 
G., et. al. 1996]. If the consensus SH3 domain-binding motifs of rpde6 and 
PDE46 are compared (figure 6.5.), they are seen to be highly homologous. 
However, if the first consensus sequence is considered, the amino acids between 
the two prolines of the PxxP motif (residues 4-7) are different. Wliile one of these 
is a conserved substitution of Ala^ to Val*^ , the other is a change of an aliphatic 
residue to an aromatic residue, Ala^ to Tyr^. If this sequence confers association 
with SH3 domains in both species, then it may represent a divergence in 
specificity of SH3 domain interaction between rat and human. Furthermore, Gly^^ 
in rpde6, which is immediately N-terminal to the second PxxP motif (figure 6.5) is 
changed to Gln^^ in PDE46. A similar change of Ser^  ^to Gln^^ occurs in the third 
PxxP motif, which might imply that this mutation also reflects an evolutionary 
divergence.
The functional significance of PDEs binding to SH3 domains remains to 
be determined. One possible role is to form part of a system allowing the 
compartmentalisation of cAMP signals. It has been known for a number of years 
that, although a number of hormones work by elevating cAMP levels, they each 
have discrete effects within the same cell, as discussed in the introduction to this
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rpde6 (1-11) M E P F A A F S E R 0 #
pde46 (1-11) M B F F T V F $ B R INK
rpde6 (31 -42) 0 1 H L IN I G F R g F NNNN # î IIK#
pde46 (31-42) Q H L w R Q F R T F I R 1 Q
rpde6 (54-66) s E T E R S F H R F I E R A
pde46 (54-66) A R E R Q F H R ; ^ I B R A
Figure 6.5. Alignment of the SH3-binding consensus sequences in rpdc6 with 
its human homologue pde46
Shows alignment of the rat PDE4A species, rpde6 and the human PDE4A species, 
PDE46. Prolines of the SH3-binding consensus motif, PxxP are in bold text. 
Absolute homology between the rat and human species is shaded.
thesis. Clearly for this to occur, cAMP produced from certain receptor systems 
must only activate specific populations of PKA and be prevented from activating 
other populations. A means of achieving this may be via the localisation of PDE 
enzymes to specific subcellular compartments where they could prevent cAMP 
from diffusing into other regions of the cell. As discussed in the introduction, 
PKA-II, itself can be localised to specific areas of the cell via interaction with a 
number of AKAP isoforms. Colocalisation of PDEs would serve to ensure 
activation of a specific PKA population. A means by which PDEs could be 
localised themselves is via protein-protein interactions, or more specifically SH3 
domain binding, such as that that has been demonstrated in this thesis.
Chapter 6: General D iscussion  and C onclusions 190
Binding of PDE4 isoforms to a number of SH3 domains has been 
demonstrated in this thesis. Further work, investigating the binding of more SH3 
domains will be necessary, since evidence for binding by the methods used does 
not conclusively prove that they represent the domains that the PDEs bind to in 
vivo. Mutagenesis studies would be interesting to discover which proline-rich 
regions in rpde6 and PDE4D4 are responsible for interaction with SH3 domains. It 
is also possible that figures may be put to affinities for SH3 domains with the use 
of a Biacore machine. The work does  ^ however, demonstrate the first linlc of 
PDEs to SH3 domain containing proteins and provides the first suggestion as to a 
mechanism by which PDEs may be localised to specific locales within the cell. It 
also assigns a function to the alternatively spliced N-terminal domains of the 
PDE4A species rpde6 and the PDE4D species PDE4D4, giving insight into the 
necessity of the multiple splice variants.
' i
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